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Abstract
An insertion sequence - IS901 - present in pathogenic strains of M. avium (RFLP type 
A/I) was sequenced. The nucleotide and amino acid sequences revealed that IS901 belongs 
to a family of widespread atypical insertion sequences present in Actinomycetes and other 
bacteria. It is almost exclusively found in isolates from birds and animals, including the wood 
pigeon bacillus, being invariably associated with M. avium serotypes 1, 2 and 3 - the 
’classical’ M. avium strains. IS901 is absent in M. avium isolates from AIDS patients.
IS901 appears to be involved in pathogenicity of M. avium. Type A/I strains evolved 
from an M. avium parent strain (RFLP type A) by acquisition of multiple copies of IS901.
Primers derived from the nucleotide sequence of this insertion sequence and from 
IS900 (present in M.paratuberculosis) have been used to differentially amplify DNA from 
various members of the M. avium complex.
MAI infections in AIDS patients from the developed world are caused predominantly 
by RFLP type A strains. In African AIDS patients with MAI, however, RFLP type H was 
the most common strain identified; the exact identity of type H remains unclear. Both type 
A and type H were found in their corresponding environment, clearly identifying the 
environment as the likely source of MAI infections in AIDS patients. Infection may occur 
through direct inoculation via the respiratory and digestive tracts or by reactivation of an 
endogenous colonisation.
Unlike type A strains, type H strains do not possess plasmids commonly associated 
with AIDS isolates. However, no significant difference in plasmid content was found between 
MAI isolates from AIDS and non-AIDS patients, suggesting that plasmids play no role in 
pathogenicity.
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INTRODUCTION
1.1 THE GENUS MYCOBACTERIUM
1.1.1 History of mycobacteria
Members of the genus Mycobacterium are still a major cause of disease 
throughout the world. The two main diseases associated with mycobacteria, 
tuberculosis and leprosy, have been afflicting mankind for many millenia. The fear 
and suffering associated with these two diseases is reflected by some of the historic 
terms used to describe them. Whilst tuberculosis has been known as the Captain o f 
all o f these men o f Death and the King o f Diseases, leprosy, on the other hand has 
been referred to as the Disease o f Kings. Indeed, the Scottish king Robert the Bruce 
and the Roman emperor Constantine, were afflicted by leprosy. Grange (1988) 
divides the history of mycobacterial disease into three eras, namely ignorance, hope 
and enlightenment. Ignorance was overcome towards the end of the last century 
through the identification of the causative agents of tuberculosis and leprosy. Robert 
Koch first described the isolation of the causative agent of tuberculosis, 
Mycobacterium tuberculosis in 1882, having been preceded by Armauer Hansen’s 
description in 1874 of Mycobacterium leprae, the causative agent of leprosy. These 
discoveries gave rise to the hope that the diseases might soon be conquered, 
especially with the introduction of immunotherapy in the 1950s. The enlightenment 
has as yet failed to achieve the conquest of these diseases, but, due to technological 
advances, enormous progress has been made in the fields of mycobacterial ecology, 
taxonomy, structure, biochemistry, genetics and immunology.
Although a discussion about mycobacteria often focuses on Mycobacterium 
tuberculosis and Mycobacterium leprae, it has now been recognised that other 
mycobacterial species, far from simply being saprophytes, are potentially infective
1
and occur at relatively high frequencies. In particular, the opportunistic pathogens 
grouped in the Mycobacterium avium-intracellulare Complex (MAI) have received 
renewed attention, not least since their significance in the Acquired Immunodeficiency 
Syndrome (AIDS) has been established (Collins, 1986). At the same time the high 
prevalence of tuberculosis in AIDS has renewed the interest in this typical 
mycobacterial disease. Therefore, it seems inaccurate to refer to the abundant 
saprophytic mycobacteria, other than Mycobacterium tuberculosis and Mycobacterium 
leprae, as atypical mycobacteria.
It is now clear that tuberculosis and leprosy, sometimes misleadingly called 
tropical diseases are far from being eradicated and that mycobacterial diseases due 
to atypical mycobacteria are on the increase.
1.1.2 The Acid Fast Stain
The most distinctive characteristic of the genus Mycobacteriaceae is their 
ability to resist decolourisation by acid when stained with an arylmethane dye, such 
as carbol fuchsin. This property is known as acid fastness but is not confined to 
mycobacteria, for related organisms, such as Nocardia and some Corynebacteria 
exhibit a weak acid fastness. The acid fast stain, or Ziehl-Neelsen stain is widely used 
for microscopic detection of mycobacteria in clinical or environmental samples 
(Collins et al, 1985). Although this property was recognised over 100 years ago, the 
exact chemical basis for this phenomenon is still poorly understood. Stodola et ah, 
(1938) suggested the involvement of the mycobacterial mycolic acids in a form of 
dye-trapping. However, Kanai’s (1962) observation that acid fastness was lost when 
mycobacterial cells were broken open suggests that intact cells are required and also
diminishes the role of mycolic acids. Goren (1972) found that dye retention is 
associated with the mycolic acids covalently bound to the arabinogalactan rather than 
those lying freely in the cell wall, thus confirming their involvement in acid fastness.
1.1.3 Morphology
Mycobacteria are rod-like Gram-positive aerobes, sharing a common ancestor 
with the Gram-positive genera Corynebacterium and Nocardia. Their sizes range from 
1 to lOjum in length and 0.5 to Ifim in width. They are non-motile and non -sporing 
and form smooth or rough colonies on solid media; the latter form usually being 
associated with virulence (Silva et ah, 1985). Mycobacteria exhibit colouration 
ranging from white to orange. A cord factor (CF), produced as an outer cell wall 
component in M.tuberculosis and other species and consisting of two mycolic acid 
molecules («-branched and Jl-hydroxylated with 90 carbon atoms), is thought to be 
involved in virulence, and other functions such as involvement in inhibition of 
leukocyte migration, conferment of cellular hydrophobicity and immunostimulation 
(Silva era/., 1985).
1.1.4 Taxonomy
The generic term Mycobacterium was first described by Lehmann and 
Neumann in their "Atlas der Bakteriologie" in 1896 and refers to the fungus-like 
pellicular growth of the tubercle bacillus in liquid media. Initially the genus only 
consisted of the tubercle and the leprosy bacilli, the latter because it had the acid 
fastness characteristic for mycobacteria. Subsequent isolations of other acid fast bacilli 
from birds, animals and inanimate sources, increased the list of mycobacterial species
in the Index Bergeyana of 1966 to a total of 128 species. Runyon (1959) grouped the 
species in a now outmoded fashion, according to their speed of growth and 
pigmentation:
1) photochromogens (form yellow pigment in the light)
2) scotochromogens (form yellow pigment in the dark)
3) non-chromogens
4) rapid growers.
The simplest way of classifying mycobacteria is according to their growth rate, 
in that species may be placed into two main groups, namely the fast growers and the 
slow growers. In the former, colonies are observed within a few days and this group 
is mainly comprised of saprophytic species, whilst in the latter colonies are usually 
observed in weeks rather than days and this group consists usually, but not 
exclusively of pathogenic species. A more rational approach to the taxonomy of 
mycobacteria relies on the analysis of mycobacterial antigens. The antigens may be 
divided into cytoplasmic or soluble antigens and cell-wall bound or insoluble antigens. 
Stanford & Grange (1974) described four groups of soluble antigens which have been 
employed for taxonomic purposes. These are Group 1 antigens, common to all 
mycobacteria. Group 2 antigens, those exclusive to slow growers. Group 3 antigens, 
those exclusive to fast growers and Group 4 antigens, those unique to each 
mycobacterial species. Thus, mycobacteria may be classed using the distribution of 
these antigenic groups (Figure 1.1.1).
Soluble Antigens
Mycobacteria 1 2 3 4
Slow growers + + +
M. leprae + - +
M. vaccae + - +
Fast growers + - + +
+ Possession or absence of group-specific antigens
Figure 1.1.1: Classification of mycobacteria according to soluble antigen profile.
Two species, M.leprae and M.vaccae do not follow this antigenic distribution 
in that they do not possess antigens associated with slow growers and fast growers, 
respectively. Also, some Nocardia possess group 1 and 3 antigens, whilst related 
genera such as Listeria and Corynebacteria exhibit group 1 antigens.
The Approved List Of Mycobacterial Names (Table 1.1.1) (Skerman et al. , 
1980) is widely quoted in reference to mycobacterial taxonomy and consists of 41 
approved species. However, the list omits some species and does not include species 
isolated subsequent to 1980. The list of approved mycobacterial species employs a 
clinical classification system (Goodfellow & Wayne, 1982; Grange, 1980).
Approved species name Synonym
M.ajricanum
M.asiaticum
M.aurum
M.avium
M.bovis
M. chelonei
M. chitae
M.duvali
M.farcinogenes
M.flavescens
M.fortuitum
M.gadium
M.gastri
M.gilvum
M.gordonae
M. haemophilum
M. intracellulare
M.kansasii
M.komossense
M.leprae
M. lepraemurium
M.malmoense
M.marinum
M.microti
M. nonchromogenicum 
M.neoaurum 
M. parafortuitum 
M. paratuberculosis 
M.phlei
M. scrofulaceum
M.senegalense
M.simiae
M.smegmatis
M.szulgai
M.terrae
M. thermoresistible 
M.triviale 
M.tuberculosis 
M. ulcerans 
M. vaccae 
M.xenopi
African M.tb variant
MAC, MAI, MAIS, Avian Tb bac. 
Bovine Tb variant 
M.abscessus, Turtle Tb bac.
M.ranae, M.giae, Frog Tb bac.
MAI, MAIS, Battey bacillus 
M. luciflavum
Hansen’s bac.. Leprosy bac. 
Mouse leprosy bacillus
M.balnae, M.platypoecilus 
Vole Tb variant
M.johnei, Crohn’s/Johne’s bac. 
Timothy grass bacillus 
M.marianum, MAIS
M.habana 
Smegma bacillus
Radish bacillus
Human tubercle bacillus 
M.buruli
M.littorale
Clin Classif.
1 2 3 4 5
+ + - - - 
- + - - -
+  +  -  -  -
“  +  “  “  “
-  -  4" -  -
-  -  -  +  -
-  -  -  +  -
1: human pathogen 
2: animal pathogen 
3: opportunistic pathogen 
4: rarely pathogenic 
5: not normally pathogenic
Table 1.1.1: List of approved mycobacterial species, synonyms and clinical 
classification (Tb: tuberculosis; Bac: bacillus.).
Mycobacteria exhibit other distinct properties which allow for their 
classification. Characteristically, mycobacteria contain an extremely lipophilic cell 
wall with a high lipid content (approx. 60%), (Draper, 1982), which is responsible 
for the cells’ extreme hydrophobicity and is also thought to contribute to the slow 
growth of mycobacteria as it hinders uptake of nutrients into the cytoplasm. The cell 
wall lipids are largely composed of mycolic acids (Ratledge, 1982). Mycolic acids are 
a complex group of long-chain «-alkyl, h-hydroxy fatty acids of varying lengths 
which are often modified and covalently linked to sugars. Two-dimensional 
chromatography showed that although mycobacteria contain complex mixtures of 
mycolic acids, they fall into four basic patterns as exhibited by M.tuberculosis, 
M.avium, M.fortuitum and M.chelonei (Minnikin, 1982).
1.1.5 Classification of mycobacteria at the species and strain level
Mycobacterial species and strains may be identified by a number of techniques
involving biochemical tests, immunological analysis and DNA homology studies.
Although there is no universally accepted procedure for the identification of
mycobacteria, a protocol using a range of microbiological and biochemical tests has
been described by the International Working Group of Mycobacterial Taxonomy 
1%0
(IWGMT),which is now widely accepted. This identification method includes testing 
for the temperature spectrum of growth, pigmentation, sensitivity to thioacetazone, 
nitratase productionrjkulphafproduction, catalase production. Tween hydrolysis, 
tellurite reduction, growth on medium containing ammonium sulphate as sole source 
of nitrogen and resistance to a number of antibiotics, including streptomycin, 
ethambutol, ethionamide and rifampicin. In addition, urease activity may be used in
this method. However, this series of tests is not only applicable for slow growing 
species. In order to identify rapidly growing species, such as the clinically important 
species M. chelonei and M.fortuitum, a number of additional parameters are employed 
in the IWGMT approved scheme, including the measurement of growth rate, 
production of acid from sugars (Gordon & Smith, 1953), liberation of ammonia from 
amides (Bonicke, 1962) and utilisation of organic acids for growth. Several other 
methods exist for the identification of mycobacteria. Minnikin and Goodfellow (1980) 
demonstrated that mycobacterial lipid patterns may be identified by means of thin 
layer chromatography. The use of immunodiffusion analysis by Stanford and Grange 
(1974) has been discussed above. Several other identification methods involving gas- 
liquid chromatography and mass spectroscopy are also available but are not used for 
diagnostic purposes. The use of DNA hybridisation techniques to demonstrate the 
relatedness of mycobacteria at species and strain level is largely due to work by Baess 
(1979) and Imaeda (1985). Baess demonstrated that the M.avium complex (MAC) 
may be divided into distinct members, namely M.avium and M.intracellulare. 
Similarly, M.scrofulaceum was shown to be distinct from those two species. Baess 
(1982) has also shown the DNA relatedness of a number of fast growing species. 
Recently, McFadden et al., (1987) used DNA hybridisation techniques to demonstrate 
the isolation of M.paratuberculosis from Crohn’s disease specimens and also showed 
M.paratuberculosis to be genetically distinct from M.avium. The use of specific DNA 
probes and the utilisation of the polymerase chain reaction (PCR) has now become 
a popular means of identifying mycobacteria at the species and strain level.
1.1.6 Mycobacterial Insertion Sequences
Prokaryotic insertion sequences (IS), first detected in E.coli (Starlinger & 
Saedler, 1976), are small, generally 0.8 - 2.0 kbptransposable elements which appear
T»ie$e se<jaences
to contribute significantly to the evolution of the genome. are one of three 
classes of transposable elements which may stimulate DNA rearrangements, 
interactions between chromosome and plasmid, and transposition, not only of 
themselves but also of other DNA sequences flanked by IS elements (Calos & Miller, 
1980). The structural characteristics of IS elements has been reviewed extensively by 
several authors (Kleckner, 1981; lida et al., 1983). Briefly, IS elements, although 
different in sequence, share a common form of organisation. Each element possesses 
short "inverted terminal repeats", commonly between 15 and 25 bp long. Often the 
two copies of the inverted repeat are closely related rather than identical. When an 
IS element transposes, a sequence of host DNA at the site of insertion is duplicated. 
This duplication can be demonstrated by comparing the sequence of the target site 
before and after an insertion has taken place, which shows that insertion results in the 
presence of very short "direct repeats" flanking the IS element.
Several IS elements have been isolated from mycobacteria, including IS900, 
IS986, 1S6110. In addition, a dispersed repetitive sequence, RLEP, has been 
identified in Mycobacterium leprae.
IS900, isolated from Mycobacterium paratuberculosis, was the first 
characterised example of a mycobacterial insertion element (McFadden et al., 1987). 
It consists of 145Ibp with a G+C content of 66% (Green et al., 1989) . However, 
it lacks terminal inverted and direct repeats, characteristic for E.coli insertion 
sequences but shows a degree of target sequence specificity. At the amino acid level.
this element shows significant homology to ISllO, an insertion element of 
Streptomyces coelicolor A3(2) (Chater et ah, 1985). It has been suggested that IS900, 
ISllO  and other similar insertion sequences recently identified in M.avium isolates are 
members of a phylogenetically related family. 1S900 is repeated 15-20 times in 
Mycobacterium paratuberculosis, thus making it a useful marker for the precise 
identification of this organism and in defining its relationship to disease in both 
animals and humans.
1S986, isolated from Mycobacterium tuberculosis (Zainuddin & Dale, 1989) 
consists of a 1358bp long insertion sequence with 30bp inverted terminal repeats 
(McAdam et ah, 1989). Using this IS element as a DNA probe enables precise 
epidemiological investigations as to the genetic identity of the highly polymorphic 
M.tuberculosis complex (Hermanns et ah, 1990). The sequence of 1S986 is virtually 
identical to that of another element isolated from Mycobacterium tuberculosis, 1S6110 
(Thierry et ah, 1990), suggesting that two copies of the same IS element were 
isolated independently.
A family of dispersed repeats in Mycobacterium leprae, RLEP, has been 
isolated (Woods & Cole, 1990). The genome contains at least 28 copies of this 
dispersed repetitive sequence; RLEP consists of a 545bp core flanked by a lOObp left 
end and a 44bp right end. Both left and right ends exhibit variation among different 
copies. Similarly, the central core displays variation allowing them to be grouped into 
twelve different classes, indicating that no two RLEP sequences are identical. These 
elements have very few features in common with classical insertion sequences.
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1.2 MYCOBACTERIAL DISEASES
1.2.1 Tuberculosis
Tuberculosis, the most common mycobacterial disease, has become one of the 
major health problems associated with the developing world. Its relative absence in 
the developed world, due to improvements in public health, sanitation and effective 
vaccination belies the fact that tuberculosis was until recently one of the major 
infectious diseases in the developed world.
World-wide the annual infection rate of tuberculosis is thought to be 100 
million, of which up to 20% develop the disease. Similarly, in a significant 
proportion of cases the disease results in death (Collins et aL, 1985).
Two types of tuberculous infections are recognised, namely primary 
tuberculosis, in which the patient has had no prior exposure to the tubercle bacillus, 
and secondary tuberculosis, in which the disease occurs as a result of exogenous 
reinfection or as endogenous reactivation. The latter case has gained in prominence 
with the advent of AIDS (see: Mycobacteria and AIDS). The most frequent route of 
transmission of tubercle bacilli is through inhalation of airborne droplets, often only 
containing a few bacilli, produced by persons suffering from the disease. Although 
the lung is the most frequently infected organ in tuberculosis, any other organ may 
be affected by the disease. This very often leads to mimicking of other diseases, 
hindering diagnosis of the actual disease.
M.tuberculosis, like other intracellular parasites, achieve their virulence by 
being able to survive in macrophages. The protection afforded against tuberculosis is 
a cell-mediated immune (CMI) response, involving T-lymphocytes, which helps to 
enhance the ability of the macrophages to inhibit and destroy the invading tubercle
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bacilli. Antibody production, involving B-lymphocytes and mediated by the humoral 
immune response, is also involved but is not thought to play a vital role (Grange, 
1988). Lenzini et al. (1977) described a spectrum for tuberculosis which is made up 
of four different forms of the disease, characterised by their immune response (Table 
1.2.1). As with leprosy, the position of a patient within this spectrum depends on the 
degree of cellular immunity expressed upon infection.
Disease spectrum
1. Reactive form (RR)
2. Reactive intermediate (RI)
3. Unreactive intermediate (UI)
4. Unreactive (UU)
Infection
localised lesions 
early response to 
chemotherapy
dissemination 
poor response to 
chemotherapy
Immune response 
CMI
Little/no antibody
Some CMI
Some CMI
No CMI 
High levels of 
antibody
Table 1.2.1: Disease spectrum of tuberculosis.
Although a number of drug regimens have been devised since the onset of 
chemotherapy, lasting up to 2 years, a multiple drug regimen lasting 9 months 
recommended by the British Thoracic and Tuberculosis Association (1976) suggests 
daily administration of isoniazid and rifampicin for nine months, and, in addition, 
ethambutol for the first two months.
The anti-tuberculous vaccine BCG (Bacille Calmette-Guerin) is an attenuated 
strain of M.bovis which was repeatedly passaged over a period of thirteen years. It 
is the most widely used vaccine in the world.
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1.2.2 Leprosy
Leprosy, the second most important disease associated with mycobacteria,is 
caused by the obligatory intracellular parasite M.leprae, which was first isolated by 
Hansen in 1873. Today, the disease, which has been known for many millenia (Stewart- 
Tull, 1984) is largely confined to the developing world, being concentrated in the Indian 
subcontinent and Africa, where it is thought to affect up to 15 million people.
The study of leprosy has been hindered by the inability to grow the leprosy 
bacillus in vitro or in a convenient laboratory animal. The cultivation of the leprosy 
bacillus in mice footpads, developed by Shepard (1960), established the transmission of 
human leprosy in an animal model. Kirchheimer & Storrs (1971) found that the nine- 
banded armadillo was naturally susceptible to the bacillus and although mice footpads and 
nude mice are still being used for immunological and sensitivity purposes, M.leprae is 
now cultivated routinely in large quantities in armadillos, mainly for research purposes 
and trial vaccine production.
The principal sites of involvement in leprosy are the skin, superficial nerves and 
the mucous membranes of the upper respiratory system, such as the nose. There is only 
speculative evidence as to the portal of entry of the bacillus. Several possible routes of 
entry have been suggested, eg. through cuts and abrasions of the skin, transmission 
through insect bites and through ingestion of contaminated food. Inhalation and 
subsequent dissemination through the blood stream is also thought to be another route of 
entry (Grange, 1988). Characteristically for leprosy, the majority of infected persons only 
develop subclinical infections which usually heal spontaneously and in the small number
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of infected individuals who develop the disease, clinical symptoms develop only after an 
incubation period of several years. Similar to tuberculosis, the chief protective immune 
response involved in leprosy is cell-mediated immunity (CMI). High antibody titres due 
to a humoral immune response are observed in lepromatous leprosy but do not appear 
to confer significant protection. The clinical manifestations of leprosy exhibit a 
remarkable degree of diversity. Ridley & Jopling (1966) described a spectrum of the 
disease, concerning clinical, immunological and histological features, into which a patient 
may be placed according to their immune responses (Table 1.2.2). The spectrum of 
leprosy ranges from tuberculoid leprosy (TT) to lepromatous leprosy (LL). Intermediate 
forms of the disease include borderline tuberculoid leprosy (BT), mid-borderline, or 
borderline leprosy (BB), and borderline lepromatous leprosy (BL). The polar forms of 
the disease (TT and LL) are usually immunologically stable, whilst there may be 
movement among the intermediate forms of the spectrum.
Feature TT BT BB BL LL
Bacilli in lesions + /- ± /+  + + +  + + +
Bacilli in nasal discharge - - - + + + +
Granuloma formation + + + + +  +
CMI + + + + +  + i
Lepromin reaction + + + +
Antibody levels ± ± + + +  + + +
Macrophage maturity mature---------------------> immature
Response to therapy good----------------------- > poor
Table 1.2.2: Characteristics of the leprosy spectrum.
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For a very long time control of the disease consisted merely of isolating the 
patients from the rest of the population. This is a reflection of the stigma of the disease, 
for this form of control is wholly unjustified and morally wrong and only added to social 
prejudice which still exists today.
The WHO Scientific Working Group on the Chemotherapy of Leprosy 
recommend a multiple-drug regimen for the treatment of both, paucibacillary and 
multibacillary leprosy cases. For patients at the lepromatous end of the spectrum a triple­
drug regimen, consisting of dapsone, rifampicin and clofazimine (or ethionamide) was 
suggested. Rifampicin, which binds to RNA polymerase and inhibits RNA synthesis, was 
not only found to be more effective than dapsone in killing M.leprae cells (Rees et al., 
1970) but was also effective against bacilli resistant to dapsone. The emergence of both 
dapsone and • rifampicin-resistant strains is prevented by the inclusion of the third 
antibiotic, clofazimine or ethionamide, these being administered for a minimum of two 
years, until skin smears are negative. Patients at the tuberculoid end of the spectrum are 
treated for up to six months with dapsone and rifampicin only.
Two major anti-leprosy vaccine trials are currently in progress in Venezuela 
(Zuniga & Convit, 1985) and Malawi (Williams, 1985). The trials, sponsored by the 
UNDP/World Bank/WHO Special Programme employ the IMMLEP vaccine (heat-killed, 
gamma-irradiated M.leprae) in conjunction with BCG, the rationale being that the former 
would afford immunoprophylaxis, whilst the latter would act immunotherapeutically by 
stimulating cell-mediated immune response (Convit et ah, 1982).
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1.2.3 Other Mycobacterial Infections
Whilst the two major disease-causing members of the genus Mycobacterium are 
strictly host-dependent, the vast majority of mycobacterial species are environmental 
saprophytes. They are found particularly in wet environments, including open water and 
piped water supplies. Diseases associated with these environmental saprophytes are 
commonly referred to as opportunistic infections. Unlike leprosy and tuberculosis, these 
diseases are not transmitted from person to person but from a person’s contact with the 
bacillus in the environment. Grange (1988) grouped the species responsible for 
opportunistic infections according to the frequency they cause disease and to their locality 
(Table 1.2.3).
Widespread causes
M. avium
M. intracellulare
M. scrofulaceum
M.kansasii
M. chelonei
M.fortuitum
M.malmoense
Geographically 
restricted causes
M.marinum
M.simiae
M. ulcerans
M.xenopi
Rare causes
M.asiaticum
M.gordonae
M.szulgai
M.flavescens
M. thermoresistible
M. haemophilum
M. nonchromogenicum
M.shimoidei
M.terrae
M. triviale
Table 1.2.3: Mycobacteria causing opportunistic infections.
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Grange (1988) divided opportunistic infections into two main categories, Those 
resulting from inoculation of the bacillus into the skin and deeper tissues, resulting in 
local lesions, and those which result from inhalation and/or ingestion of the organism. 
Patients of the latter group exhibit tuberculoid symptoms, such as localised pulmonary 
lesions, discrete non-pulmonary lesions, localised lymphadenitis and disseminated 
disease.
ThQ Mycobacterium avium-intracellulare complex (MAC) accounts for most cases 
of the opportunistic mycobacterial infections and its involvement in the Acquired 
Immunodeficiency Syndrome (AIDS) has recently been recognised (see: Mycobacteria 
& AIDS).
M. chelonei is associated with localised lesions in open wounds, often acquired in 
hospitals. M.fortuitum is one of the few fast growing opportunistic pathogens and causes 
similar disease as M.chelonei (Borghans & Stanford, 1973). M.kansasii is often the cause 
of pulmonary infections (Grange & Yates, 1986). M. ulcerans causes a disease known as 
Buruli ulcer, first identified by MacCallum et al. (1948). Although the agent has never 
been isolated from the environment, it is thought that bacilli are inoculated into the skin 
via plant thorns. Similar to lepromatous leprosy, there is transient suppression of specific 
immune responses, after which there is a disappearance of bacilli and healing of lesions. 
It is thought that an endotoxin produced by the organism is involved in this disease 
(Hockmeyer et al., 1978). M.marinum causes "swimming-pool" granuloma and is a 
condition associated with water. Linell & Norden (1954) described clinical manifestations 
of the disease including localised skin lesions which are usually self-healing.
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1.3 THE MYCOBACTERIUM AVIUM  COMPLEX
1.3.1 History
The Mycobacterium avium complex (MAC, MAI or MAIS) consists of a 
number of organisms whose taxonomic relationships are disputable. In general, two 
species make up the MAC, namely M.avium and M.intracellulare. At a phenotypic 
level these two species are essentially indistinguishable. Biochemical tests do not 
allow for a differentiation between them. The complex is also referred to as M. avium- 
intracellulare, or MAI, emphasizing the difficulty in differentiating between these two 
species. Often, another species, M.scrofulaceum, is grouped within this complex. 
Identified by Prissik & Mason (1956) and also associated with human disease, 
although genetically distinct from MAC, it exhibits many phenotypic similarities to 
the above two species in the MAC. The complex is then referred to as the MAIS 
complex. Although M. avium was originally identified as the agent causing 
tuberculosis in birds, it is now recognised that the MAC constitutes the major 
mycobacterial pathogen in man other than the leprosy and tuberculosis bacilli, 
particularly since the advent of the Acquired Immunodeficiency Syndrome (AIDS).
The causative agent for avian tuberculosis was identified by Straus & Gamaleia 
(1891) and was termed M.avfwm by Chester (1901). Runyon (1967) found that another 
species, causing disease in humans, described as Nocardia intracellularis by Cuttino 
& McCabe (1949), possessed phenotypic characteristics very similar to M. avium and 
thus renamed this organism M. intracellulare. A group of strains known as the Battey 
bacilli, isolated in a tuberculosis sanatorium, were also grouped into the species 
M.intracellulare. However, even today there is a great deal of controversy as to 
whether these two species, strains of which account for the majority of MAC
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members, are in fact distinct species or simply different strains.
Several other species are often included within the MAC. M.paratuberculosis, 
which causes hypertrophic enteritis in cattle, known as Johne’s disease, and may be 
involved in Crohn’s disease, is often referred to as a sub-species of the complex. 
Similarly, M.lepraemurium, the rat leprosy bacillus described by Stefansky (1903), 
is often referred to within this context as part of the complex.
Characteristically, some members of the MAC are mycobactin-dependent when 
grown in vitro, that is they have a requirement for this iron-binding lipid. These 
include strains isolated from deer, pigs and the wood pigeon, the "woodpigeon" 
bacillus, which are serologically similar to avian M. avium strains, as well as 
M.paratuberculosis. The degree of mycobactin-dependence is variable amongst these 
strains, as in some strains this dependence is only observed at primary isolation.
Several parameters may be applied to distinguish the MAC from other slow- 
growing mycobacteria. Sommers & Good (1985) describe common characteristics of 
the MAC which include slow growth at 37°C; smooth, thin or rough colonies; 
negative niacin tests, negative nitrate reduction, negative Tween hydrolysis, negative 
urease activity, and positive tellurite reduction at 3 days.
1.3.2 Classification of the MAC
It is now widely accepted that the MAC consists of a large number of 
members, which may be differentiated through several tests, all of which make use 
of the variation in antigenic structure of the organisms in question. In addition, 
genetic studies have been employed to differentiate between members of the MAC. 
Griffith (1925) showed that the avian tubercle bacillus, M.avium, may be readily
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distinguished from its human and bovine counterparts, M.tuberculosis and M.bovis, 
by agglutination with absorbed antisera. Schaefer (1965; 1967) demonstrated that 
members of the MAC could be distinguished in terms of agglutination serology, 
thereby describing distinct serovars. The antigens involved in this test are the 
carbohydrate components of the polar glycopeptidolipids, which are a class of cell 
wall surface lipids involved in capsule formation, bacteriophage attachment, colony 
morphology, and, perhaps, virulence. The antigenic carbohydrate component usually 
contains four sugars; the internal L-rhamnose and deoxyhalose sugars are constant, 
while the outer two vary according to the serotype. Wolinsky & Schaefer (1973) 
identified 23 different serovars, namely 1 to 3 consisting of M.avium, 4 to 20 
consisting of M.intracellulare, and serovars 41 to 43, comprised of M.scrofiilaceum. 
However, some strains cross-react whilst others are sometimes untypable. Good & 
Beam (1984) describe 28 distinct serovars of the MAC. Marks et al. (1971) used thin 
layer chromatography of glycolipids to identify mycobacteria and found that each of 
the distinct serovars of the MAC corresponds to a distinct glycolipid pattern. 
However, this correlation is as yet incomplete.
Stanford & Grange (1974) employed immunodiffusion serotypes; here soluble 
mycobacterial antigen from ultrasonicated bacteria was detected by means of double 
diffusion. Members of the complex were shown to share many of the species-specific 
Group IV antigens, suggesting that these are in reality strains of the same species 
rather than different species. Differences within this group of antigens allowed 
grouping of MAC members accordingly into group A for M. avium and groups B and 
C for M.intracellulare. The mycobactin-dependent "woodpigeon" strains fell into 
group A, M.paratuberculosis strains fell into groups A and B. M.lepraemurium
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was found to fall into another, distinct group. This classification suggests that there 
are four distinct species within the MAC, namely M.avium (type A), M.avium 
brunense (type B), M.avium intracellulare (type C) and M.avium lepraemurium. 
However, this classification ignored crucial differences amongst these species with 
regard to the disease they cause. In addition, the former three species are not easily 
distinguishable from each other.
Meissner & Anz (1977) and Magnusson (1980) have employed sensitin typing 
to divide the MAC. A laboratory animal is challenged with an appropriate 
mycobacterial strain and is then skin tested with sensitins from the homologous and 
heterologous organisms. The diameter of the skin test due to delayed type 
hypersensitivity reaction is then a measure of the relatedness of the organism. In 
essence, sensitin typing allows for a division of the MAC into three groups which 
appear to correspond to the groups obtained from immunodiffusion.
Baess (1979) used DNA homology studies, which are thought to give the most 
reliable evidence of taxonomic relationships, to demonstrate that M.avium and 
M.intracellulare are in fact two distinct species. Subsequently, Baess (1983) 
demonstrated using DNA homologies that some of the M. intracellulare serovars were 
M.avium strains.
Crawford et al. (1981) developed a phage typing system for the MAC. 
My cobacteriophages, propagated in M.smegmatis, were used to produce phage lysis 
patterns among MAC strains. At least half the strains tested were sensitive to at least 
one of the phages tested. There was a wide variation in the phage lysis patterns and 
this allowed the subdivision of these strains according to phage sensitivity. This 
demonstrated the suitability of the MAC for phage typing, although such a scheme
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has not been detailed.
Portaels (1978) used a system to classify members of the MAC which 
compared certain characteristics of such isolates, such as their pigmentation, catalase 
and urease activity. This classification was not sufficient for taxonomic purposes and 
is not widely used.
A commercially available gene-probe for the M.avium complex (Gen-Probe 
Inc., San Diego, Ca.,) consists of two ^^^I-labelled cDNA probes complementary to 
the corresponding ribosomal RNA (rRNA) of M. avium and M. intracellulare, allowing 
for differentiation between these two species. Here, the two species are defined as 
determined through DNA:DNA hybridisation studies by Baess (1983). This form of 
identification relies on the formation of stable DNA/RNA hybrids which may be 
detected with a gamma counter. Saito et al., (1989) showed, with the use of these 
probes, that the species-division within the M.avium complex is distinct, thus 
supporting Baess’s findings regarding the erroneous grouping of certain 
M.intracellulare serovars. Similarly, McFadden et al., (1987) and Picken et al.,
(1988), comparing restriction fragment length polymorphisms, arrived at the same 
conclusion. This commercially available DNA probe is now routinely used as a tool 
for identification. Drake et ah, (1987) demonstrated that the probe is highly accurate 
in differentiating between the two species concerned. The manufacturer suggests that 
a hybridisation of >10% indicates a positive test. However, Sherman et ah, (1989) 
compared the Gen-Probe with conventional methods for accuracy, applicability, and 
speed of the identification of putative isolates of the MAC. The comparative study 
suggests that a cut-off value of >15% hybridisation may be more appropriate. Apart 
from its high specificity and sensitivity, this probe has the advantage of being
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extremely rapid, thus greatly reducing the identification time for the MAC. For these 
reasons the Gen-Probe was used in the context of this study.
Recently, Boddinghaus et al., (1990) compared 16S rRNA sequences from 
various MAC serovars in order to establish a phylogenetic relationship between these 
serovars. Although their findings in general reflect the classification obtained with 
sensitin tests, the rRNA sequences obtained allow grouping of the strains tested into 
five groups, (1) M.avium serovar 1, (2) M.intracellulare serovars 4, 5, 6, 8, 9, 10, 
and 11 as well as M.paratuberculosis, (3) M.intracellulare serovars 12, 13, 14, 15, 
17, 19, and 20, (4) M.intracellulare serovar 7, and (5) M.intracellulare serovar 18. 
An extension of this investigation by Rogall et al., (1990) covering a larger number 
of mycobacterial species (analysing and comparing rRNA sequences) suggested that ' 
this classification corresponds to the traditional division of the genus Mycobacterium 
into fast and slow growers but does not conform with the classification of species into 
photochromogens, scotochromogens, non-chromogens and rapidly growing species. 
Table 1.3.1 summarizes the above mentioned methods for classification of the 
M.avium complex.
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Agglutination Immunodiff. Sensitin Conventional DNA:DNA GenProbe
serology analysis testing taxonomy homology rRNA
M.<mum 1 -3  1 -3  1 -3 ,8  1 -3  1 6, 8 - 11,211 - 6 .8  - U
M.avium - 4-10,20,21
brunense
M.intracellulare 4 -2 4  4 -7 ,9 - 2 1  7. 12 - 21 7, 12 - 20 7, 12 - 20,
’Intermediate’ 4 - 6, 8 - 11
M.avium - 11-19
itoracelMare
Not tested 22 - 24 22 - 24 22 - 24
Table 1.3.1: Subdivision of M.avium complex
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1.3.3 Plasmids in the MAC
The detection of plasmids in MAC strains has become widespread since it had 
been suggested that these may play a role in virulence and pathogenicity of 
isolates (see ’Mycobacteria and AIDS’).
A procedure for the isolation of plasmids from mycobacteria was first 
described by Crawford & Bates (1979), who identified plasmids in several MAC 
strains thought to be human pathogens. Subsequently, the same authors (1981a) 
isolated a number of plasmids from various MAC strains. One such strain, LR25 was 
found to contain three plasmids, including a large plasmid with a molecular weight 
of > 10*. It was found that plasmids were present in several serotypes, including 2, 
4, 12, and 18, but absent in others, including 1 ,3 , and 5. In conjunction with their 
development of a phage typing system, Crawford & Bates (1981b) examined MAC 
strain LR25 in terms of its sensitivity to my cobacteriophage JF2. In an experiment 
designed to eliminate the plasmids from strain LR25 and subsequent testing of this 
cured strain for phage sensitivity, it was found that the supposedly "cured" strain 
was, unlike the parent strain, sensitive to several phages. Crawford & Bates 
concluded that this was due to the presence of a plasmid encoded restriction- 
modification system. Crawford & Bates (1984) analysed one of the "small" plasmids 
from strain LR25, plasmid pLR7, by restriction endonuclease mapping and cloned the 
entire plasmid into an E.coli plasmid. This enabled the generation of large amounts 
of the mycobacterial plasmid for analysis, manipulation and use as a DNA probe to 
investigate the MAC for the presence of other related plasmids.
Franzblau et ah, (1986) screened MAC isolates for the presence of plasmids, 
to establish a possible relationship to antibiotic resistance in the MAC. Up to 50% of
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clinical MAC isolates were shown to carry one to three plasmids. Compared to 
colony morphology and antibiotic resistance patterns, it was found that whilst 
plasmid-less strains exhibited a range of antibiotic sensitivities to kanamycin, 
streptomycin, and rifampicin, all the plasmid-containing strains had high levels of 
resistance to these three antibiotics, suggesting the possibility of a permeability barrier 
in the plasmid-bearing strains. However, Masaki et al., (1989) found no relationship 
between plasmid contents and drug resistance when analysing MAC isolated from 
swine and humans. Some swine and human isolates carried plasmids differing in 
molecular weights, but Southern hybridisation revealed that small plasmids from 
swine MAC strains were homologous to those from human origin.
Meissner & Falkinham (1986) explored the possibility of using plasmid DNA 
profiles as epidemiological markers for clinical and environmental isolates of the 
MAIS complex. They showed that not only are plasmids frequently present in clinical 
isolates but also exhibit a large degree of heterogeneity. This heterogeneity makes 
MAC plasmids an unlikely candidate as an epidemiological marker.
Pethel & Falkinham (1989) investigated plasmid-influenced changes in 
M.avium catalase activity, using strains LR25, containing plasmids, and LR163, the 
supposedly "cured" derivative, as models. It was found that differences in growth 
temperature, effect of culture aeration and susceptibility to hydrogen peroxide existed 
between these two strains. These differences were attributed to a plasmid-encoded 
catalase activity, and it was therefore concluded that plasmid-encoded genes influence 
M.avium catalase activity in general.
Recently, Hellyer et al., (1991) analysed plasmids of MAC strains isolated 
from patients with and without AIDS. No significant difference was found in the rate
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of plasmid carriage in MAC strains from these two groups of patients in the U.K. 
American AIDS-derived MAC strains exhibited a higher rate of plasmid carriage. The 
majority of "small" plasmids (<30kb) were found to exhibit homology to pLR7; 
these plasmids predominated in MAC serotypes 4 and 8 which themselves 
predominate in AIDS.
Possible roles of plasmids in clinical isolates are discussed in section 
’Mycobacteria & AIDS’.
27
1.3.4 Mycobacterium paratuberculosîs
Johne & Frothingham (1895) described a condition of chronic hypertrophic 
enteritis in cattle, which they thought was caused by the avian tubercle bacillus. This 
disease, now referred to as "Johne’s disease", is a contagious, chronic and usually 
fatal condition, which affects a variety of domestic as well as wild herbivorous 
animals rather than just cattle. It was found that the mycobacterial isolates from 
animals afflicted by this disease fail to synthesise the lipid-soluble iron-binding 
compound mycobactin, which is thus added as a supplement to media when 
M.paratuberculosis is grown in vitro (Matthews et al., 1977).
The organism is also thought to be involved in a human condition known as 
"Crohn’s disease". This disease, first described by Crohn et ah, (1932) manifests 
itself as a chronic inflammatory disease of the gastrointestinal tract. Chiodini et al., 
(1984a,b,c, 1986) isolated a number of slow-growing mycobacteria from Crohn’s 
disease patients, some of which were found to be M.paratuberculosis. Similar results 
were also found by McFadden et al., (1987). Although the aetiological association of 
mycobacteria with this disease is still unclear, Chiodini (1984a) and Gitnick et al.,
(1989) suggest an involvement of M.paratuberculosis, even when the organism is only 
present in low numbers. Recent improvements in identification techniques, namely 
the polymerase chain reaction, are currently being used to further investigate the role 
of M.paratuberculosis in Crohn’s disease (McFadden, personal communication).
The controversy associated with this organism concerns its taxonomic status 
within the MAIS complex. M.paratuberculosis is classed as a sub-species of M.avium, 
for it possesses many characteristics which resemble those of M.avium (Meissner et 
al., 1974). McFadden (1987) isolated a number of slow-growing mycobacteria from
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Crohn’s disease patients and using DNA from these as a probe showed that these 
were identical to M.paratuberculosis. The DNA homologies of isolates of 
M.paratuberculosis and M.avium was found to be greater than 90%. Subsequently 
insertion sequence, IS900, was identified in a human Crohn’s disease isolate of 
M.paratuberculosis which was unique to this organism thus clearly distinguishing it 
from the rest of the MAIS complex. The complete sequence of this element, which 
is the first example of an insertion element found in mycobacteria, has been 
determined (Green et al., 1989).
Saxagaard & Baess (1988) investigated the relationship between M.avium, 
M.paratuberculosis and "wood pigeon" mycobacteria, the latter being a group of 
atypical avian strains (Jorgensen & Clausen, 1976). DNA homology studies revealed 
that M.avium and M.paratuberculosis are closely related, leading the authors to 
consider these two organisms as two variants of M.avium, namely M.avium subsp. 
avium and M.avium subsp. paratuberculosis, respectively. The "wood pigeon" 
bacillus was found to be closely related to type strains of both subspecies, thus 
affording the classification as an atypical strain of M.avium, M.avium subsp. 
columbae (wood pigeon = Columba palumbus).
A novel technique, field inversion gel electrophoresis, was employed by Lèvy- 
Frèbault et al., (1989) to identify DNA polymorphisms amongst these three 
organisms. Pulsed-field electrophoretic restriction patterns showed that identical 
profiles were found for M.paratuberculosis strains and mycobacteria isolated from 
Crohn’s disease. Furthermore, there was homogeneity among the "wood pigeon" 
mycobacteria. Both groups gave distinct pulsed-field profiles allowing for 
differentiation from each other and from MAIS serotypes; such differentiation of the
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"wood pigeon" bacillus from M.paratuberculosis or both groups from the MAC was 
not achieved using phenotypic methods.
Chiodini (1989) selected the 5S rRNA gene as a reference DNA to examine 
changes in restriction fragments of M.paratuberculosis and related organisms of the 
MAC. All strains examined contained identical restriction patterns, lacking 
polymorphisms, even between those separated geographically. The organism was, 
again, found to be closely related to the MAC, and it was suggested that although it 
should be grouped within the MAC but its species status should be emphasized 
(MAIP complex), allowing for its unique biological and environmental niche. This 
uniqueness is reflected in the lack of genetic heterogeneity for most species and has 
been brought about by a unidirectional genetic selection due to biological and 
environmental isolation. Recently Collins et al., (1990) have shown that 
M.paratuberculosis demonstrates genetic differences between different strains which 
are detectable with DNA probes.
Thorel et ah, (1990) analysed a number of mycobactin-dependent 
mycobacteria by means of a variety of biochemical and microbiological tests to enable 
their classification. The main conclusion was the grouping of MAC strains according 
to their pathogenicity and host-range characteristics. Three subsepecies of M.avium 
are described. Firstly, M.avium subsp. avium, which is thought to be in the 
environment and causes tuberculosis in birds. Other animals, including cats, cattle, 
goats, pigs and sheep, are also thought to be infected by this subspecies. In humans 
this causes pulmonary infections in adults, submandibular infections in children and 
disseminated disease in patients with AIDS. Secondly, M.avium subsp. 
paratuberculosis, which is an obligate pathogen not found in the environment but
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which causes paratuberculosis and may also be involved in Crohn’s disease. Thirdly, 
M.avium subsp. silvaticum, whose members are obligate pathogens for animals, 
causing tuberculosis in birds and paratuberculosis in mammals.
1.3.5 M.lepraemurium
Another mycobacterial species often classed within the MAIS complex is 
M.lepraemurium, which, although not related to M.leprae, causes a leprosy-like 
disease in rats (Stefansky, 1903). Several other mammals, including cats and dogs, 
are, if rarely, afflicted by this disease, which involves the skin and lymph nodes 
(Mori & Kohsaka, 1986). "Rat leprosy" may be demonstrated in laboratory mice, 
experimental infection often being the only confirmation of the pathogen being 
responsible for disease.
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1.4 MAIS AND DISEASE
1.4.1 Disease In Animals
The most common disease in animals associated with the MAI complex is 
avian tuberculosis, caused by M.avium. Almost all species of birds are susceptible to 
the avian tubercle bacillus, to varying degrees. This chronic and invariably fatal 
disease is caused by M.avium serotypes 1,2,3 and 6 (Schaefer et al., 1973). The 
strains involved in this disease exhibit variation in virulence, not only from serotype 
to serotype but also for different species of birds. Symptoms are rarely observed in 
afflicted birds until the latter stages of the disease. At post-mortem lesions can be 
observed in the liver, spleen, intestines and bone marrow (Thoen et al., 1980). Avian 
tuberculosis in woodpigeons is caused by an atypical M.avium strain, the 
"woodpigeon" bacillus, requiring mycobactin for growth in vitro (McDiarmid, 1961). 
This strain has also been isolated from other diseased animals, including deer, pigs 
and hares.
Many other animals, whether domestic animals, such as pigs, cattle, horses, 
cats, and dogs, or wild animals, such as marsupials, wild mice, rats, and snakes are 
infected by members of the MAI complex (Cassidy et al., 1968), (Smith et al., 
1973), (Thoen & Himes, 1980). MAI infections in pigs have often been attributed to 
M.intracellulare although serotypes 1 ,2 , and 3 are also often found (Tsukamura & 
Nemoto, 1973). These M.intracellulare serotypes are now recognised as M.avium 
strains, serotypes 4, 6, and 8. In common with MAI infections in general, there 
appears to be no spread from animal to animal. Kauker & Rheinwald (1972) 
suggested contaminated food to be the source of these infections. MAI infections in 
cattle are usually progressive and generalised, but commonly lesions are only found
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in the mesenteric lymph nodes. Whilst in the USA serotype 1 appears to predominate, 
in Europe serotype 2 is predominant. Other ruminants, such as deer, are often 
infected by the "woodpigeon" bacillus. MAI in other animals is encountered rarely. 
In such cases, however, there appears to be a predominance of serotypes 1, 2, 3, 6, 
and 8, and to a lesser extent serotype 18 (Grange et ah, 1990).
The M.avium complex is clearly an important group of environmental 
saprophytes and pathogens of birds and mammals (including humans). However, 
whilst some members always cause localised infection, such as M.lepraemurium 
causing skin disease in rats, and M.paratuberculosis causing localised gut infection, 
the vast majority of MAC strains, including M.avium and M.intracellulare may cause 
localised and disseminated disease as well.
1.4.2 Disease in Humans
Apart from tuberculosis and leprosy, MAI infections constitute the most 
prevalent mycobacterial disease in humans. Unlike tuberculosis and leprosy, these 
infections are not spread from person to person but are thought to be contracted from 
the environment. There is little information available as to the route of infection and 
pathogenesis of human disease due to MAI.
The first report of MAI infection in humans dates back to Feldman et ah, 
(1943). Subsequently, Timpe & Runyon (1954) reported cases of MAI infections and 
proposed a classification of non-tuberculous mycobacterial disease. Several studies 
carried out in the 1960s in the USA showed that such infections commonly involve 
patients with prior chronic pulmonary disorders and that the disease is more common 
in rural rather than urban settings. Spread of MAI infections from patients to close
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contacts was not detected, indicating that MAI infections require contact with the 
organism in the environment. Response to antituberculous drug treatment was often 
poor, indicating a high degree of resistance of these organisms to the majority of 
drugs (Lewis et al., 1960; Bates, 1967; Yeager et al., 1973).
The distribution in nature and the sources of infection of MAI have largely 
been established. Organisms of MAI have been isolated from a variety of 
environmental sources, including soil (Kubica et al., 1961), and water (Goslee & 
Wolinsky, 1976). Reznikov & Dawson (1980) found that there was a correlation 
between the prevalence of isolates from the soil in Australia and the frequency of 
human disease isolates, indicating that the source of infection was the environment. 
Reznikov et al., (1971) showed that there was a correlation in terms of serotypes 
among house dust isolates and human disease isolates. Parker et al., (1983) have 
shown that MAI may be concentrated and form aerosols with water, suggesting that 
aerosols may be the major source of infection in humans.
Grange & Yates (1986) describe three main types of the disease, localised 
primary lymphadenitis, pulmonary infection and disseminated disease. There is a 
degree of geographic diversity in the causative agent of mycobacterial lymphadenitis. 
In general, the disease is caused by M.tuberculosis. In the UK only a few cases are 
caused by other mycobacteria, including MAI, M.chelonei, M.kansasii and M.xenopi. 
In the USA, Australia and Japan, M.scrofiilaceum is the most common cause for this 
disease (Grange, 1988). Primary infection in the nasopharyngeal region leads to 
involvement of the cervical nodes. Removal of the nodes involved is usually sufficient 
to cure the patient (Smith & Grange, 1989). The clinical picture of pulmonary 
infection is almost identical to that of tuberculosis. The isolation and identification of
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the causative agent enables diagnosis of a tuberculosis or MAI infection. Pulmonary 
disease due to MAI is commonly associated with persons suffering from chronic lung 
disease and immunocompromised individuals. Similar to tuberculosis, there are also
Central Nervous Systepi
non-pulmonary sites of the disease, such as bone, tendon, and(CNS)(Wolinsky, 1979). 
A similar drug regimen used in the treatment of tuberculosis, involving rifampicin, 
isoniazid and ethambutol, is employed in MAI chemotherapy; however, all three 
components of the mixed drug regimen are given for 18 to 24 months (Hunter et ah, 
1981). The third type of the disease, disseminated MAI infection, is associated with 
individuals suffering from immunosuppression; this may be either congenital, such 
as Severe Combined Immunodeficiency (SCID), or acquired, such as the Acquired 
Immunodeficiency Syndrome (AIDS).
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1.4.3 MAI and BCG Vaccination
It is now generally recognised that prior exposure to environmental 
mycobacteria plays an important role in the efficacy of BCG vaccination. Palmer & 
Long (1966) refer to a "natural vaccination", demonstrating that BCG is only 
effective in areas with no prior exposure to environmental mycobacteria. In areas with 
prior exposure, the degree of protection given by BCG vaccination depends on the 
extent of previous mycobacterial exposure.
It has also been suggested that BCG vaccination may result in protection 
against MAI infection. Engbaek & Jespersen (1966) studied the effect of BCG 
vaccination on acute and chronic infection with M. avium in a number of laboratory 
animals on the basis of survival times, mortality and number of bacteria in the organs 
involved. They were able to show that in rabbits, previous BCG vaccination 
prolonged the average survival time subsequent to challenge with M.avium. This was 
found to be due to the inhibition of growth of the organism during the first few 
weeks. Protection was incomplete in that chronic disease symptoms associated with 
tuberculosis developed. In other animals, there was a significant reduction in 
mortality and also a reduction in the number of bacilli present, suggesting that BCG 
vaccination may afford some protection against MAI infection.
Collins (1985) investigated the protection to mice afforded by BCG vaccines 
against an aerogenic challenge by three mycobacteria of decreasing virulence. 
Vaccination induced substantial levels of resistance to tuberculosis and elevated 
tuberculin hypersensitivity. The study also showed that the protective activity of BCG 
vaccines does not depend on the virulence of the infecting organism. Orme & Collins 
(1985) measured the prophylactic effect in mice of BCG vaccination against non-
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tuberculous infections. A protective effect was found against infection with M.avium 
and M.kansasii, but no protection was observed against infection with 
M.intracellulare and M.simiae, regardless of the route of vaccination. This indicates 
that BCG vaccination, given prior to contact, does afford some degree of protection 
against some non-tuberculous infections. This may explain the fact why MAI 
infections in US AIDS patients is more prevalent than in European AIDS patients (see 
section: MAI and AIDS).
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1.5 MAI AND AIDS
1.5.1 The Acquired Immunodeficiency Syndrome (AIDS)
Until the early 1980s there was a common belief that infectious disease was 
no longer a threat in the developed world. The previous decades had seen the control 
of many of the most important diseases of public health concern. The conventional 
wisdom was that the new challenge for public health would be more concerned with 
the eradication of non-infectious disease, such as cancer and heart disease. However, 
the advent of AIDS, in both the developed and developing world, has shown that an 
infectious disease is still a major health problem. The AIDS epidemic is now regarded 
as the number one health problem of the closing stages of the twentieth century. 
Although there has been a huge response by science to understand and combat the 
disease leading to the early achievements, of identification and isolation of the 
causative agent, the only known methods for controlling the disease are the use of 
condoms (during sexual intercourse), sexual abstinence and the non-sharing of 
hypodermic needles among intravenous drug users. The endemic will spread for the 
foreseeable future, with a devastating effect on public health.
1.5.2 Human Immunodeficiency Virus
The causative agent of AIDS, the human immunodeficiency virus (HIV) 
belongs to the retrovirus family, which have a single-stranded RNA genome. The 
retroviruses characteristically possess the enzyme reverse transcriptase, which allows 
for the viral RNA to be used as a template to synthesize viral DNA, which in turn 
may integrate into the genome of the host. Here the viral DNA remains until 
activated, when the formation of new virus particles is initiated.
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Following identification in the laboratories of Montagnier (Barré-Sinoussi et 
al.., 1983) and Gallo (Gallo et al., 1984), much of the molecular biology of the virus 
has now been elucidated. The genetic material of the virus is contained in roughly 10^  
nucleotides of RNA, which code for nine genes flanked by long terminal repeats 
(LTR). These LTRs do not code for proteins but initiate the expression of other viral 
genes. Three genes, gag, pol and env are involved in the synthesis of viral particles, 
the other genes being involved in the regulation of the virion gene expression 
(Haseltine & Wong-Staal, 1989). The virus particle replicates and causes damage 
upon entering the host cell. In the case of HIV, entry into the cell is initiated by virus 
binding to the CD4 antigen on the cell-surface. Since CD4 antigens are predominantly 
found on the surface of T helper cells of the immune system, the targeting of these 
cells results in the characteristic and deleterious effect of gradual depletion of the 
function of the immune system. This is brought about by the continual loss of these 
T helper cells. F©ii®/»gbinding of the viral envelope glycoprotein to CD4 antigen, the 
genetic material of the virus is eventually incorporated into the host DNA. It is 
thought that entry may result from direct fusion of the virus with the cell membrane, 
thereby injecting the core of the virus into the host cell. Subsequently, reverse 
transcriptase activity allows for incorporation of the viral genetic material into the 
host’s DNA. Once incorporated in the host genome, the infection is chronic for the 
life-span of the host cell. The virus may either remain silent or act in one of several 
ways (Weber & Weiss, 1989). First, the virus causes chronic infection with formation 
of new virus particles but killing only a few cells. Secondly, as a result of infection, 
syncytia, cell aggregates without distinguishing cell walls, are formed which 
eventually die off. Thirdly, HIV infection results in rapid death of target cells without
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the formation of syncytia.
1.5.3 Epidemiology of AIDS
AIDS is a serious health problem on a global scale. Although there are few 
reliable figures as to the extent of the spread of AIDS, it is estimated that in the USA 
alone there will be some 350,000 cases by 1992, with some 1.5 million Americans 
being HIV-positive. In the USA and other developed areas of the world, such as 
Europe, AIDS is still concentrated among a number of "high risk groups" such as 
homosexual men, haemophiliacs and intravenous drug users. In these areas there has 
not been a great spread of the disease into the general population, with the exception 
of inner city areas of certain major cities (Heyward & Curran, 1989).
On a global level there are estimated to be some 250,000 reported AIDS cases 
with between 5 and 10 million people being HIV-positive. This has resulted in serious 
health problems, particularly in certain sub-Saharan countries in Africa, in which 
AIDS is pandemic amongst the heterosexual community.
Transmission of HIV occurs through sexual intercourse, by injection or 
administration of contaminated blood or blood products and by transmission from an 
infected mother to the infant. There is no evidence that HIV may be transmitted in 
other ways, particularly through casual contact with other people.
Infected individuals may remain symptomless for years, after which AIDS- 
related symptoms develop. The fatality rate is thought to be 75-90%. Although 
patients may survive for several years, there is great variation in the average survival 
time. In the developed world, 50% of patients die within 18 months of diagnosis, 
with 80% dying within 3 years. In Africa, the survival times appear to be shorter.
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However, this appears to attributable to late diagnosis of the disease.
Due to the long incubation period, epidemiologically the numbers of HIV- 
positive individuals is of greater interest than the actual cases of AIDS patients. 
Seroprevalence data suggests that there are three distinct patterns of AIDS globally. 
The first pattern is seen in the developed world including parts of Latin America. 
Most cases are concentrated in certain high-risk groups and large-scale spread into 
the community at large is not observed. Here, the male to female ratio of reported 
cases lies between 10 and 15 to 1. The second pattern is seen in sub-Saharan Africa 
and in some Caribbean countries. Here, most cases occur in heterosexuals, with a 
male to female patient ratio of 1 to 1, suggesting spread through sexual intercourse. 
A third pattern is observed in North Africa, the Pacific and the Middle and Far East. 
Here the pattern suggests an importation of the disease into the community as a 
whole, but actual numbers suggest that the disease is not pandemic as yet (Mann et 
a l ,  1989).
1.5.4 Clinical Features of AIDS
HIV infection results in a predictable and progressive impairment of the 
immune system, immunodeficiency. This immunodeficiency is brought about by a 
gradual depletion of the T helper cells, o r l y m p h o c y t e s , whose functions include 
recognition of antigens or antigenic markers. This then helps to stimulate B 
lymphocyte production specifically directed against the recognised antigen. T4 cells 
are also involved in cell-mediated immunity; in the activation of cytotoxic killer cells, 
such as T8 lymphocytes and monocytes and macrophages, which scavenge foreign 
particles and infected cells by the process of phagocytosis. A gradual loss of T4 cell
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activity leaves the body more and more prone to invasion by opportunist pathogens: 
viruses, fungi, parasites and certain bacteria, including mycobacteria.
The clinical features are best described by the Walter Reed (WR) classification 
system, a system which describes the stages of the disease in terms of T4 cell 
depletion and is useful in understanding the progression of the disease. The WR 
system consists of six stages, through which the patient progresses, the last stage 
being AIDS. Stage 0 is assumed to be the point of infection with HIV. At this stage
the
the T4 cell count is near to^normal of 800-1000 cells/ml blood. Once the presence of 
the virus has been established the patient moves to stage 1 (WRl), which represents 
an acute infection. Very few symptoms are observed in this stage. Stage 2 (WR2) is 
characterised by the appearance of chronic lymphadenopathy, resulting from 
hyperstimulation of B cells by the virus. A continual drop in T4 cell count to levels 
of >400/ml blood is observed during this period, which may last for up to 5 years. 
A drop in T4 cell count to less than 400 characterises stage 3 (WR3) which lasts for 
up to 2 years, after which stage 4 (WR4) is entered. At this stage there is impairment 
of the cell-mediated immune response, demonstrated by the inability of the patient to 
mount a cellular immune response as shown in a skin-test response. T4 cell counts 
drop dramatically below 100/ml. Onset of stage 5 (WR5) is usually associated with 
immune defects related to the skin and mucous membranes. Persistent viral and 
fungal infections are common. The final stage, stage 6 (WR6), is characterised by 
complete or systemic immune deficiency; T4 cell counts are usually less than 100/ml. 
At this terminal stage opportunistic infections, such as MAI, pneumocystis 
pneumoniae, and cryptosporidiosis are seen. The survival time of a patient at WR6 
does not usually exceed 2 years (Redfield & Burke, 1989). The WR classification
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system has been devised in reference to US AIDS patients. The course of the disease 
in African patients, for instance, may differ. The WR classification system includes 
some symptoms which have unknown causes and whose relation to the 
immunodeficiency is not known, such as unexplained fevers, persistent night sweats, 
chronic diarrhoea and wasting. These symptoms are collectively referred to as the 
AIDS-related complex (ARC).
The Global Programme on AIDS of the W.H.O. has published a clinical 
staging system for HIV infection and disease, which includes a list of clinical markers 
of prognostic significance (WHO Weekly Epidemiological Record, 20/7/90). This 
clinical staging system resembles that of the WR classification system.
1.5.5 Mycobacteria and AIDS
Two types of mycobacterial disease are recognised in AIDS patients. Firstly, 
tuberculosis due to both M. tuberculosis and MAI and secondly opportunistic 
infections due to MAI infection. There is a marked geographic contrast in the 
incidence of these two diseases. MAI infection is predominant in AIDS patients from 
developed countries, particularly the USA, whilst tuberculosis due to M.tuberculosis 
constitutes the most frequent mycobacterial infection in AIDS patients in countries 
where tuberculosis itself is endemic. This is particularly seen in the sub-Saharan 
African countries and other countries, such as Haiti. In the USA tuberculosis, 
although showing an increase which parallels the increase in HIV infection, appears 
to be limited to certain groups of AIDS patients, such as intravenous drug users and 
immigrants from countries with tuberculosis pandemics (Pitchnick et al., 1984).
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1.5.6 Tuberculosis and AIDS
Tuberculosis due to M.tuberculosis is the main mycobacterial associated 
with African AIDS cases, although there is very little data available on the actual 
incidence of tuberculosis in African AIDS patients. It is one of the few contagious 
respiratory diseases that occur in AIDS patients and is both treatable and preventable 
(Snider et al., 1987). Tuberculosis in AIDS patients is generally thought to be due 
to endogenous reactivation rather than exogenous reinfection. Several studies have 
shown that there is a marked discrepancy in the incidence of tuberculosis in AIDS 
patients from areas with a high incidence of tuberculosis among the community as a 
whole, such as Africa, as compared to areas with a low incidence of tuberculosis 
within the community, such as the USA (Collins, 1985). Tuberculosis may be found 
in 30-40% of AIDS patients with a previous history of tuberculosis. Significantly, 
tuberculosis usually develops prior to the emergence of AIDS-associated symptoms. 
Clinically, AIDS-related tuberculosis is more often lymphatic or disseminated rather 
than pulmonary. However, about 50% of extrapulmonary tuberculosis observed in 
patients with AIDS are associated with a pulmonary condition, too (Spencer & 
Jackson, 1989).The extrapulmonary form of tuberculosis in AIDS involves the 
intestines, liver, spleen, kidneys, central nervous system, joints, bone and bone 
marrow. Even the vaccine strain BCG can give rise to progressive mycobacteriosis 
in immunocompromised patients (CDC, 1985). This has serious implications on the 
use of BCG in AIDS patients.
Most AIDS patients with M.tuberculosis infections respond quite well to anti- 
tuberculous treatment, which includes a regimen of streptomycin, isoniazid, and 
rifampicin or ethambutol (CDC, 1986). However, due to an increase of drug
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resistance observed in African (and Haitian) AIDS patients, additional drugs, 
including ansamycin, amikacin and pyrazinamide, are employed in this treatment. 
Due to their immunosuppression, these patients will have to continue with 
antituberculous treatment indefinitely to prevent recurrence of the disease (Pinching, 
1987).
In countries with a large AIDS and tuberculosis problem, such as African 
countries in which AIDS is pandemic and tuberculosis is highly prevalent, there is an 
expected increase of tuberculosis in AIDS patients which in turn will increase the 
numbers of tuberculosis cases in the HIV-negative population (Sutherland, 1990).
1.5.7 Non-tuberculous Mycobacterial Infection In AIDS Other Than MAI
Mycobacteria other than M.tuberculosis and MAI have been isolated less 
frequently from AIDS and ARC patients. These include M.bovis, M.asiaticum, 
M.flavescens, M.fortuitum, M.gordonae, M.kansasii, M.malmoense, M.scrofulaceum, 
M.szulgai and M.xenopi (Portaels, pers comm.). Like MAI and M.tuberculosis these 
species are potentially pathogenic in AIDS patients and although there are no strict 
guidelines as to a treatment regimen, several drugs, including ciprofloxacin, isoniazid, 
ethambutol and rifampin have been used (Pitchenik, 1988).
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1.5.8 Epidemiology of MAI Infection in AIDS
Ever since the emergence of AIDS at the beginning of the 1980s, there has 
been a dramatic increase in MAI infections, associated with this disease. MAI 
infection in an AIDS patient was first descibed by Zakowski (1982) and since then 
numerous reports, regarding the incidence, pathogenicity, genetic make-up, origin and 
source of infection and microbiological data of MAI in AIDS have been published.
Although MAI infections were reported to occur in AIDS patients almost from 
the very beginning of the AIDS epidemic, most of these were reported at post­
mortem, being identified by large numbers of acid-fast bacilli present in the lung and 
the gut (Berlin, 1984). The majority of atypical mycobacteria are non-pathogenic for 
normal humans. Thus, due to a lack of clinical data which suggested possible 
involvement of these mycobacteria in immunocompromised humans, the relevance of 
a presence of MAI in AIDS-patient derived autopsy material was not recognised 
(Chester, 1986). It is now clear that MAI infection plays a major role in the overall 
clinical picture of AIDS. Tissue involvement in MAI infection in AIDS, on a massive 
scale, has been demonstrated by Dryjanski & Gold (1984); this was found to be of 
a type resembling lepromatous leprosy and Johne’s disease. Early epidemiological 
studies in the USA showed that up to 50 % of AIDS patients examined were found to 
be infected with MAI (Dryjanski & Gold, 1984; Kiehn et al., 1985). It has been 
established that MAI infections are the most common cause of systemic bacterial 
infections in patients with AIDS (Young, 1988). Horsburgh & Selik (1989) examined 
2269 cases of disseminated nontuberculous mycobacterial infection in patients with 
AIDS over a period from 1981 and 1987 and found that 96% of cases were caused 
by infection with MAI. Estimates of the prevalence of MAI infection in AIDS vary
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from 30% (Chaisson & Hopewell, 1989) to over 50% (Kiehn et al., 1985). These 
figures refer to the prevalence of MAI infection in patients with AIDS in the USA. 
Studies carried out on European AIDS patients suggest that the incidence of MAI 
infection is significantly lower. Helbert et al (1990) examined stool samples from 
AIDS patients in the UK, finding less than 10% of patients exhibited MAI infection. 
Similarly, a study carried out by Ruf et al., (1989a) in the ERG, on the analysis of 
blood samples from patients with AIDS suggested an incidence of MAI infection of 
less than 15%. A similar incidence of MAI infections in AIDS patients (17.3%) was 
found in Australia (Dawson, 1990). Although there appears to be a difference in the 
incidence of MAI infection at a geographic level, differences in isolation rates in 
general may be attributable to differences in isolation techniques.
One of the characteristic features of MAI infection in patients with AIDS is 
the predominance of certain serotypes of the MAI complex in AIDS-derived isolates. 
In many studies both in the USA and Europe, serotypes 1, 4 and 8 are the most 
prevalent serotypes (Armstrong et al, 1985; Young et al., 1986). However, Hoffner 
et al., (1990) showed that serotype 6 predominates in both AIDS and non-AIDS 
patients in Sweden, suggesting a geographical as well as disease-related difference in 
the distribution of clinically important MAI serovars. This study also showed the 
incidence of MAI infection in AIDS patients in Sweden to be 10%, much lower than 
the incidence in the USA. This geographic difference is supported by another study 
carried out recently in the ERG, in which MAI isolates from patients with AIDS were 
examined by Ruf et al., (1989b). Here 30% of all AIDS patients examined were 
found to exhibit MAI infection. However, a predominance of serotype 8 was 
observed, again suggesting that geographic differences do exist in the distribution of
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different serovars.
In Australia the predomonant serovars appear to be serovars 4,5,8 and 9 
(Dawson, 1988). Interestingly, Dawson (1990) found that Australian AIDS patients 
were often infected with at least two different serovars.
Yakrus & Good (1990) examined several hundred MAI isolates from AIDS 
patients from various parts of the USA, the majority of isolates (>50%) coming from 
California and New York. Although the majority of isolates were serotypes 1, 4 and 
8, a geographical difference in the distribution of serotypes was observed such that 
serotype 4 was more abundant in New York than California, whilst serotype 8 
appeared more frequently in California. Even among Californian isolates, AIDS 
patients in Los Angeles had a significantly higher abundance of serotype 8 and lower 
abundance of 4 than either patients from either San Francisco or New York.
Guthertz et ah, (1989) found that MAI isolates from both AIDS and AIDS- 
related Complex (ARC) patients were invariably M. avium, in contrast to MAI isolates 
from non-AIDS patients, which were invariably M.intracellulare (as defined by Gen- 
Probe). This trend, that M.avium is more commonly found in AIDS patients as 
compared to M. intracellulare found more often in immunocompetent patients with 
MAI infection has also been substantiated by Drake et ah, (1988). This suggests 
either that AIDS and ARC patients are predisposed to develop MAI infection due to 
M. avium or that there is a significant difference in the route of infection or the source 
of environmental exposure between the two groups. Collins (1986) raised the question 
as to the possibility of MAI being a causal cofactor in AIDS rather than a casual 
opportunist. He suggests that the presence of acid fast material in an HIV-positive 
person should be taken as positive diagnosis of AIDS, for MAI may provide the
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secondary stimulus, in this case infectious, which is thought to push AIDS into the 
final, terminal stage.
1.5.9 Identification of MAI in AIDS
Acid-fast bacilli can be isolated from body fluids, faeces, and biopsies of the 
liver and intestinal tract. Although MAI may be isolated from various sources, the 
obvious source is blood, for dissemination of the infection results in high titres of 
bacilli (cfu/ml) in the blood. Kiehn et ah, (1985) found that up to 1(/ to 10^  cfu/ml 
may be isolated from blood. Several methods are employed in the identification of 
acid-fast bacilli and members of the MAI complex in patients with AIDS. Kiehn & 
Cammarata (1986) used the BACTEC 12A system (Johnson Labs Inc.,) to identify 
MAI strains. The usefulness of conventional mycobacterial culture media, such as L-J 
or Middlebrook agar was also demonstrated. These methods of isolation always 
precede purification methods described by many authors (Kiehn & Cammarata, 1986). 
Nussbaum et ah, (1990) describe the use of a rapid diagnostic method involving a 
buffy coat smear of the bacteria. Recently, DNA probes have been employed to aid 
identification of MAI material from AIDS-derived sources. The commercially 
available M.avium-intracellulare probe (Gen-Probe, San Diego) is widely used but 
requires primary isolation of bacilli followed by culturing (see discussion above).
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1.5.10 Clinical Features of MAI Infection in AIDS
MAI infection in patients with AIDS causes pulmonary disease and 
lymphadenitis only in the minority of cases. In the majority of cases, disseminated 
disease is observed. Young (1988) and Grange et al., (1990) reviewed the clinical 
aspects of MAI infection in AIDS.
MAI presents itself as a late opportunistic infection, usually at the terminal 
phase of AIDS. The clinical features of disseminated MAI infection are generally 
associated with systemic symptoms, such as fever and weight loss. Often lesions in 
the bone cause localized pain. Chills, night sweats and diarrhoea are also commonly 
observed. The symptoms may persist for weeks or even months. An abnormal liver 
function can be demonstrated by the presence of granulomas in a liver biopsy. 
Generally, the clinical features of MAI infection in patients with AIDS, unlike those 
of non-AIDS patients, resembles the stages of advanced extrapulmonary tuberculosis.
It is generally assumed that the life-expectancy of the patient, diagnosed as 
having MAI, is measured in months rather than years (Horsburgh & Selik (1989). 
Rothenberg et al., (1987) found the mean survival times of AIDS patients without 
MAI infection to be approximately one year following diagnosis. Horsburgh & Selik 
(1989), however, found that patients with MAI survived on average for only 7.4 
months, as compared to 13.3 months for patients without MAI infection. They 
concluded that disseminated non-tuberculous mycobacterial infection in patients with 
AIDS does contribute to patient mortality and warrants diagnosis and therapy. 
Chaisson & Hopewell (1989) suggest that the survival time is longer than a few 
months, the discrepancy stemming from a late diagnosis of MAI infection. However, 
there is no evidence as to whether MAI actually causes death or patients simply die
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with MAI present. Demopulos et ah, (1985) showed that MAI infection does not 
affect survival time of the patient, suggesting that patients die of progressive 
immunodeficiency rather than of this particular opportunistic infection. This raises the 
important issue that although prevention and elimination of opportunistic infections 
in AIDS patients is clearly desirable, the main aim of therapy lies in the elimination 
of the human immunodeficiency virus and the restoration of immunity.
1.5.11 MAI Response to Antibiotic Treatment
Treatment of MAI in patients with AIDS is hindered by widespread resistance 
of many MAI strains to traditional antibiotic therapy, with single drug regimens being 
of very little use. Zimmer et ah, (1982) studied the effects of a number of drugs on 
the MAI complex, including ethambutol, isoniazid, kanamycin, rifampicin and 
streptomycin. The study, carried out before the AIDS epidemic began, found that a 
combination of drugs, such as rifampin and ethambutol are inhibitory against most 
strains of the MAI complex; rifampin on its own proved to be of little value. Varying 
in vitro susceptibilities to other drugs, including clofazimine, rifabutin, cycloserine 
ciprofloxacin, amikacin and azithromycin have been demonstrated by several workers 
(Inderlied, 1990; Yajko et ah, 1987; Saito et ah, 1988).
The indications for an effective drug regimen are manifold and should include 
a reduction in bacteraemia, amelioration of symptoms and healing of lesions, i.e. 
there should be an improvement in the overall survival of the patient. Unlike 
tuberculosis, which may be treated easily, there is no consensus as to the 
contributions of MAI infection on AIDS morbidity and mortality as such. The need 
for a multiple drug regimen has also been demonstrated by a study by Horsburgh et
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al., (1985), in which patients treated with a single drug showed lower responses than 
those treated with a combination of drugs. It was also noted that patients with such 
a condition failed to respond to any of the drug treatments, indicating that the large 
number of bacilli present represents a severe generalised immunodeficiency or a 
specific host defect in reacting to MAI, which in turn would explain the failure of 
treatment. Helbert et a/., (1990) determined in vitro antibiotic sensitivities of MAI 
strains from a number of AIDS and ARC patients in the UK, which corresponded to 
high resistance patterns obtained from US isolates. Two types of multiple drug 
regimens were employed to treat a small number of patients, the first involving the 
conventional combination of rifampicin, isoniazid, ethambutol and pyrizinamide, 
whilst the second included ansamycin, isoniazid and pyrizinamide. The latter regimen 
produced a clinical improvement, whilst the addition of amikacin appeared to aid 
improvement in two further patients. However, it should be stressed that to date no 
treatment has been identified for patients with disseminated MAI infection and AIDS 
which consistently reduces the amount of bacteraemia or affects overall survival.
Pitchenik (1988) recommends the following drug regimen for treatment of 
MAI infection in AIDS and ARC patients: isolation of acid fast bacilli from AIDS 
patients or those of being suspected of having AIDS should initiate standard anti­
tuberculous drug treatment. If disease symptoms are due to large numbers of invasive 
MAI, then one of two multiple drug regimens may be administered. The first consists 
of rifabutin, clofazimine, ethambutol and amikacin. The alternative consists of 
ciprofloxacin, amikacin, ethambutol, rifampin and clofazimine. All drugs except 
amikacin are administered orally until a clinical response is induced, after which 
therapy should be continued for the rest of the patient’s life.
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1.5.12 Virulence and Pathogenicity of MAI in AIDS
The majority of MAI strains isolated from patients with AIDS are serotypes 
1, 4 and 8; this would suggest that these serotypes are more virulent than other 
environmental strains. Hampson et al, (1989) showed that there is an 
overrepresentation of a single highly conserved strain of MAI infecting AIDS patients 
as demonstrated by restriction fragment length polymorphisms (RFLP). This suggests 
the sharing of a specific genetic element across the serotype-spectrum observed 
amongst these isolates. The study also showed that serotyping corresponded poorly 
to the genetic identity of these strains. The authors suggested that the distribution of 
MAI isolates from AIDS patients simply reflected their distribution in the 
environment. Grange et al., (1990) suggested that this supports earlier work by Masur 
(1982) that the type of immunosuppression found in patients with AIDS allows MAI 
infection. Indeed, Collins (1986) suggested that MAI infection plays an active part in 
immunosuppression rather than simply taking advantage of it.
Current views as regards to virulence and pathogenicity of MAI strains found 
in AIDS centre around the presence of plasmids in these strains. Plasmids in the MAI 
complex have been described earlier. Crawford & Bates (1986) analysed 26 strains 
of MAI isolated from AIDS patients for plasmids. All strains were found to carry 
"small" plasmids, whilst ten also carried "large" plasmids. All small plasmids were 
found to contain some sequences homologous to plasmid pLR7, although a 
considerable degree of heterogeneity was observed. The widespread abundance of 
plasmids in AIDS-derived MAI strains suggested the possibility of plasmid encoded 
virulence and pathogenicity factors. Morris et al., (1990) characterised plasmids 
isolated from AIDS-associated MAI isolates further classifying these into groups
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based on hybridisation to plasmid pLR7. Meissner & Falkinham (1986) obtained 
plasmid profiles of a variety of clinical and environmental MAI isolates. The high 
incidence of plasmids in clinical isolates corresponded to a high incidence in isolates 
from aerosol but not to isolates from soil, dust, sediment or water, indicating a 
significance for these plasmids in infection. Jensen et al., (1989) analysed MAI 
strains from AIDS patients, patients with cervical lymphadenitis and the environment 
in Denmark. Their findings suggested that the prevalence of plasmids is much lower 
than that observed in US AIDS patients.
Gangadharam et al., (1988) inoculated beige mice with MAI strain LR25, 
which carries 3 plasmids and determined the virulence of this strain by mortality and 
progressive increase in organisms in the spleen and lungs (cfu/ml of biospy material). 
The supposedly "cured" derivative of this strain, LR163 (see Section: Plasmids in the 
MAC), was used in a similar fashion. Strain LR25 was found to be highly virulent, 
whilst strain LR163 was shown to be of low virulence. This suggested a plasmid 
involvement in virulence of MAI in AIDS. In a subsequent study Gangadharam et ah, 
(1989a,b) tested 24 AIDS-derived MAI strains as above with virulence assessed by 
mortality, cfu in the spleen, cfu in the lung and weights after 28 days. The most 
virulent strains were found to be those containing "large" plasmids and there was also 
a correlation with total number of plasmids in a strain and virulence. Virulence was 
found to be independent of serotype, drug susceptibility, source of specimen, 
biochemical characteristics and phage types. This suggested that plasmids in the MAI 
complex may in fact play a role in virulence and pathogenicity. Gangadharam et ah, 
(1989c) also suggested that MAI infection in AIDS, rather than being acquired from 
the environment through inhalation or ingestion is contracted by means of inoculation
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through the alimentary canal. Beige mice were challenged with a dose of MAI via 
different routes, including intravenous, intraperitoneal, intranasal, oral, and intrarectal 
route. Intravenous challenge resulted in high mortality and cfu of bacilli in spleen, 
lung, liver and lymph nodes. Intraperitoneal challenge resulted in high organ cfu 
counts but not mortality, whilst intrarectal challenge resulted in massive involvement 
of the viscera. It was also noted that multiple challenges by intravenous, oral, and 
rectal routes yielded higher cfu counts than a single inoculation.
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STATEMENT OF AIMS
2. STATEMENT OF AIMS
The aims of this thesis were:
1. Sequencing, characterisation and analysis of 1S901, an insertion sequence present 
in pathogenic strains of M. avium.
2. Identification of members of the M. avium complex (MAI) by means of polymerase 
chain reaction (PCR).
3. Genetic analysis of MAI isolates from AIDS patients by means of restriction 
fragment-length polymorphism (RFLP) studies and analysis of MAI plasmids.
4. Identification of the source of MAI infections in AIDS patients by screening of 
MAI isolates from various sources.
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MATERIALS & METHODS
3.1 MATERIALS
3.1.1 Supplies 
Amersham International
Hybond-N nylon membranes; Radiolabelled nucleotide (a^^P-dCTP, ^^S-dATP); 
Multiprime labelling kit.
Applied Biosystems
Material for synthesis of oligonucleotides.
BDH
Acrylamide; Ammonium persulphate; Boric acid; Bromophenol blue; Calcium 
chloride; D-Glucose; Glycine; Magnesium sulphate; Paraffin; Phenol;
Polyoxyethylene sorbitan mono-oleate (Tween 80), ; Potassium dihydrogen
orthophosphate; Sodium acetate; Sucrose; Tri sodium citrate.
BCL
ATP; Caesium chloride; Calf intestinal phosphatase (CIP); EDTA; IPTG; T4 DNA 
ligase; Taq polymerase; X-gal.
BRL
All molecular biology enzymes, unless otherwise stated; Acrylamide; Agarose; DNA 
markers; DH5o! cells; Formamide; Sealing tape.
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CalBiochem
Pronase.
Cambridge Bioscience 
Sequenase-2 kit.
Fuji Photo Film Co Ltd.
X-ray RX film.
Genetic Research Instruments 
Saran wrap.
May and Baker Ltd.
Chloroform; Dipotassium hydrogen phosphate; Ethanol; Glacial acetic acid; 
Hydrochloric acid; Isopropanol; Methanol.
Oxoid
Agar No.3; Bacto tryptone; Bacto Yeast extract.
Polaroid
Polaroid film (both negative only and positive/negative).
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Sigma
All antibiotics; Brij; BSA; Dithiothreitol; Ethidium bromide; Herring testes DNA; 
8-hydroxyquinoline; Lysozyme; 2-Mercaptoethanol; SDS; Sodium chloride; Sodium 
hydroxide; Subtilisin; TEMED; Trizma base; Urea;
Stratech Scientific Ltd.
GeneClean kit
Whatman
3MM paper.
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3.1.2 Bacterial Strains
Escherichia coli JM109 (recAl, endAl, hsdR17, supE44, relAl, F ’, traD36, lacIqôZ 
M15)
Purchased from Pharmacia Ltd.
Escherichia coli DH5a maximum high efficiency cells.
Purchased from BRL.
Mycobacterium avium Complex strains: These were obtained from mycobacteria 
laboratories around the world.
Belgium: Françoise Portaels, ITM, Antwerpen
Denmark: Dorthe Askgaard, Statens Serum Institute, Copenhagen
Holland: Arendt Kolk, RTI, Amsterdam
Sweden: Sven Hoffner,NBL, Stockholm
U.K.: Tobin Hellyer, St. Mary’s Hospital, London
Ruth Cromie, UCMSM, London 
Martin Woodward, CVL, Weybridge 
Johnjoe McFadden, University of Surrey, Guildford 
U.S.A.: Sheldon Brown, Sloan Kettering Hospital, New York
Jack Crawford, Memorial Veterans’ Hospital, Little Rock 
Joe Falkinham, Virginia Polytechnic Institute, Blackburg 
Other U.S.A. isolates came from F.P.
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3.1.3 Plasmids
pJC20 Jack Crawford
pJC70 Jack Crawford
pMB19 Johnjoe McFadden
pMCB20 Johnjoe McFadden
pMB22 Johnjoe McFadden
pUC18 Purchased from Pharmacia Ltd.
pUS410 This thesis
pUS411 This thesis
pVTlOO Joe Falkinham
pVTlOl Joe Falkinham
3.1.4 Bacteriophages
M13mpl8 Amersham Int.
M13 K2 This thesis
M13 K l l  This thesis
3.1.5 Plasmid Libraries
pMAI pUC18 plasmid library of BamHI digested goat-derived M. avium,
FP8589. Received from Johnjoe McFadden
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3.1.6 Culture Media
AU media and reagents were sterilised by autoclaving at 121°C for 15 minutes or by 
filtration through a 0.2ixm FlowPore filter. Unless stated otherwise, all media were 
prepared in distilled water, whilst all reagents were prepared in double-distilled water, 
previously autoclaved where needed. Supplements to media, such as antibiotics, were 
added immediately prior to use.
Luria broth Bacto tryptone 15g
Bacto yeast extract 5g
NaCl 5g
water to 1000ml., autoclaved.
Luria agar 
2xTY broth
L agar containing 15g/l Bacto agar.
Bacto tryptone 16g
Bacto yeast extract lOg
NaCl 5g
Water to 1000ml, autoclaved.
2xTY agar 
H Top agar
2xTY broth containing 15g/l Bacto agar.
Bacto tryptone lOg
NaCl 8g
Bacto agar 8g
water to 1000ml, autoclaved.
H agar H top agar containing 15g/l Bacto agar.
SOC broth Bacto tryptone
Bacto yeast extract
NaCl
KCl
MgCl^
MgS04
Glucose
2 %
0.5%
lOmM
2.5mM
lOmM
lOmM
20mM
filter-sterilised Mg-salts and glucose added after autoclaving.
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3.1.7 Antibiotics
All antibiotics were purchased from Sigma and prepared as recommended by the 
manufacturer (see specific method for concentrations).
3.1.8 General Buffers, Reagents and Solutions
These are listed in alphabetical order. Some specific buffers, reagents and solutions 
are included in the relevant method. Section 3.2.
Acrylamide Acrylamide
Bis-acrylamide
40%
2 %
Alkaline lysis 
solution 1
Glucose 50mM
EDTA lOmM
Tris.HCl pH 8.0 25mM
autoclaved.
4mg/ml lysozyme prior to use.
Alkaline SDS 
solution 2
NaOH 
SDS (w/v) 
autoclaved.
0.2M
1.0 %
Alkaline lysis 
solution 3
Potassium acetate, 5M pH 4.8 60ml
Acetic acid 11.5ml
H2 O 28.5ml
autoclaved.
Ammonium acetate Ammonium acetate 
pH 4.6, autoclaved.
2mM
Ammonium persulphate Ammonium persulphate
autoclaved.
10%
ATP Adenosine triphosphate 
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lOOmM
BSA Bovine serum albumin 
filter-sterilised.
200mg/ml
Brÿ/DOC Brij 1%
Sodium deoxycholate (lOmM Tris) 0.4% 
EDTA ImM
pH8.0, autoclaved.
Caesium chloride/ 
isopropanol
Solid caesium chloride (high grade) saturated 
in isopropanol.
Chloroform Prepared with isoamyl alcohol at 24:1 (v/v).
Colony denaturing 
solution
NaOH
NaCl
autoclaved.
0.5M
0.5M
Colony neutralising 
solution
Tris.HCl
pH 7.5, autoclaved.
0.5M
Denaturing solution NaOH 0.5M
Denhardt’s solution Eicon (MW 400,000) 5.0g
Polyvinylpyrrolidone (MW40,000) 0.5g 
Bovine serum albumin 0.5g
Sterile water, 1ml aliquots.
DNA loading buffer, 6x Bromophenol blue (w/v) 
Xylene cyanol (w/v) 
Sucrose (w/v)
0.25%
0.25%
40%
Ethidium bromide Ethidium bromide 20%
Fixing solution Methanol 
Acetic acid
10%
10%
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Glycerol
Herring testis DNA
Glycerol
autoclaved.
10%
DNA lOmg/ml
boil for lOmin, 1ml aliquots at -20°C.
Hybridisation buffer SSC
Denhardt’s solution 
SDS
Herring testis DNA 
NaHgPO^ pH 7.0
3x
Ix
1%
lOmg/ml
lOmM
Neutralising solution Tris.HCl
pH 7, autoclaved.
0.5M
PEG/NaCl Polyethylene glycol-6000 
NaCl
autoclaved.
20%
2.5M
Phenol Saturated in TE buffer.
Phenol/ chloroform Prepared as a 1:1 mixture (v/v) containing 
0.1% 8-hydroxy quinoline.
Probe removal solution 1 NaOH
autoclaved.
0.4M
Probe removal solution 2 SSC
SDS
Tris.HCl
pH 7.5, autoclaved.
O.lx
0 . 1%
0.2M
Repel solution 
Stick solution
Dimethyl dichlorosilane 10ml
Ethanol (absolute) 10ml
Methacryloxypropyl-trimethoxy 
silane 30jul
acetic acid, 10% ISOfxl
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Sodium acetate Na acetate 
pH 5.2, autoclaved.
3M
Sodium chloride NaCl
autoclaved.
2M
Spermidine Spermidine hydrochloride 
filter-sterilised.
400mM
SSC. 20x NaCl
Sodium citrate 
pH 8.0, autoclaved.
3M
0.3M
STET buffer Tris
NaCl
EDTA
pH 7.5, autoclaved.
lOmM
lOOmM
ImM
Sucrose Sucrose 25 %
in 50mM Tris.Cl ph8.0, autoclaved
TAE buffer Tris, acetate
NaCl
EDTA
pH 8.2, autoclaved.
40mM
20mM
2mM
TBE buffer Tris-borate 
Boric acid 
EDTA
pH 8.3, autoclaved.
90mM
90mM
2mM
TE buffer Tris
EDTA
pH 8.0, autoclaved.
lOmM
ImM
TEN buffer Tris
NaCl
EDTA
pH 8.0, autoclaved.
50mM
150mM
lOOmM
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Transfer buffer NaHzPO^
pH 7.0, autoclaved.
25mM
Wash solution 1 SSC 3x
low stringency SDS
preheated to 65°C.
0.1%
Wash solution 2 SSC Ix
medium stringency SDS
preheated to 65°C.
0.1%
Wash solution 3 SSC O.lx
high stringency SDS
preheated to 65°C.
0.1%
3.1.9 Enzyme Buffers
Most enzyme buffers were supplied with the respective enzyme by the mar
Restriction buffers lOx buffers supplied with enzymes.
Calf Intestinal Tris.HCl pH 8.0 SOOmM
Phosphatase buffer, lOx MgClz lOmM
ZnClz
autoclaved.
ImM
Ligase buffer, 5x Tris.HCl pH 7.6 250mM
MgClz 50mM
ATP 5mM
DTT 5mM
PEG-8000 (w/v) 
filter-sterilised.
25%
Polynucleotide Kinase Tris.HCl pH7.6 0.5M
buffer, lOx MgClz O.IM
Dithiothreitol 50mM
Spermidine. HCl ImM
EDTA ImM
filter-sterilised.
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3.2 METHODS
3.2.1 Extraction of DNA from mycobacteria grown on slopes
The extraction involved a modified method by Visuvanathan et al., (1989).
Reagents:
TEN buffer
Subtilisin (40mg/ml in TEN)
Lysozyme (50mg/ml in TEN)
SDS (10%)
Pronase (20mg/ml in TEN)
Ribonuclease A (lOmg/ml)
Sodium chloride (NaCl) (2M)
Phenol/chloroform 
Chloroform 
Absolute ethanol 
70% ethanol 
TE buffer
Procedure:
(frofi) caitare$ on solid  ifijco bade rial medluM provided by colla.bofa.tors)
Bacterial cells were recovered/vby adding 5ml of TEN buffer to the slope. The cells 
were harvested by carefully removing bacterial growth with a plastic loop. Following 
washing, the cells were pelleted by centrifuging in a bench-top centrifuge at 4000g 
at 4°C. A loopful of cell pellet was resuspended to a volume of 250ul in a large 
Eppendorf tube and the bacteria were heat-killed by incubating at 70°C for Ihr. 
Subsequently, subtilisin was added to a final concentration of lOmg/ml and this was 
incubated at 37°C for 3hr. Following the addition of lysozyme to a concentration of 
Img/ml the cell suspension was incubated at 50°C for another 3hr. Then, SDS and 
pronase were added to final concentrations of 1% and 3mg/ml, respectively and the 
suspension was incubated at 37°C overnight (o/n). Pronase treatment was continued 
for another 4hr (using another 3mg/ml of enzyme). Following heat treatment of the 
lysed cells at 65°C for Ihr cellular RNAs were digested by addition of Ribonuclease 
A (RNase A) to Img/ml and incubation at 37°C for 30min. Mycobacterial DNA was
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purified by extracting three times with an equal volume of phenol/chloroform, 
followed by one extraction with chloroform. NaCl was added to 0.2M to the final 
aqueous layer, followed by two volumes of ethanol. This was mixed gently and stored 
at -20°C, o/n. The DNA was precipitated by centrifuging at 12000rpm for 15min at 
4°C. Following removal of all supernatant, the DNA was washed in 70% ethanol and 
spun briefly again, after which the pellet was dried in a dessicator for 5min. The 
DNA was resuspended in lOOul of TE at 4°C overnight. DNA concentrations were 
determined by measuring the optical density at 260nm or by running a fixed amount 
on a 0.8% agarose gel.
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3.2.2 Precipitation of DNA
Reagents:
Ethanol (absolute)
Isopropanol 
70% ethanol 
Sodium acetate (3M)
TE buffer
Procedure:
To a volume of DNA solution, 1/lOth of sodium acetate and 2 to 2.5 volumes of 
ethanol were added and gently mixed. This was incubated on ice or at -20^C for 30 
minutes and then centrifuged at 4°C for 15 to 20 minutes. The supernatant was 
decanted and any remaining liquid was removed with a pipette. The DNA pellet was 
washed in 70% ethanol and dried in a vacuum dessicator. Finally, the DNA was 
resuspended in an appropriate volume of TE buffer (or H2O in some cases). When 
isopropanol was used, only 1 volume instead of 2 to 2.5 was added.
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3.2.3 Determination of DNA concentrations
DNA concentrations were determined by measuring its absorbance 
spectrophotometrically at wavelengths of 260nm and 280nm. The optical densities of 
diluted DNA samples were determined through quartz cuvettes in a Pye Unicam 
PU88020 UV/VIS spectrophotometer. The ratio of the two readings, 260/280, also 
allows estimation of the extent of contamination due to protein. The DNA 
concentration may be derived from the following formulae:
Genomic DNA = O.D .2 6 0  x 50 x dilution factor = /xg/ml 
Plasmid DNA = O.D .2 6 0  x 40 x dilution factor = jug/ml 
Alternatively, the concentration of a DNA sample was estimated by comparing it to 
a DNA sample of known concentration. Briefly, a volume of DNA was 
electrophoresed in the presence of DNA markers of known quantity (usually 
lambdaEinélll or phiXllA  Haelll). Following staining of the gel with ethidium 
bromide to visualise the DNA under UV-light, the DNA concentration of the sample 
was estimated in a comparative manner.
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3,2.4 Restriction digestion of mycobacterial DNA for RFLP and Plasmid
analysis
Reagents:
Bovine serum albumin (BSA) (200mg/ml)
Spermidine hydrochloride (400mM)
Restriction endonuclease 
Restriction buffer (lOx)
NaCl (2M)
Absolute ethanol 
70% ethanol 
TE buffer
Procedure:
0.1 to 1 ug of DNA was digested in 200ul of buffer containing BSA (lOug/ml), 
spermidine hydrochloride (4um/ml), 20ul of lOx appropriate react buffer and lul of 
restriction endonuclease (lOu/ul). Digestion was allowed for 2-3 hours at 37°C. 
Following complete digestion, 0.5M EDTA and 2M NaCl were added to lOmM and 
0.2M, respectively. Two volumes of absolute ethanol were added and the suspension 
was stored at -20°C, overnight. The following morning the solution was spun in an 
Eppendorf centrifuge at 12000rpm at 4°C for 15min. The supernatant was removed 
and the pellet was washed briefly in 70% ethanol. Subsequent to drying the DNA 
pellet in a vacuum dessicator the pellet was resuspended in lOul of TE and stored at 
4°C until further use.
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3.2.5 Gel electrophoresis of DNA 
Reagents:
Agarose
Tris acetate buffer (TAE) (Ix)
Tris borate buffer (TBE) (Ix)
5x gel loading buffer 
Ethidium bromide (2mg/ml)
Procedure:
The following gel electrophoresis kits were used depending on their purpose. For 
daily use a "Biorad Mini-Sub Cell" was used and samples were run in IxTAE buffer 
at 100 Volts, while for Southern blotting a "Biorad Sub-Cell" was used and samples 
were run at 140 Volts. Agarose concentration, gel running buffer, amount of DNA 
and running times depended on the purpose of electrophoresis.
3.2.6 Restriction digestion of DNA for general purposes 
Reagents:
DNA to be digested
Restriction endonuclease (usually lunit/ul) 
lOx Restriction buffer 
double-distilled water
Procedure:
DNA was commonly digested in volumes of 10 to 20 ul at temperatures 
recommended by the manufacturer. Briefly, DNA was digested in a solution 
containing appropriate restriction buffer to Ix and 1 unit of enzyme. Digestion was 
carried out at the appropriate temperature for 1 to several hours, depending on the 
purity of the sample (but never overnight).
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3.2.7 Purification of DNA from agarose gels
This method relies on the "Gene-clean" kit which allows for rapid and efficient 
recovery of DNA band from agarose gels. The DNA is bound to glassmilk and 
following several purification steps is eluted in TE buffer.
Reagents:
Sodium iodide (Nal)
"New" buffer 
Glassmilk 
TE buffer
Procedure:
The DNA of interest was run on an agarose gel containing TAE buffer as 
electrophoresis buffer. The DNA band to be recovered was excised using a scalpel 
in a minimum amount of agarose and transferred to a large microfuge tube of known 
weight. For every lOOmg of agarose, 2.5 volumes of Nal was added and the 
suspension was vortexed briefly before being incubated at 55°C for 5 minutes. During 
this time the glassmilk provided was resuspended thoroughly. 5ul of glassmilk 
suspension was added to the now molten agarose and the suspension was kept on ice
centrifuocdicfl
for 5minutes, mixing the contents every minute or so. Following for 5 seconds 
the supernatant was removed and the glassmilk was washed three times. This was 
achieved by resuspending the pellet in 200ul of NEW buffer followed by  ^ for 
5 seconds and removal of the supernatant. The final glassmilk pellet was resuspended 
in lOul of TE buffer and incubated at 55°C for 3-4 minutes. The suspension was 
centrifuged for 30 seconds and the supernatant containing the excised DNA band was 
recovered. This procedure was repeated, thus yielding 20ul of recovered DNA.
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3.2.8 Phosphorylation of DNA
This method utilises the "forward reaction" of T4 polynucleotide kinase (PNK), in 
which the enzyme phosphorylates DNA in the presence of excess ATP.
Reagents:
PNK buffer
Adenosine triphopsphate (ATP, lOOmM)
EDTA (0.5M, pH 8)
Procedure:
The DNA was phosphorylated in a reaction volume of 50ul, containing lul of ATP 
and incubated at 37°C for 1 hour. Subsequent to this, 2ul of EDTA was added to stop 
the reaction and the mix was extracted once with phenol/chloroform followed by one 
chloroform extraction and an ethanol precipitation. Since the phosphorylated DNA 
was commonly used in a ligation reaction, it was resuspended in a minimal volume 
of TE buffer.
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3.2.9 Déphosphorylation of DNA
Déphosphorylation of vector DNA used in a ligation is often used to prevent self­
religation. Phosphates at the 5’ end of the molecule may be removed by the action 
of bacterial alkaline phosphatase (BAP) or calf intestinal phosphatase (CIP). 
Reagents:
BAP or CIP 
Restriction buffer (lOx)
Procedure:
Vector DNA, digested with a suitable restriction endonuclease was dephosphorylated 
in the same restriction buffer using 1 unit of either enzyme at 37°C for 1 hour, after 
which the BAP or CIP was inactivated by heating at 70°C for 30 minutes, followed 
by a phenol/chloroform extraction and an ethanol precipitation. The DNA was 
resuspended in a minimal volume of TE buffer.
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3.2.10 DNA Ligation
Reagents:
T4 DNA ligase 
Ligase buffer (5x)
Procedure:
The DNA to be ligated was first digested with a suitable restriction endonuclease and 
then often modified, such as blunt-ended, dephosphorylated, joined to synthetic 
linkers. Typical ligation reactions were carried out in volumes of 20ul at 14°C for 18 
hours for sticky end ligations and at 9°C for 18 hours for blunt-end ligations. The 
ratio of vector to insert DNA varied according to the purpose of the ligation carried 
out. For instance, cloning a specific DNA fragment required a ratio of 1:1, whereas 
in the construction of genomic libraries, a ratio of 1:4 is favourable.
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3.2.11 Transformation of E.coli using competent cells
Transformation of E.coli cells was achieved by using competent "MAX Efficiency 
DH5oj" cells. This method relies on a PEG-mediated transformation. These competent 
cells can be used for a variety of plasmids, including pUC and pBR plasmids, and can 
also serve as a host for the M13 cloning vectors. The cells have a high transformation 
efficiency of up to 1x10^ ® transformants/ug of pUC control with non-saturating 
amounts of DNA.
Reagents:
Competent DH5a cells (maintained at -70°C) 
plasmid DNA (recombinant and non-recombinant)
SOC medium
Procedure:
A lOOul aliquot of competent cells were thawed on ice, and a large microfuge tube 
chilled at the same time. The cells were transferred to the ice-cold tube and 10-20ul 
of DNA were added. The transformation mix was incubated on ice for 30 minutes 
and then heat-shocked at 42°C for 45 seconds. The mix was added to 0.9ml of room 
temperature SOC medium contained in a small plastic Bijou and shaken at 37°C for 
1 hour. 200ul and lOOul samples were plated on L agar plates containing the 
appropriate antibiotic at 37°C, overnight.
78
3.2.12 Preparation of competent E.coli cells for electro-transformation
Reagents:
L broth
Cold water (autoclaved)
Glycerol (10%)
Procedure:
One litre of L broth was inoculated with 10ml of an overnight culture of appropriate 
E.coli host cells and grown vigourously at 37°C to an optical density at 600nm of 0.5- 
1.0. To harvest the cells, the culture was chilled on ice for 15-30 minutes and 
centrifuged in a rotor at 4°C at 4000rpm for 15 minutes. As much supernatant as 
possible was removed and the cells were resuspended in 1 litre of cold water and 
centrifuged as above. The supernatant was removed and the cells were resuspened in 
500ml of cold water and centrifuged as above. Following removal of the supernatant, 
the cells were resuspended in approximately 20ml of cold glycerol and centrifuged 
as above. The supernatant was removed and the cells were resuspended to a final 
volume of 2-3ml in cold glycerol. This suspension was frozen on dry ice in aliquots 
and stored at -70°C for up to 6 months.
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3.2.13 Transformation of E.coli by electroporation
Transformation by electroporation results in transformation efficiencies greater than 
chemical methods. Up to 10^  to 10^ ° transformants/jwg of DNA may be obtained with 
various hosts and plasmids by subjecting the suspension of host cells and plasmid 
DNA to exponentially decaying electrical fields of very high initial amplitude. Here, 
the Bio Rad gene puiser was employed.
Reagents:
SOC medium
L agar plates (containing appropriate antibiotic)
Procedure:
Competent E. coli cells prepared beforehand and stored at -70°C were thawed gently 
at room temperature and stored on ice. A 40/d aliquot was transferred to a large, cold 
microfuge tube to which 1-2/d of DNA was added.. The suspension was mixed well 
and left on ice for V2 -I minute. The gene puiser of the electroporator was set at 25/tF 
and 2.5kV, whilst the pulse controller was set to 2000. The cell/DNA mixture was 
transferred to a cold, 0.2cm electroporation cuvette, the suspension being shaken to 
the bottom of the cuvette. The cuvette was placed in a chilled safety chamber slide, 
which was pushed into the chamber until the cuvette was seated between the contacts 
in the base of the chamber. One pulse at the above setting was applied which 
produced a pulse with a time constant of 4-5msec, field strength of 12.5kV/cm. The 
cuvette was removed from the chamber and immediately 1ml of SOC medium was 
added to the cuvette and using a glass Pasteur pipette the cells were resuspended 
quickly. The suspension was transferred to a plastic Bijou and incubated at 37°C for 
1 hour before aliquots, usually 200/d and 100/d, were plated on L agar containing an 
appropriate antibiotic.
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3.2.14 Small-scale plasmid preparation - alkaline lysis method
Reagents:
L broth 
Antibiotic
Alkaline lysis solution 1 
Alkaline lysis solution 2 
Alkaline lysis solution 3 
Phenol/chloroform 
Ethanol (absolute)
70% ethanol 
TE buffer 
Ribonuclease A
Procedure:
2ml of Lbroth medium was inoculated with a single colony of bacteria and grown at 
37°C for 4-8 hours. The culture was amplified overnight by the addition of 
appropriate antibiotic. The culture was spun in a benchtop centrifuge at 4°C to pellet 
the cells. Any remaining supernatant was removed by inverting the tube for a few 
minutes. Subsequently, the cells were homogenised by vigourous vortexing and the 
cells were resuspened in 150/d of ice-cold solution 1, and stored for 5 minutes at 
room temperature. 300/d of freshly prepared solution 2 at room temperature was 
added, the tube was closed and the contents mixed by inverting the tube rapidly 
several times (not vortexing). The suspension was stored on ice for 5 minutes. 300/d 
of freshly prepared solution 3 was added and following gentle mixing, the suspension 
was stored on ice for another 5 minutes. Following centrifugation for 5 minutes, 
500/d of supernatant was transferred to a large microfuge tube and incubated at 65°C 
for 15 minutes. This was extracted once with phenol/chloroform, by shaking 
vigourouly for 5 minutes followed by centrifugation for 5 minutes. 400/il of the 
supernatant was transferred to a fresh centrifuge tube, to which 800/d of ethanol was 
added. This was stored at room temperature for 2 minutes before centrifugation for
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5 minutes. The supernatant was carefully removed without disturbing the pellet; the 
pellet as washed in 1ml of 70% ethanol and following re-centrifugation the 
supernatant was carefully removed. The DNA pellet was dried in a vacuum dessicator 
and resuspended in 50/il of TE buffer containing 20/tg/ml ribonuclease A.
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3.2.15 Large-scale plasmid DNA extraction of E.coli plasmids (Maniatis et
al., 1982)
Reagents:
Luria broth (LB)
Lysozyme (20mg/ml in 0.25M EDTA)
Sucrose (25% in 50mM Tris.Cl pH 8)
EDTA (0.25M)
Brij/DOC solution
Antibiotic (chloramphenicol or spectinomycin)
Ethidium bromide (20mg/ml)
Caesium chloride
Caesium chloride saturated isopropanol 
Isopropanol
Sodium acetate (3M, pH 5.6)
Absolute ethanol 
70% ethanol 
TE buffer
Procedure:
A volume of 10ml of L broth, containing the appropriate antibiotic was inoculated 
with a single colony of a recombinant E.coli strain and incubated in a shaker at 3TC, 
overnight. 4ml of the overnight culture was used to inoculate 150ml of prewarmed 
LB, containing the same antibiotic, and was incubated at 37°C for a few hours until 
the optical density of the culture at 650nm reached 0.9. At this stage, 
chloramphenicol was added to a final concentration of 170ug/ml and the culture was 
shaken at 37°C for a further 12 to 18 hours (usually overnight). The cells were 
harvested by centrifugation at 4°C at 8000rpm for 20 minutes (MSE High Speed 18 
centrifuge) and resuspended in 2.6ml of sucrose solution. The suspension was 
maintained on ice. 0.4ml of freshly prepared lysozyme solution was added and the 
suspension was kept on ice for 5 minutes, swirling intermittently. Subsequently, 
2.6ml of EDTA was added and the suspension was maintained as above. 4ml of 
Brij/DOC soultion was added rapidly through a 10ml pipette and after the suspension
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was drawn up and down several times to ensure even mixing, the mixture was kept 
on ice for 20-30 minutes. In order to remove cell debris and the majority of the 
chromosomal DNA, the suspension was centrifuged at 15000rpm, 4°C for 45 minutes. 
The supernatant was transferred to a fresh tube and the volume was measured 
accurately. Solid caesium chloride was added at a rate of 0.95g/ml and dissolved by 
gentle agitation. Ethidium bromide was added to a final concentration of 0.5mg/ml 
and the suspension was transferred to a labelled Beckman Ti 50 polyallomer 
ultracentrifugation tube. Tubes were balanced in pairs to within 50mg and sealed as 
recommended by the manufacturer. The tubes were spun in a Beckman ultracentrifuge 
using a Ti70 rotor at 40000rpm at 18°C for 36-48hours, thus enabling separation of 
the plasmid DNA from the chromosomal DNA on the gradient. The lower, plasmid 
DNA band was visualised and recovered under U.V. light with a 1ml syringe. A 
needle placed in the top of the tube facilitated smooth recovery of the plasmid by 
allowing air to replace the liquid being removed. In order to remove the ethidium 
bromide, the suspension was extracted several times with an equal volume of caesium 
chloride saturated isopropanol. This was achieved by adding 1ml of isopropanol to 
the plasmid solution and then drawing the mixture into a plastic Pasteur pipette, thus 
allowing separation of the two phases in the neck of the pipette, the lower, 
isopropanol phase was extruded each time. Finally, the caesium chloride was removed 
by adding 0.1ml of sodium acetate and 0.5ml of water to every 0.4ml of aqueous 
phase. Following mixing, 1ml of isopropanol was added for every 1ml of suspension 
and kept at room temperature for 15 minutes. The best results were achieved when 
this was carried out in 1.5ml microfuge tubes. The DNA was recovered by 
centrifuging at 12000rpm at 4°C for 15 minutes. The supernatant was removed and
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the DNA pellet was resuspended in 200ml of TE buffer. In order to further purify the 
plasmid DNA, the sample was precipitated with ethanol. The resultant pure plasmid 
DNA pellet was usually resuspended in 200ul of TE buffer and stored at 4°C for 
further use. The DNA concentration was determined as outlined previously.
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3.2.16 Southern blotting (Southern, 1975)
Reagents:
Agarose
DNA loading buffer 
Ethidium bromide (2mg/ml)
Denaturing solution 
Neutralising solution 
Transfer buffer 
SSC (2x)
Procedure:
Following digestion of the DNA to analysed, the sample was electrophoresed as 
described under ’Gel Electrophoresis’. This was then stained and photographed. The 
gel was then placed in two volumes of denaturing solution and gently agitated at room 
temperature for 45-60 minutes, after which it was transferred to two volumes of 
neutralising solution and shaken similarly. After a brief rinse in distilled water, the 
gel was placed on a piece of 3MM paper, supported by a glass plate, with both ends 
of the paper dipped in transfer buffer. A piece of Hybond-N membrane filter, cut 
marginally larger than the gel, was marked appropriately and placed on top of the gel. 
Two pieces of 3MM paper, soaked in transfer buffer were placed on top of the 
membrane filter, followed by two pieces of dry 3MM paper. Air bubbles were 
removed by gently rolling a glass pipette over the paper. An 8cm layer of blotting 
paper (Kimwipe blue steel roll), cut to size accordingly, was placed on top of the dry 
3MM paper, followed by a glass plate. This was supported by a weight of roughly 
500g. Southern blotting was allowed to proceed overnight for 16 to 18 hours. On 
completion, the blotting materials were removed and the membrane was carefully 
peeled off. Following a brief rinse in 2xSSC, the membrane was air-dried for 15 
minutes and then the DNA was bound onto the membrane by baking it, sandwiched
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between 3MM paper, at 80°C for 1 hour. Filters were stored at room temperature in 
the dark until further use.
3.2.17 Radiolabeling of DNA by random primers 
This method relies on the annealing of random hexanucleotides to denatured DNA at 
various points of a given strand, thereby initiating DNA synthesis along the DNA 
strand. The inclusion of one radioactively labelled dNTP (usually ^^P-dCTP) with 
three unlabelled dNTPs, results in a radiolabelled DNA probe. The Amersham 
"Multiprime" labelling kit was used here under recommended conditions. Generally, 
labelling was performed at 37°C for Ihr. Prior to labelling and hybridisation, the DNA 
was denatured by heating in a boiling water-bath for 3 minutes followed by immediate 
cooling on ice to prevent renaturation.
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3.2.18 DNA hybridisation
Reagents:
Hybridisation buffer 
Radiolabelled DNA probe
Procedure:
Hybridisation was performed in a "Hybaid hybridisation oven" as recommended by 
the manufacturer. A Hybond-N filter membrane was briefly moistened in 2xSSC and 
sandwiched between two pieces of nylon mesh slightly larger than the membrane 
filter. This sandwich was rolled up using a 10ml pipette for support and placed in a 
hybridisation oven. If several filters were being hybridised together, a multilayered 
sandwich was prepared in the above manner. Depending on the number of membranes 
present in one given bottle, between 15ml (1-2 filters) and 25ml (3-6 membranes) of 
hybridisation solution was added to the bottle. The cap was tightened firmly and the 
bottle was rotated in the hybridisation oven to allow adhesion of the sandwich to the 
wall of the bottle. Prehybridisation was carried out at 68°C for 1-4 hours, after which 
the prehybridisation solution was decanted. Fresh, prewarmed hybridisation buffer, 
5ml less than above, was added to the bottle followed by the denatured labelled 
probe, diluted in 5ml of prewarmed hybridisation buffer. The cap was screwed on 
tightly and covered by a plastic bag to minimise spraying of radioactive material in 
case of leakage. Hybridisation was carried out at 65°C for 18-24 hours.
3.2.19 Filter washing
The stringency of filter washing may be manipulated in two ways. A decrease in salt 
concentration of the wash buffer results in an increase of stringency, whilst an 
increase in washing temperature also results in an increase of stringency.
Reagents:
Wash solution 1 
Wash solution 2 
Wash solution 3
Procedure:
Filters were rinsed in the bottle several times in wash solution 1, followed by washing 
in solution 1 at 65°C for 30 minutes. This was followed by a wash in solution 2 at 
65°C for 30 minutes. Then the filters were removed from the bottle and briefly rinsed 
in 2xSSC (bottles and meshes decontaminated as described by the manufacturer).
3.2.20 Autoradiography
The washed and wet filter was placed on a glass plate, covered with Saran wrap and 
placed in an X-ray cassette containing intensifying screens. A piece of X-ray film 
(Fuji or Kodak) was placed on top of the wrap and held in position by masking tape. 
Autoradiography was allowed to proceed at -70°C for a few hours to several days 
depending on the counts detectable. Filters were kept at -70°C prior to probe removal.
3.2.21 Removal of radioactive probes
Reagents:
Probe removal solution 1 
Probe removal solution 2
Procedure:
The filter was washed in 200ml of solution 1 at 45°C for 30 to 60 minutes, followed
by washing in 200ml of solution 2 at 45°C for a further 15 minutes and briefly rinsed
in 2xSSC. The filter was autoradiographed overnight to monitor the success of the 
removal procedure. Filters were stored at room temperature in the dark.
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3.2.22 Colony library screening
Screening of recombinant plasmid libraries with a suitable DNA probe enables the 
identification and isolation of recombinant plasmid carrying DNA inserts of interest. 
In this case colony library screening was used to identify different copies of the 
mycobacterial insertion sequence IS901. Screening consisted of two steps, namely a 
primary screen and a secondary screen.
Reagents:
L agar plates containing appropriate antibiotic 
Nitrocellulose filter discs and Nylon filter discs 
SDS (10%)
Colony dénaturation solution 
Colony neutralisation soulution 
SSC (3x)
Wash solution 1
Procedure:
1) Primary screen:
A recombinant plasmid pUC18 library was plated on L agar plates containing 
50/ig/ml ampicillin and grown until colonies were just visible. This was achieved by 
incubation at 30°C, overnight, followed by 2 to 3 hours at 37°C. Up to several 
thousand colonies were spread on each plate, which required dilution of the library 
stock. The colonies were lifted onto a dry nitrocellulose filter disc by placing this on 
top of the agar dish and gently pressing the disc down with a colony replicator to 
ensure even picking of colonies across the disc. The nitrocellulose disc was placed, 
colony side up, onto a fresh L agar, ampicillin plate and incubated at 37°C for up to 
2 hours to ensure firm adhesion of colonies to the filter. This filter constituted the 
master filter. A nylon filter disc, prewetted on a fresh media plate, was placed on top 
of the master filter and pressed down firmly as described above. Alignment marks
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using a pin were applied for future orientation. Following careful removal of the 
nylon disc, a second nylon disc was applied in a similar manner, including the 
application of alignment marks. The two nylon filters were placed, colony side up, 
on L agar, ampicillin plates and incubated at 37°C until the colonies were 
approximately 1mm in diameter. Subsequently, the nylon filters were transferred to 
fresh plates containing 170jug/ml chloramphenicol, and amplified overnight by 
incubation at 37°C. The nylon filters were then removed and treated to break open 
the bacteria and liberate the plasmid DNA. This was achieved by placing the discs, 
colony side up, for 3 minutes onto 3MM paper saturated with 10%SDS. This was 
followed by 5 minutes on paper with colony denaturing solution, followed by 5 
minutes on paper with colony neutralising solution. Finally, the discs were placed for 
5 minutes on paper soaked in 3xSSC. Subsequent to air-drying, the DNA was fixed 
by baking the discs at 80°C for 1 hour. Prior to hybridisation, the discs were washed 
at 65°C for 30 minutes in wash solution 1 and cell debris was wiped off the filter. 
Hybridisation was performed as described above. Following autoradiography of the 
hybridised filter, the autoradiograph was aligned to the respective nylon disc, thus 
enabling the identification of positive colonies on the master filter with the 
autoradiograph. Whenever possible, single positive colonies were picked and 
resuspended in 1ml of L broth. If this was not possible, a general area containing the 
positive colony, not exceeding a few colonies, was picked and screened at low density 
of about 100 colonies per plate.
2) Secondary screen:
Using dilutions of the positive colony identified in the primary screen, up to 100 
colonies of this were plated on Lagar, ampicillin plates. Colony lifts were performed
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as described above; however, this time the original plate was treated as the master 
filter, thus eliminating the lift on to a nitocellulose filter disc. Also, colonies were 
grown initially at 37°C, overnight. Lifts were performed in duplicate as above.
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3.2.23 Cloning into M13 phage
Cloning DNA into the single-stranded M l3 phage facilitates DNA sequencing by the 
Sanger "dideoxy chain termination" method. Within its E.coli host cell the phage 
exists in a double-stranded replicative form (RF), thus allowing the RF molecule to 
be used as a cloning vector. Upon infection of the host cell, single-stranded viral 
DNA is synthesised from the RF molecule, which is then packaged into viral coat 
proteins and extruded from the host cell. This single-stranded DNA can be stripped 
of its viral protein coat yielding pure single-stranded DNA for DNA sequencing. The 
procedure follows the method described in the "M13 cloning and sequencing 
handbook" published by Amersham Int (1984). The discrimination of recombinant 
M13 plaques is based on the presence or absence of the enzyme B-galactosidase. 
E.coli host cells infected with M13 vector strains will, in the presence of the lac 
operon inducer isopropyl-13-D-thiogalactopyranoside (IPTG), produce a functional B- 
galactosidase. Such cells will hydrolyse the substrate 5-bromo-4-chloro-3-indolyl-B- 
galactoside (X-gal). Insertion of foreign DNA into an appropriate site within the 
multiple cloning site of M l3 interferes with the production of B-galactosidase in 
infected cells. Thus recombinant M13 gives colourless plaques on an E.coli lawn, in 
contrast to the blue plaques given by the intact vector. The procedure includes 
digestion of both vector and insert DNA, dephosphorylation of vector DNA, ligation 
of vector to insert, preparation of competent cells, transformation, plating out, 
preparation of doudle-stranded RF DNA and isolation of single-stranded template 
DNA for DNA sequencing. Single-stranded template DNA is discussed below.
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Reagents:
Insert DNA digested with a suitable restriction endonuclease
M13 vector DNA restricted with the same enzyme and dephosphorylated
T4 Ligase (1 unit/ul)
Ligase buffer (5x)
E.coli JM109 host cells 
2xTY medium
Calcium chloride (CaCl2 , 50mM)
2xTY agar 
IPTG (lOOmM)
X-gal (2% in dimethylformamide)
H top agar 
H plates
Procedure:
1. Digestion, dephosphorylation and ligations were carried out as described 
previously.
2. Competent E.coli cells were prepared by inoculating a single colony from a 
glucose/minimal medium plate into 10ml of 2xTY medium and grown at 37°C, 
overnight. 2ml of this overnight culture was used to inoculate 40ml of 2xTY medium 
and this was shaken at 37°C for two hours or until the optical density at 650nm was 
0.3. Simultaneously, 1ml of overnight culture was inoculated into 20ml of medium 
to provide fresh plating cells. The 40ml culture was spun at 2000rpm in a bench-top 
centrifuge to pellet the cells and were resuspended in 20ml of ice-cold CaCl2 . This 
was kept on ice for 20 minutes and then spun as above, after which the pellet was 
resuspended in 4ml of ice-cold CaCl2 . In order to increase the transformation 
efficiency, these competent cells were stored on ice for several hours prior to use.
3. Transformation was carried out by transferring 0.3ml aliquots of competent cells 
to 15ml sterile tubes on ice, adding 5ul of ligation mix and leaving them on ice for
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up to 1 hour, subsequently the cells were heat-shocked by incubation at 42°C for 3 
minutes.
4. Transformed E.coli cells were plated out by preparing the following mix in large 
microfuge tubes:
40^1 IPTG 
30^1 X-gal 
200)ul plating cells
This mix was added to the transformation mix and 3ml of molten H top agar (42°C) 
was added and plated out on H plates. Following incubation at 37°C, overnight, 
recombinant M13 plaques were selected as described as above. Recombinant M13 
plaques were toothpicked and stored in 50ul of storage buffer.
5. Small-scale preparations of RF DNA followed the initial steps of a single-stranded 
DNA preparation. Fresh 1.5ml cultures contained in plastic Bijous (see 2.2.24.2) 
were inoculated with either a single colourless plaque or a phage suspension of 
10^°pfu/ml and shaken at 37°C for 5 hours. These cultures were transferred to large 
microfuge tubes and centrifuged for 5 minutes. All supernatant was removed and the 
cell pellet, containing the RF of M13 was treated as described under "small-scale 
plasmid DNA preparation" previously.
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3.2.24 Preparation of single-stranded M13 DNA
Reagents:
E.coli JM109 
2xTY medium
PEG/NaCl ( 20% PEG-6000, 2.5M NaCl)
TE buffer 
Phenol/chloroform 
Proteinase K (5 units/ul)
Sodium acetate (3M)
Absolute ethanol 
70% ethanol
Procedure:
1ml of an overnight culture of host cell was inoculated into 100ml of 2xTY medium 
and dispensed into 1.5ml aliquots. An aliquot was inoculated with a recombinant M13 
plaque or phage suspension (lOiopfu/ml) and shaken at 37°C for 5 hours. The culture 
was transferred to a large microfuge tube and spun for 5 minutes. 1ml of supernatant 
containing the phage particles was carefully transferred to a fresh tube and following 
the addition of 250ul of PEG/NaCl was left on ice for 15 minutes. The PEG was 
precipitated by spinning at 12000rpm, 4°C for 15minutes. The supernatant was 
discarded and the pellet re-spun briefly at room temperature. Any remaining 
supernatant was removed with a drawn-out Pasteur pipette. The pellet was 
resuspended in lOOul of TE buffer. An equal volume of phenol/chloroform was 
added, vortexed and then left to stand for 5 minutes and re-vortexed prior to spinning 
at room temperature for 5 minutes. This was either followed by a chloroform 
extraction and an ethanol precipitation or by an ethanol precipitation alone. In the 
latter case the DNA was resuspended in lOOul of TE buffer and treated with lul of 
proteinase K at room temperature for 30 minutes, this being followed by a 
phenol/chloroform and chloroform extraction and an ethanol precipitation. In both
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cases the DNA was resuspended in 20ul of H2O. It was found that either method 
yielded DNA pure enough for sequencing. 2ul of DNA sample was run on a 1% 
agarose gel to estimate its concentration.
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3.2.25 Removal and deprotection of synthetic oligonucleotides 
Reagents:
Fresh ammonia solution (spec, gravity 0.88)
Sodium acetate (3M)
Ethanol (absolute)
70% ethanol
Procedure:
A 2ml syringe was attached to one end of the column (Applied Biosystems) containing 
the synthesized oligonucleotide. 1ml of ammonia was taken up in a second 2ml 
syringe and attached to the other end of the column. 0.2ml of ammonia was passed 
into the empty syringe and left at room temperature for 20 minutes. Another 0.2ml 
of solution was passed into the column and left at room temperature for another 20 
minutes. This procedure was repeated several times. The ammonia solution was then 
squirted back and forth a few times before it was transferred to a screwtop microfuge 
tube. This was placed in a glass Universal and incubated at 55°C for a minimum of 
8 hours but not longer than 18 hours. The glass vial was removed and left to cool 
prior to opening. 300ul of solution was precipitated with ethanol as described 
previously and resuspended in lOOul of water. In order to determine the DNA 
concentration, the optical density of the sample was read at 260nm. The DNA 
concentration for oligonucleotides is derived from the equation below and the sample 
was diluted accordingly.
[DNA] = O.D .2 6 0  X 33 X dilution factor = jUg/ml
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3.2.26 DNA sequencing
This method of DNA sequencing relies on the dideoxy chain-termination and utilises 
the "Sequenase 2" kit from US Biochem Corp. The method involves the synthesis of 
a DNA strand by a DNA polymerase in vitro using a single stranded DNA template. 
Synthesis is initiated at the one site where an oligonucleotide primer anneals to the 
template. The synthesis reaction is terminated by the incorporation of a nucleotide 
analog that will not support continued DNA elongation. The chain terminating 
nucleotide analogs are 2’,3’-dideoxynucleoside 5’-phosphates (ddNTPs), which lack 
the 3’-OH group necessary for DNA chain elongation. When proper mixtures of 
dNTPs and one of the four ddNTPs are used, enzyme-catalysed polymerisation will 
be terminated in a fraction of the population of chains at each site where the ddNTP 
can be incorporated. Four separate reactions, each with a different ddNTP give 
complete sequence information, since a radioactively labeled nucleotide is also 
included in the synthesis, so that the labeled chains of varying lengths can be 
visualised by autoradiography after separation by polyacrylamide gel electrophoresis. 
Reagents:
Template DNA
Oligonucleotide primer (5ng/ul)
Sequencing buffer (5x, 200mM Tris.Cl pH 7.5, lOOmM MgCl2 , 250mM
NaCl)
DTT (dithiothreitol, O.IM)
Labeling mix dGTP (5x, 7.5uM dGTP, 7.5uM dCTP, 7.5uM dTTP) 
^^S-dATP (lOOOCi/mmol)
Termination mixes - ddA, ddC, ddG, ddT (each consisting of 80uM of each 
dNTP, 50mM NaCl, and 8uM of the respective ddNTP)
Enzyme dilution buffer (lOmM Tris.Cl pH 7.5, 5mM DTT, 0.5 mg/ml BSA) 
Sequenase -2 enzyme
Stop solution (95% formamide, 20mM EDTA, 0.05% bromophenol blue,
0.05% xylene cyanol ff)
Procedure:
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DNA sequencing consists of three steps, annealing, labeling and extension.
1. Annealing - the following annealing reaction was incubated at 65°C for 2 minutes
and then left to cool to 25-30°C in water at 65°C:
Xjul template DNA (2jHg)
2jul sequenase buffer (5x)
IjLtl primer (5ng/ul)
H2O to lOixl
The cooled, annealed mix was briefly spun and maintained on ice prior to use, as this 
enhanced sequencing.
2. Labeling - dGTP labeling mix was diluted 5-fold in H2O; similarly, Sequenase 
enzyme was diluted 8-fold in ice-cold enzyme dilution buffer. The following labeling 
reaction was carried out:
lOfxl template-primer 
ljul DTT (O.IM)
2[jX dilute labeling mix 
IfjLl label
Ifjd dilute enzyme.
The labeling reaction was incubated at room temperature for 3-4 minutes (room 
temperature was defined as 18-20°C). Prior to the labeling step 2.5ul of each of the 
four termination mixes were aliquoted into four large microfuge tubes, respectively, 
which were maintained on ice but incubated at 3TC for 1 minute immediately before 
use in the termination step. A 3.5ul aliquot of the labeling reaction was added to each 
of the tubes containing the termination mix, mixed well and incubated at 3TC for 4-5 
minutes. Immediately, 4ul of stop solution was added to each of these tubes, mixed, 
briefly spun and maintained for up to 2 days at -20°C until use.
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3.2.27 Direct sequencing of PCR products
Sequencing of PCR products was performed using a modified method by Casanova 
et û/.(1990). Although this method utilised the Sequenase-2 kit, several important 
parameters differ from those of conventional M l3 sequencing. Here, the 
primer/template DNA ratio is crucial. In addition, dénaturation of template DNA, 
annealing temperature and the time course of the labeling reaction are also altered. 
Reagents:
DNA of PCR product ( "Gene-cleaned" to remove primers)
Primer (140ng///l)
All materials supplied in the Sequenase-2 kit.
Procedure:
Template and primer DNA were denatured together at a ratio of 20:1 by boiling for 
10 minutes. Annealing was allowed for 30 seconds in a dry-ice bath at -70°C for 30 
seconds. Labeling was carried out at room temperature for 45-60 seconds; extension 
being carried out for 15 minutes. The exact keeping of these time courses was found 
to be crucial to the success of this sequencing method.
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3.2.28 Sequencing of double-stranded plasmid DNA (Zhang,e/ «/., 1988)
This method follows the general protocol of DNA sequencing, using the Sequenase-2
kit, as described above. However, prior to sequencing the double-stranded template
DNA is denatured in the presence of an alkaline agent.
Reagents:
Sodium hydroxide (2M NaOH)
EDTA (2mM)
Ammonium acetate (2M, pH 4.6)
Ethanol 
70% ethanol
Procedure:
To 3fig of gradient-purified plasmid DNA contained in a large microfuge tube, NaOH 
was added to 0.2M and EDTA to 0.2mM, and incubated at room temperature for 30 
minutes. The denatured DNA was neutralised by adding 2/d of ammonium acetate 
and, after mixing quickly, 60/d of ethanol. This was mixed well and left at -20°C for 
30 minutes. Following spinning at 12000rpm at 4°C for 15 minutes, the DNA pellet 
was washed in 70% ethanol and dried in a vacuum dessicator. The DNA was 
resuspended in 7/d of water and used immediately for sequencing as described above.
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3.2.29 Preparation of a DNA sequencing gel
Reagents:
Stick solution
Repel solution
Tris borate buffer (lOx)
Urea
Acrylamide
Fresh ammonium persulphate (10%)
TEMED
Procedure:
For all DNA sequencing performed, BRL sequencing plates (50x40cm long plate) 
were used. In order to avoid contamination, the pre-treatment of plates was performed 
successively rather than concurrently. Both plates were scrubbed thoroughly with 
detergent and water, rinsed in hot water and finally rinsed well with distilled water. 
Both plates were sprayed with ethanol, swabbed with tissue and left to dry. The 
larger, back-plate was coated with stick solution and left to dry in a fume hood. 
Similarly, the shorter, front plate was coated with repel solution and left to dry. Both 
plates were sprayed with ethanol which was dispersed with tissue paper. Plastic 
spacers were placed on the back plate and the lower plate was placed into position 
with the treated surfaces innermost, ensuring that both plates fitted tightly. The sides, 
bottom and bottom comers of the plates were sealed with sealing tape, ensuring that 
no air-bubbles were trapped which might cause leakage at a later stage. The plates 
were positioned at a 10° angle for pouring. The gel was prepared prior to treating the 
plates and consisted of 9.3ml of acrylamide, 31.5g of urea made up to 75ml and kept 
in a 37°C waterbath. The mixture was dissolved by gentle stirring and returned to the 
waterbath. Immediately before pouring 420/d of ammonium persulphate solution and 
75ul of TEMED were added to the gel mixture and this was drawn into a 75ml
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syringe. The gel was poured into the space between the plates strating at one side and 
working across the face of the plate, ensuring that no air-bubbles were trapped. On 
completion of pouring, the blunt end of the shark-tooth spacers were inserted about 
0.5cm deep into the gel and two bulldog clips were placed on either side close to the 
spacers. The protruding part of the long plate was flooded with remaining acrylamide. 
If the gel was not used at on the same day, the top was covered with cling-film to 
prevent drying out.
3.2.30 Running of polyacrylamide DNA sequencing gel 
Reagents:
Running buffer (TBE buffer) (Ix)
Fixing solution
Procedure:
The bulldog clips and spacers were gently removed from the plates and the seal was 
removed from the bottom of the plates. The well of the gel was rinsed repeatedly 
with running buffer. The shark-tooth combs were placed gently on to the well of the 
gel, piercing the gel slightly. The plates were placed and clamped firmly in the 
electrophoresis apparatus. The top reservoir was flooded with running buffer to a 
level exceeding the combs by 1cm; similarly, the bottom reservoir was flooded with 
running buffer. The apparatus was checked for leaks and all wells were flushed prior 
to running. DNA samples were heat-treated for 5 minutes at 80°C and briefly spun 
down. For "long" runs (bottom dye of "short" run to bottom of gel), 5/d samples 
were applied, whilst for "short" runs (loaded when top dye of "long" run was at 
bottom of gel), 4/d samples were applied. The voltage was set to maximum and the 
current at 75mA for sequencing of mycobacterial DNA. After running the gel, the
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combs were removed from the plates and the buffer from the top reservoir was 
drained off. the plates were removed from the apparatus and left to cool for a few 
minutes. Then the seals and side spacers were removed and the smaller plate was 
separated from the bottom plate by piercing one of the bottom comers with a thin 
spatula thus allowing separation of the plates. The plate containing the gel was placed 
in fixing solution for 20 minutes at room temperature and then rinsed thoroughly 
under the tap before drying the gel at 80°C for 1 hour. The plate was allowed to cool 
to ambient temperature and placed in a suitable autoradiogram with X-ray film and 
exposed in the dark at room temperature for 24-72 hours.
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3.2.31 Polymerase Chain Reaction Amplification of Mycobacterial DNA
The polymerase chain reaction (PCR), developed by Saiki et al (1985; 1988) allows 
for enzymic amplification of DNA. Target DNA is denatured by heating. This is 
followed by annealing of DNA oligonucleotides, usually 20-25 bases long, 
homologous to sequences 50-2000 bases apart on the target DNA. This step, which 
is analogous to DNA hybridisation, governs the specificity of the reaction; although, 
the temperature of each individual step also affects specificity. The annealed DNA 
oligonucleotides are then allowed to prime DNA synthesis, which results in the 
synthesis of both strands. The DNA is then denatured and the cycle is repeated; thus, 
repeated cycles yield exponential amplification of target DNA. Conditions for PCR 
amplification of any DNA are dependent on a number of parameters, including the 
melting temperature (T J of the DNA to be amplified. As this is directly related to 
the G+C content of the DNA, amplification of mycobacterial DNA is usually carried 
out at high temperatures. In this work, DNA fragments between 300-1100 bp in 
length were generated. Unless stated otherwise, conditions employed here were as 
described below.
Reagents:
Template DNA (usually 0.1 to l.Ong)
Reaction Buffer (lOx) 
deoxy-nucleotide triphosphate mix (dNTPs)
DNA primer pair (100ng//tl)
Tag polymerase (5units//d)
Reaction buffer (lOx)
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PCR reaction: Target DNA 1/d
Reaction buffer 5/d
dNTPs 8/d
MgClz 1/d
Taq polymerase 0.2/d
Primer pair 1/d
Water to 50/d.
Liquid paraffin 50/d.
Procedure:
PCR reactions were carried out in volumes of 50/d using the Biometra apparatus. The 
conditions included an initial dénaturation at 94°C for Imin; this was followed by a 
30 cycle reaction consisting of an annealing step at 60°C for 30sec, extension at 72°C 
for 150sec and dénaturation at 94°C for 30sec. A final cycle consisted of one 
annealing at 60°C for 2min followed by extension at 72°C for 5min. Upon completion 
of amplification the reaction was cooled to 4°C and stored for the short-term at 4°C 
or for the long-term at -20°C. The PCR products were, when required, sequenced 
directly as described above.
3.2.32 All other standard molecular biology techniques
These were carried out as described in Molecular Cloning: A Laboratory Manual by
Maniatis et al. Cold Spring Harbour Laboratory, 1982.
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EXPERIMENTAL WORK
4.1 IS901, A NEW MEMBER OF A WIDESPREAD CLASS OF ATYPICAL
INSERTION SEQUENCES AND ITS ASSOCIATION WITH 
PATHOGENICITY IN MYCOBACTERIUM AVIUM
Summary
An insertion sequence (IS901), found in pathogenic strains of Mycobacterium 
avium, but absent in M.avium complex isolates from AIDS patients, has been 
isolated and sequenced. This insertion element has a nucleotide sequence of 
1472bp, with one open reading frame (ORFl), which codes for a protein of 401 
amino acids. The amino acid sequence of ORFl, termini and target site of IS901, 
are similar to those of IS900, present in Mycobacterium paratuberculosis. 
However, the DNA sequences of these two IS elements exhibit only 60% 
homology, compared to a DNA homology of 98% between their respective hosts. 
IS901, like IS900, appears to belong to a family of related insertion elements 
present in Actinomycetes and other bacteria. M. avium strains containing 1S901 
were found to be more virulent in mice than closely-related strains lacking 1S901, 
1S901 may be a useful tool to study the genetics of virulence in the 
Mycobacterium avium complex and to obtain stable integration of foreign genes 
into mycobacteria. Both IS900 and IS901 have been used in PCR amplification 
of M.avium complex DNA.
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4.1.1 Introduction
Members of the Mycobacterium avium complex (MAC or MAI) display a 
range of pathogenicities for man and animals. They are not easily diffentiated from 
each other. Commonly, serological differentiation, based on agglutination serology, 
is employed to describe members of the MAI (Wolinsky &Schaefer, 1973). One 
characterisitic common to many pathogenic members of the MAI, including 
pathogenic M.avium strains, isolated from birds and other animals, and 
M.paratuberculosis, isolated from both Crohn’s and Johne’s disease tissue, is their 
mycobactin dependence; that is their requirement for this iron-binding lipid when 
grown in vitro. This dependence, however, varies among these members of the MAI, 
in that some M.avium strains are mycobactin-dependent only at primary isolation, 
whilst M.paratuberculosis is always mycobactin-dependent.
McFadden et al (1987; 1990) demonstrated that the MAC can be differentiated 
by the use of DNA probes which identify restriction fragment-length polymorphisms 
(RFLPS). McFadden et al (1987) isolated a repetitive element, IS900, from 
M.paratuberculosis. This 1.45kb insertion sequence is present in 10-20 copies of the 
host genome. The element clearly distinguishes M.paratuberculosis from other 
members of the MAC. DNA sequence analysis by Green et al (1989) demonstrated 
that IS900 was an atypical bacterial insertion sequence, which lacks terminal inverted 
repeats and does not duplicate the target site upon insertion. The single open reading 
frame (ORFl) of IS900 codes for a protein of 399 amino acids which shows 
homology to proteins encoded by insertion sequences found in other genera of the 
family of Actinomycetes, namely the IS elements isolated from Streptomyces. These 
include ISllO, present in Streptomyces coelicolor A3(2) (Bruton & Chater, 1987);
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IS116, present in Streptomyces clavigerus (Leskiw et al., 1990); and 1S117{or "mini­
circle"), the transposable element also present in Streptomyces coelicolor A3 (2).
Although M.avium and M.paratuberculosis have a DNA homology of 
approximately 98 %, strains of these two species may be clearly distinguished from 
each other by screening their DNAs with a recombinant plasmid, pMB22, containing 
a copy of IS900 flanked by genomic DNA on either side of the copy. This probe 
(pMB22) has been used extensively in epidemiological studies of MAI. Hampson et 
al (1989) demonstrated by means of RFLP studies that MAC strains infecting AIDS 
patients in the developed world are highly conserved in genetic terms. Although there 
is a predominance of several serotypes in AIDS-derived isolates (see previous 
discussion: MAI and disease), namely seovars 1, 4 and 8 (Yakrus & Good, 1990; 
Guthertz et al., 1989; Kiehn et al., 1985), a highly conserved strain is the most 
common M.avium strain isolated from AIDS patients from the developed world. 
Hampson et al (1989) referred to this as RFLP type A strain. Characteristically, this 
strain lacks IS900. These strains are not normally pathogenic for man and are only 
associated with disease in opportunistic infections in humans.
The host-range of typical M.avium strains is far reaching, causing disease in 
birds and other animals, such as cattle and other livestock (Collins et ah, 1983; 
Thoen et ah, 1984). Other members of the MAC exhibit a defined host-range, such 
as M.paratuberculosis and M.lepraemurium, the latter causing murine leprosy. When 
screening M.avium strains isolated from birds and other animals,including the 
"woodpigeon bacillus" isolated from birds, McFadden (unpublished) found that most 
of these isolates contained a repetitive element which exhibits a degree of homology 
with IS900; these isolates were referred to as RFLP type A/I. A pUC18 plasmid
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DNA library of a mycobactin-dependent goat-derived M. avium RFLP type A/I strain, 
FP8589, was screened with 1S900 by McFadden (unpublished) in order to isolate 
recombinant clones harbouring this lS900-rt\2Xt6. element. Three positive clones were 
identified in this manner. One clone, designated pUS410, was chosen as the starting 
material for the isolation and characterisation of this element, which forms the basis 
of the work described in this section.
4.1.2 Methods
In order to characterise the repetitive element present in pathogenic strains of 
M. avium, and subsequently referred to as 1S901, sequencing of insert DNA of clone 
pUS410, identified in the manner described above, was chosen as the first line of 
investigation. Clone pUS410 consisted of plasmid pUC18, which contained an insert 
of 2.8kb of M. avium DNA in its BamHI-site of the multiple cloning site. For details 
of the methods employed refer to section "Materials and Methods".
I l l
4.1.3 Results
4.1.3.1 Cloning of insert from pUS410 in M13
DNA of plasmid pUS410 (l^tg) was digested with restriction endonuclease 
BamHI and electrophoresed in a horizontal gel tank. The 2.8kb insert of this 
recombinant plasmid was recovered from the agarose gel by the GeneClean method 
and subcloned into the single-stranded M13 phage. Cloning was carried out using the 
double-stranded (RF) form of the phage. Twelve recombinant phage plaques were 
identified and purified (clones M13,K1 to K12). Small-scale DNA preparations of the 
double-stranded RF of these clones were analysed for the presence of insert DNA by 
examination of BamHI-derived restriction patterns. All twelve clones contained the 
desired 2.8kb insert from pUS410. In order to be able to sequence the insert 
simultaneously in both directions, restriction digest patterns derived from single 
digests by a number of restriction endonucleases, including BamHI, Clal, Kpnl and 
PvuII, and double-digests, derived from digests using restriction endonucleases 
Clal/BamHI, Clal/PvuII, BamHI/PvuII and PvuII/Ball, were employed to reveal the 
orientations of the insert DNAs in these twelve clones. Two clones, M13,K2 and 
M13,K11, containing the 2.8kb insert were identified in this manner. Figure 4.1.1 
shows a Southern blot of DNA of clones pUS410, M13K2 and M13K11 digested in 
the manner described above and probed with o:32P-dCTP-labelled pMB22, clearly 
demonstrating the two orientations of pUS410 insert in M13. These two M13 clones, 
K2 and K ll, were used for sequencing.
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1 2 2 4 5 6 7 8 9 TO 11 12 13 "M 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
•5*
éé
Lane DNA Enzyme Lane D N A Enzyme
1 XHindlll 16 M 13K2 Clal/BamHI
2 ------- 17 M13K2 Clal/PvuII
3 pUS410 Clal 18 M 13K2 BamHI/PvuII
4 pUS410 BamHI 19 M13K2 PvuII/Ball
5 pUS410 Kpnl 20 —
6 pUS410 PvuII 21 M13K11 Clal
7 pUS410 Clal/BamHI 22 M13K11 BamHI
8 pUS410 Clal/PvuII 23 M13K11 Kpnl
9 pUS410 BamHI/PvuII 24 M13K11 PvuII
10 pUS410 PvuII/Ball 25 M13K11 Clal/BamHI
11 ------- 26 M13K11 Clal/PvuII
12 M13K2 Clal 27 M13K11 BamHI/PvuII
13 M13K2 BamHI 28 M13K11 PvuII/Ball
14 M13K2 Kpnl 29 -------
15 M13K2 PvuII 30 AHindlll
Figure 4.1.1: Southern blot of pUS410, M13K2 and M13K11 DNA digested with 
several enzymes and probed with pUS410, showing M13K2 and M13K11 represent 
different orientations of pUS410 insert DNA.
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4.1.3.2 Sequencing of insert from pUS410 (clones M13,K2 and M13,K11)
Single-stranded DNA of M13 clones K2 and K ll was prepared for 
sequencing. To ensure that each sequencing reaction carried out used identical 
recombinant M13 DNA, large amounts of DNA of plaque-purified clones K2 and K ll 
were prepared and stored at -20°C in aliquots containing 2-3fj.g each. This eliminated 
the possibility of recombination events taking place in subsequent M13 manipulations, 
which may alter the DNA sequence of inserts K2 and K ll and thus hinder accurate 
sequencing of IS901. DNA sequencing of clones K2 and K ll using the "dideoxy 
chain termination" method was used. Figure 4.1.2 shows a diagramatic representation 
of the sequencing strategy: Initially, commercially available universal primers, 
commencing sequencing in the multiple cloning site of M l3 were employed. 
Subsequently, synthetic primers, synthesised using sequences derived from each 
previous sequencing reaction, were used to sequence both clones in their entirety. 
Table 4.1.1 lists all primers employed to sequence the inserts of M13 clones K2 and 
K ll. Each sequencing step was carried out in duplicate; and sometimes in triplicate 
where sequence data was deemed to be of low quality.
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Sequencing strategy to sequence Ml3 clones K2 and Kll
K2.12_ 
K2.6__________
K2.4_____ K2.8_______
K2.3________
K2.2----------  K2.9_____
K2.1------------
Universal — — ■ ■ K2.10
M13 . Insert K2 ^  . M13
Insert K11
Universal
K11.3
K11.4
K11.5
K11.7
K11.6
K11.8
Figure 4.1.2: Sequencing strategy of pUS410 insert DNA in M13
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Primers for M13, clone K2 
K2.1 AGCCGGTCAGGTAGACCTCG 
K2.2 GTTCTTGAGGATCTGCAGCA 
K2.3 GGTAGTGGATTTTGGCCGAC 
K2.4 CGACGACCTGCGCGAGATGG 
K2.5 AGCTACACACCAGGCAGTGA 
K2.6 ACCGAGCTCGACGACGCGTG 
K2.7 TCGATCCTGAGGCTGGACAG 
K2.8 TCGCCCGGAGTCGACATAGC 
K2.9 ACTCATCGTGTTAACCGTGC 
K2.10 GCCAACAGGTCCTTAGAGCA 
K2.11 GACCATCGCATGGCGGGAAT 
K2.12 GCTTATCGATGTTCTTGATC 
K2.13 TGATACGGCCGGAATCGCGT
Primers for M13, clone K ll  
K l l . l  AGGAAGGAGCGGTCGAGCTC 
K11.2 CATCGGATGGTCGATTCGTC 
K ll .3 GGAACAGGTAGGTGTCGAAC 
K ll .4 GCAACGGTTGTTGCTTGAAA 
K11.5 GATTGCTAACCACGTGGTGT 
K ll .6 ATACCGGTCGGATCTGATGG 
K ll .7 GATCAAGGACATCGATAAGC 
K ll .8 GCACTGCTGCGCGACAACAG
Table 4.1.1: Oligonucleotide primers employed in sequencing of IS901 (5’ to 3’ 
direction). Not all sequencing data obtained by using these primers were employed 
in the assembly of the 1S901 sequence.
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The sequencing data accumulated was analysed using the Staden Plus-Software 
for Molecular Biology (Amersham). This programme allows assembly of a DNA 
sequence from individual sequence data. In order to establish whether pUS410 
contained the entire sequence of IS901, the complete "rough" 2.8kb DNA sequence 
of pUS410 insert was aligned to the DNA sequence of IS900 (not shown) using the 
MicroGenie Sequence Analysis Program (Beckman). This enabled an approximation 
of the putative ends of IS901, at the same time not only indicating that both insertion 
element sequences were orientated in the same direction but also suggesting that this 
particular copy of IS901 was located towards the 3’-end of pUS410 insert. This 
alignment also suggested that both sequences were similar in size, IS900 being 1.45kb 
long, whilst IS901 was found to be approximately 1.47kb long.
117
4.1.3.3 Generation of a 0.6kb IS901 PCR product (probel)
The termini of 1S901 were further determined by partial sequencing of a 
second copy of this element. For this purpose a DNA probe was used to identify such 
further copies in the initial M.avium FP8589 plasmid DNA library. Two sequencing 
primers, primers K2.12 and K ll .5 (see Table 4.1.1) were employed to generate a 
0.6kb PCR fragment using plasmid pUS410 as target DNA. Primer K2.12 is the 
reverse and complementary of primer K ll .7. These primers were thought to lie well 
within the IS901 element, thus enabling it to be used as a specific DNA probe, which 
would only detect /5907-containing clones of a plasmid DNA library. The 
amplification of this fragment was carried out under conditions described previously. 
Figure 4.1.3 shows the 0.6kb DNA fragment, referred to as probel, generated by 
PCR.
Figure 4.1.3: PCR product "probel" (lanes 1, 2 and 3; 4>X174HaeIII).
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4.1.3.4 Screening of M.avium strain FP8589 plasmid library
The M. avium FP8589 plasmid library, maintained at -70°C was resuscitated 
on LA plates containing 50mg/ml ampicillin. Using serial dilutions, the titre of the 
plasmid library was determined to be approximately 6x10  ^cfu/ml. A colony density 
of 5xl(P colonies/Petri dish was chosen for the initial screen. For this reason, five 
aliquots of the library stock, diluted to 10'^ , were plated as above.In order to 
minimise the size of colonies, the plates were incubated at room temperature for 
18hr, rather than at 37°C. Following this the plates were incubated at 37°C for a few 
hours until the colonies reached pin-prick size. These plates were used for duplicate 
colony lifts in the primary screen as described previously. a^^P-dCTP-labelled probel 
was used to screen the five filters (in duplicate). Hybridisation conditions as described 
previously were employed. The filters were washed at high stringency to remove all 
non-specific hybridisation products and mounted on autoradiograms for ovemight- 
exposure at -70°C. The autoradiograph revealed five positive colonies (or areas on the 
plate) in this primary screen. These were identified by aligning the autoradiograph to 
the Petri dish containing the respective screen. The five positive colonies were picked 
using the blunt end of a sterile glass Pasteur pipette and resuspended in 1ml of L 
broth. To rescreen these at a density of < lOVPetri dish, lOO^ ul of a 10'  ^dilution of 
each suspension was plated in duplicate and incubated as described above. A second 
screen as described above was carried out, enabling clear identification of the five 
colonies which hybridised strongly to probel. Several positive colonies from each of 
the five duplicate plates were picked; in total, 24 colonies were thus picked using the 
pointed end of a sterile glass Pasteur pipette and restreaked on LA, containing 
50mg/ml ampicillin. Small-scale plasmid DNA was prepared from all 24 clones by
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means of the alkaline lysis method. Restriction digestion using BamHI revealed DNA 
inserts in all 24 clones, ranging from < 1.0->4.0kb in size. In order to identify a 
clone suitable for sequencing, a Southern blot of DNA of these clones, digested with 
restriction endonuclease BamHI, was probed with a^^P-dCTP-labelled probel. The 
blot contained BamHI-digested M13K2 DNA as a positive control. Following a high 
stringency wash, a X-ray film mounted on the filter in an autoradiogram was exposed 
at room temperature for 4hr. Such short exposure would permit clear distinction of 
strong hybridisation bands due to 100% homologous target DNA, i.e. another copy 
of IS901, from that of less homologous target DNA, i.e. background signals. Figure 
4.1.4 shows the autoradiograph of the Southern blot of these 24 DNA samples 
digested with BamHI and probed with probel. One positive clone, clone 19 
(containing a 4.5kb insert) and referred to as recombinant plasmid pUS411, was 
selected for direct double-stranded plasmid sequencing to determine the termini of 
IS901.
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Figure 4.1.4: Southern blot of 24 recombinant pUC18 clones (lanel: lambda Hindlll; 
lanes 3-26: clones 1-24; lane 28: M13K2), identified by screening M.avium FP 8589 
plasmid library with probel. DNA samples digested with BamHI and probed with 
probel shows presence of 1S901 copies in clones 1, 4, 8, 11-15, 18-20, 22-24.
121
4.1.3.5 Double-stranded plasmid sequencing of pUS411
Two sequencing primers, primer K2.10 and K ll .8 (see Table 4.1.1), used in 
sequencing M13 clones K2 and K ll, and lying within 200 bases of what were thought 
to be the respective ends of IS901, were used to sequence the termini of 1S901 plus 
approximately 200 bases of flanking DNA contained within pUS411. This, again 
assumed that pUS411, like pUS410, contained one complete copy of the element. 
Double-stranded plasmid sequencing described by Zhang et al (1988) was used to 
sequence 3//g of recombinant pUS411, which was prepared using the small-scale 
alkaline lysis method. This yielded two sequences, both approximately 300 
nucleotides long. The sequences were aligned to the pUS410 insert sequence; one part 
of each of the two sequences exhibited complete homology to the assumed terminal 
regions of IS901 in pUS410, with the other part of each sequence diverging at what 
were thought to be the terminal nucleotides of IS901. Figure 4.1.5 shows the 
alignment around the termini of IS901. This showed that pUS411 contained a 
complete copy of IS901 including some flanking DNA, which, however, was different 
from that of the flanking DNA found in pUS410. It also demonstrated that both 
pUS410 and pUS411 contained different copies of IS901. The complete sequence of 
IS90I was thus found to be approximately 1.47bp long. Sequencing of two copies of 
the element, however, did not yield the "exact" ends of the sequence, for sequence 
homology in the immediate flanking regions of either copy may lead to 
misinterpretations. Thus, the putative insertion site within an M. avium strain lacking 
IS901 was sequenced. This would also reveal whether insertion had produced a target- 
site duplication, thus determining the character of 1S901 (i.e. typical or atypical IS 
element).
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pUS410: CATGCGCTGATTCCTT TTGAGATTCCTTTCAGGA
pUS411: CATTGGTGGCTTCCTT TTGAGATTCCGTTCGGTG
Figure 4.1.5: 1S901 termini in pUS411 aligned to IS901 copy in pUS410.
4.1.3.6 PCR amplification and direct sequencing of a putative insertion site 
of 1S901 in M. avium lacking the element 
DNA of an AIDS-derived M. avium isolate SK9 (0.1 ng) was used as target 
DNA to amplify a putative insertion site in the genome of an M. avium strain lacking 
IS901. Primers derived from the flanking regions in pUS410 were used to generate 
a PCR product for sequencing. However, using six different primer-pairs yielded non­
specific PCR products in all cases. This suggested that the flanking region of this 
particular copy of 1S901 has undergone modification thus inhibiting these PCR 
reactions. Therefore, two primers, primer FI and F2, were used in a PCR reaction 
to yield a SOObp fragment. These primers, shown in Table 4.1.2, were derived from 
the flanking regions in pUS411 (approximately 150bp along either end of the 
element). PCR conditions as described previously were employed. The PCR yielded 
a SOObp product shown in Figure 4.1.6, which was sequenced directly using the 
previously described modified method of Casanova (1990). Alignment of this
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sequence to pUS410 and pUS411-derived end sequences allowed for the determination 
of the ends of 1S901. In addition, one of its putative target sites within the M.avium 
genome was determined. It also allowed the accurate size determination of IS901 and 
the location of a putative insertion site.
Primer FI: CAGCCAGCCGAATGTCATCC
Primer F2: CAACTCGCGACACGTTCACC
Table 4.1.2: Primers derived from the flanking region of 1S901 contained in pUS411, 
used for amplification of PCR probe 1 and direct sequencing of a putative insertion 
site of 1S901 in M. avium lacking 1S901.
«m -
Figure 4.1.6: SOObp PCR product generated by amplification of M.avium DNA
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lacking 1S901.
4.1.3.7 Characterisation and Analysis of IS901
Figure 4.1.7 shows the complete nucleotide sequence and amino acid sequence 
(of the major open reading frame) of IS901, as determined from the above sequencing 
data. IS90I has a nucleotide sequence of 1472bp with a G+C content of 62%, which 
is comparible with that of the M. avium genome. A single open reading frame (ORFl) 
extends from nucleotide 224 to 1426, coding for a protein of 401 amino acids with 
an expected molecular weight (MW) of 44kDa. The predicted ATG initiation codon, 
coding for a methionine residue, is preceded by a possible Shine-Dalgarno sequence 
(SD) from position 212 to 216. The SD sequence, which consists of part or all of the 
polypurine sequence AGGAGG (in this case AG G AG), is complementary to the 3’end 
of the 16S rRNA where it is involved in binding of the ribosome to mRNA. ORFl 
terminates with the stop codon TGA at nucleotide 1427 to 1429.
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Figure 4.1.7: Nucleotide sequence of I S 9 0 1 and amino acid
s e q u e n c e  o f  O R F l. A p o s s i b l e  S D - s e q u e n c e  i s  h i g h l i g h t e d .
TTCCTTAGGGTTGAAGGGGTCTGGGATTGGATGTCCTGGATGCCCAGGACGGTGGGGTGT 
1 0  2 0  3 0  4 0  5 0  60
GGCTAATGTGTTGTTGCAACGGTTGTTGCTTGAAAGGAATGGCCGCCCTGCCGTTTTGGA 
7 0  8 0  9 0  1 0 0  1 1 0  1 2 0
CGGTCCTGGCCACTGATTGAGATCTGACGCGTACTCGATGACGCTGCTCTAAGGACCTGT 
1 3 0  1 4 0  1 5 0  1 6 0  1 7 0  1 8 0
M A E P D R
TGGCGGGGTTGTCCGCGGGGACTGCGACGACAGGAGTAGCGGTATGGCCGAACCCGACCG
1 9 0 2 0 0 2 1 0 2 2 0 2 3 0 2 4 0
V W V G I D V G K S T H H A C A I D D T
AGTGTGGGTGGGTATCGACGTCGGTAAGTCCACTCATCATGCGTGCGCGATCGATGACAC
2 5 0 2 6 0 2 7 0 2 8 0 2 9 0 3 0 0
G K V V W S K K I  P N E Q A A I  E D L I
CGGAAAGGTGGTGTGGTCGAAGAAAATCCCGAACGAACAGGCCGCGATCGAAGACCTGAT
3 1 0 3 2 0 3 3 0 3 4 0 3 5 0 3 6 0
A Q G G R I  A N H V V W A I D L T S R R
CGCCCAGGGCGGCCGGATTGCTAACCACGTGGTGTGGGCGATCGATTTGACCTCGCGCCG
3 7 0 3 8 0 3 9 0 4 0 0 4 1 0 4 2 0
R R L L I A V L L S A K A E V V Y V P G
GCGGCGGCTGCTGATCGCCGTACTGCTGAGCGCGAAAGCCGAGGTGGTGTATGTGCCGGG
4 3 0 4 4 0 4 5 0 4 6 0 4 7 0 4 8 0
R T V N T M S H A F R G E G K T D A K D
CCGCACGGTTAACACGATGAGTCATGCGTTCCGCGGCGAAGGCAAGACCGACGCCAAAGA
4 9 0 5 0 0 5 1 0 5 2 0 5 3 0 5 4 0
A R V I A E T A R H R R D L S P V V P G
CGCGCGGGTAATCGCCGAAACCGCTCGGCACCGACGAGATCTGTCCCCGGTCGTACCCGG
5 5 0 5 6 0 5 7 0 5 8 0 5 9 0 6 0 0
E D L V A E L R S L T A Y R S D L M A D
CGAAGACCTGGTTGCCGAATTGCGGTCGCTGACCGCATACCGGTCGGATCTGATGGCTGA
6 1 0 6 2 0 6 3 0 6 4 0 6 5 0 6 6 0
W V R G V N R V R S M L T A I F P A L E
CTGGGTGCGAGGCGTGAACCGCGTGCGCTCGATGCTCACCGCCATCTTCCCTGCTCTGGA
6 7 0 6 8 0 6 9 0 7 0 0 7 1 0 7 2 0
A A F D Y S T R A P L I  L V S A M C T P
AGCTGCGTTCGACTACTCCACCCGCGCGCCGTTGATCCTGGTATCCGCTATGTGCACTCC 
7 3 0  7 4 0  7 5 0  7 6 0  7 7 0  7 8 0
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G E I  R S A K R A G V I  K H L R K N R A
GGGCGAAATCCGGTCGGCAAAAAGAGCTGGCGTGATCAAGCACCTTCGGAAAAACCGGGC
7 9 0 8 0 0 8 1 0 8 2 0 8 3 0 8 4 0
W P N N I D T I A D K G L A A A A G Q I
ATGGCCCAACAACATCGACACGATCGCCGACAAGGGCCTCGCCGCGGCAGCAGGCCAGAT
8 5 0 8 6 0 8 7 0 8 8 0 8 9 0 9 0 0
I  T L P G E A G T A A L I  K Q L A A R L
AATCACCCTTCCCGGCGAAGCCGGAACCGCCGCGCTCATCAAGCAACTCGCAGCACGGCT
9 1 0 9 2 0 9 3 0 9 4 0 9 5 0 9 6 0
L D L D R Q I K D I D K Q I T N K F R E
GCTGGACTTGGATCGGCAGATCAAGGACATCGATAAGCAAATCACCAACAAATTTCGTGA
9 7 0 9 8 0 9 9 0 1 0 0 0 1 0 1 0 1 0 2 0
H P S A A I  I E S M P G M G P H L G A E
GCATCCCAGCGCCGCCATCATCGAGTCGATGCCCGGCATGGGGCCACACCTGGGCGCTGA
1 0 3 0 1 0 4 0 1 0 5 0 1 0 6 0 1 0 7 0 1 0 8 0
F L V I T G G N M A A F T N P G R L A S
GTTCCTCGTAATCACCGGCGGCAACATGGCCGCCTTCACCAACCCCGGCCGACTGGCATC
1 0 9 0 1 1 0 0 1 1 1 0 1 1 2 0 1 1 3 0 1 1 4 0
F A G L V P V P R D S G R I T G N L H R
GTTCGCCGGATTGGTACCCGTCCCACGCGATTCCGGCCGTATCACCGGCAATCTGCATCG
1 1 5 0 1 1 6 0 1 1 7 0 1 1 8 0 1 1 9 0 1 2 0 0
P 'k  R Y N R R L R R V F Y L A A L S S L
GCCCAAGCGCTACAACCGGCGCCTGCGCCGCGTGTTCTACCTCGCCGCCCTGTCCAGCCT
1 2 1 0 1 2 2 0 1 2 3 0 1 2 4 0 1 2 5 0 1 2 6 0
K I  E G P S R A F Y D R K R S E N H I  H
CAAGATCGAAGGTCCCTCGCGGGCTTTCTACGACCGCAAACGATCCGAGAACCATATCCA
1 2 7 0 1 2 8 0 1 2 9 0 1 3 0 0 1 3 1 0 1 3 2 0
T Q A L L A L A R R H V D V L W A L L R
CACCCAGGCCCTGCTTGCCCTGGCACGCCGCCACGTCGACGTCCTGTGGGCACTGCTGCG
1 3 3 0 1 3 4 0 1 3 5 0 1 3 6 0 1 3 7 0 1 3 8 0
D N R T W Q P Q Q P T V A A A *
CGACAACAGAACATGGCAACCCCAGCAACCAACCGTGGCAGCTGCCTGACGCACTCACCG
1 3 9 0 1 4 0 0 1 4 1 0 1 4 2 0 1 4 3 0 1 4 4 0
GGCGTCCTCACCGCTTGACACGCTCATTGAGA 
1 4 5 0  1 4 6 0  1 4 7 0
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Figure 4.1.8 shows the terminal regions of 1S901 and flanking genomic DNA in 
pUS410 and pUS411, together with the unoccupied insertion site in the genome of 
M. avium strain SK9, isolated from an AIDS patient. Employing RFLP-typing, strain 
SK9 was found to be a type A1 strain, the most common strain found in AIDS patients 
from the developed world (see discussion later). Figure 4.1.7 and Figure 4.1.8 show that 
IS901 commences with the sequence TTCCTT at the 5’end of the DNA sequence, 
terminating with the sequence TTGAGA at the 3’end of the element. A consensus 
sequence, CAT, exists 8 nucleotides upstream the flanking DNA and 8 nucleotides from 
the 3’-end of the sequence; similarly, a consensus sequence, CCT, is present 3 
nucleotides downstream the IS element and 3 nucleotides into the 5’-region of the 
sequence. These consensus sequences are also present at similar positions in the locus 
for IS901 in SK9. Some discrepancies in the flanking regions of 1S901 contained in 
pUS41Tand the putative insertion site in SK9 exist. Whilst the upstream flanking region 
in pUS411 reads CATTGGTGGC, the corresponding region in SK9 reads 
CATTGCTGGC; similarly, the downstream sequence in pUS411 reads 
TTCCGTTCGGTGGG, whilst that of SK9 reads TTCCTTTCGGTGGG. This minor 
change in nucleotide sequence are thought to be a reflection of the degree of 
polymorphism which is characteristic for the M.avium complex. Conversely, these 
changes may have occured during subcloning or PCR.
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CATGCGCTGA TTCCTTAG... pUS410 ...CATTGAGA TTCCTTTCAGGAGC
CATTGGTGGC TTCCTTAG... pUS411 ... CATTGAGA TTCCGTTCGGTGGG
CATTGCTGGCTTCCTTTCGGTGGGGCCGG
(locus for IS901; PCR product)
Figure 4.1.8: The sequence of two insertion sites for IS901 in M. avium, as determined 
from clones pUS410 and pUS411. Also shown is the sequence of a putative insertion site 
in an M.avium strain lacking the IS element. Consensus sites up- and down stream are 
highlighted.
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However, examination of the flanking sites for the three Actinomycetes IS 
elements IS900, IS90I and IS116, shown in Figure 4.1.9 indicates the presence of a 
similar short sequences, CAT and CCT, a few bases upstream and downstream the 
elements. This suggests a consensus insertion site of CATN(7)*TTCCNTTC (where * 
denotes the site of insertion) for IS901, which is in agreement with that of IS900, which 
was suggested to be CATGN(4-6)*CNCCTT (Green et al., 1989) and that of IS116, 
which was suggested to be CATGGTCGG*TCTCCTGGT (Leskiw et a l ,  1990). This 
suggests that similar short sequences might be involved in the integration of these related 
elements, as has been suggested for other IS elements (Grinauz et al., 1988; Murphy, 
1988; Leskiw et al., 1990). Both mycobacterial elements, IS900 and IS90I, contain the 
sequence TTCCTT at both the left end of the elements and the target sites, suggesting 
that this sequence may be involved in the recognition of the target site by the IS elements 
or in the recombination process. The former also supports the suggestion that in both 
cases insertion was site-specific.
5’-insertion site junction 3’-insertion site junction
CATGN(4-61 TCCTTA. .JS900 . .. CATTGAGA AT CNCCTT
CATN(7) TTCCTT... IS901... CTC ATTGAGA TTCCNTTC
ÇATGGTCGG TCCCTC.. ,IS116... C ATTGAGAT TCTCCTGG
Figure 4.1.9: Consensus insertion-sites for Actinomycetes IS elements IS900, IS90I and 
ISII6, upstream and downstream the IS elements, suggesting that similar short sequences 
(CAT and CCT) might be involved in the integration of these related elements.
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Figure 4.1.8 also shows that both copies of 1S901 insert in the same orientation 
with respect to the target site. Similarly, Figure 4.1.9 shows that the same is true when 
comparing the orientation of both mycobacterial IS elements.
DNA sequence alignment of 1S900 and 1S901 shown in Figure 4.1.10 revealed 
sequence homology of 60%. This compares with a DNA homology of 98% between 
their respective hosts, M.paratuberculosis and M.avium (McFadden et al., 1987), which 
clearly suggests that the insertion events occured separately and independently. 
Therefore, one may assume that these two members of the M. avium complex evolved 
independently from one common parent strain. Figure 4.1.11 outlines how the 
acquisition of IS elements by a parent type A strain may have given rise to M. avium type 
A/I, containing 1S901 and M.paratuberculosis, containing 1S900, respectively. Unlike 
the vast majority of the M.avium complex, these two members, both containing IS 
elements, have a well-defined host-range (see discussion later), which may have resulted 
from the acquisition of these IS elements.
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Figure 4.1.10: Alignment of 1S901 (top) to 1S900 (bottom). The gaps shown are created 
by the STADEN-PLUS programme to allow a maximum fit ( | : indicates sequence 
identity).
TTCCTTA GGGTTGAAGG GGTCTGGG ATTGGAT GTCCTGGA TGCCCAGGAC
I I
TCCTTACCTTTCTTGAAGGGTGTTCGGGGCCGTCGCTTAGGCTTCGAATTGCCCAGGGA
GGTGGGGTGTGGCTAATGTGTTGTTGCAACGGTTGTTGCTTGAAAG GAATGGCCGCCCTn i l
CGTCGGGTATGGCTTTCATGTGGTTGCTGTGTTGGATGGCCGAAGGAGATTGGCCGCCC
GCCGTTTTGGACGGTCCTGGCCACTGATTGAGATCTGACGCGTACTCGATGACGCTGCTC
I I
I M i l
I I I I I I  I I
I I I I
I I
GCGGTCCCGCGACGACTCGACCGCTAATTGAGA GATGCG ATTGGAT CGCTG TG
TAAGGACCTGTTGGCGGGGTTGTCCGC GGG
l l l l l l l  I I  n i l  I I I  I I I  I I  I I I
GACTGCGACGA CAGGAGTAGCGGTAT
TAAGGACACGTCGGCGTGGTCGTCTGCTGGGTTGATCTGGACAATGACGGTTACGGAGGT
GGCCGAACCCGACCGAGTGTGGGTGGGTATCGACGTCGGTAAGTCCACTCATCA TGCGTn i l n i l 11
GGTTGTGGCACAACCTGTCTGGGCGGGCGTGGACGCCGGTAAGGCCGACCATTACTGCAT
GCGCGATCGATGACACCGGAAAGGTGGTGTGGTCGAAGAAAATCCCGAACGAACAGGCCG
I I n i l
G GTTATTAACGACGACGCGCAGCGATTGCTCTCGCAGCGGGTGGCCAACGACGAGGCCG
GATTGCTAACCACGTGGTCGATCGAAGACCTGATCGC CCAGGGCGGCCGI I  I I I  n i l  I I  I I I I I I  I I I  I I  I I I  I I
CGCTGCTGGAGTTGATTGCGGCGGTGACGACGTTGGCCGATGGAGGCGAGGTCACGTGGG
GTGGG
I I  I  I
CGATCGATTTGACCTCGCGCCGGCGGCG GCTGCTGATCGCCGTACTGCTGAGCGCGAAA
l l l l l l l  I I I I I I  i n n  I I  I n n n n n i  i n  i n
CGATCGACCTCAACGC CGGCGGCGCCGCGTTGCTGATCGCCTTGCT CATCGCTGCCGG
GCCGAGG TGGTGTATGTGCCGGGCCGCACGGT TAACACGATGAGTCATGCGTTCCGCG
I I I I I llllllll I I I I I I i n *
GCAGCGGCTGCTTTATATTCCCGGGCGCACGGTCCATCACGCCGCG GGTAGTTACCGCG
GCGAAGGCAAGACCGACGCCAAAGACGCGCGGGTAATCGCCGAAACCGCTCGGCACCGACl l l l l l l
GCGAAGGCAAGACCGACGCCAAAGACGCTGCGATCATCGCCGATCAGGCCCGGATGCGCC
GAGATCTGTCCCCGGTCGTACCCGGCGAAGACCTGGTTGCCGAATTGCGGTCGCTGACCGI I  I I  I I  I l l l l l l l  I I I  I I I I I I  n i l  l i n n
ACGACTTGCAGCCTCTGCGCGCCGGCGATGACATCGCAGTCGAGCTGCGCATCCTGACCA 
CATACCGGTCGGATCTGATGGCTGACTGGGTGCGAG GCGTGAACCGCGTGCGCTCGATGI I  I I  l i n n  n n i n  n  n  i i n n n  i n n  i i
GCCGACGTTCCGATCTGGTGGCTGATCGGACCCGGGCGATCGAACCGAATGCGCGCCCAG
CTCACCGCCATCTTCCCTGCTCTGGAAGCTGCGTTCGACTACTCC ACCCGCGCGCCG
CT GCTGGAATACTTTCGGCGCTGGAACGCGCCTTCGACTACAACAAGAGCCGTGCCGCG
TTGATCCTGGTATCCGCTATGTGCACTCCGGGCGAAATCCGGTCGGCAAAAAGAGCTGGC
l l l l l l l l  I I I i n n  I n  i n  n  i i n  i
CTGATCCTGCTTACTGGCTACCAAACTCCCGACGCGCTGCGCAGCGCCGGTGGCGCTCGA
132
GTGATCAAGCACCTTCGGAAAAACCGGGCATGGCCCAACAACATCGACACGATCGCCGACI l  I I I I I I  n i l  I I I  i n n  n n  i n  n  n n  i i
GTAGCCGCGTTCTTGCG TAAAC GCAAGGCCC GCAACGCCGATACCGTCGCAGCC
AAGGGCCTCGCCGCGGCAGCAGGCCAGATAATCACCCTTCCCGGCGAAGCCGGAACCGCCI I I I  I I  I I  I I I I  I II I I n n n  I I  i i n
ACCGCGCTGCAGGCCGCTAACGCCCAACACAGCATCGTGCCCGGCCAACAACTGGCGGCC
GCGCTCATCAAGCAACTCGCAGCACGGCTGCTGGACTTGGATCGGCAGATCAAGGACATCI I I  I I I  II  I II  I I I  I I II  I I I I  n i l  I
ACTGTGGTGGCCCGCCTGGCCAAGGAGGTGATGGCCCTCGACACCGAAATCGGCGACACC
GATAAGCAAATCACCAACAAATTTCGTGAGCATCCCAGCGCCGCCATCATCGAGTCGATG
I I I I I I
GACGCGATGATCGAGGAGCGATTTCGCCGCCACCGCCACGCCGAAATCATCCTGAGCATG
CCCGGCATGGGGCCACA CCTGGGCGCTGAGTTCCTCGTAATCACCGGCGGCAACATGGCi n n
CCCGG
i n n i n n !  I  I  !  I I I
ATTCGGCGTCATCCTGGGCGCTGAGTTCCTCGCCGCCACCGGCGGGGACATGGC
CGCCTTCACCAACCCCGGCCGACTGGCATCGTTCGCCGGATTGGTACCCGTCCCACGCGA
I I  I I I I
CGCATTCGCCTCCGCCGACCGCCTCGCCGGCGTCGCCGGCCTGGCGCCGGTACCACGAGA
TTCCGGCCGTATCACCGGCAATCTGCATCGGCCCAAGCGCTACAACCGGCGCCTGCGCCG
I I I I I I I I i n n n n n n n n 11
TTCCGGCCGCATCAGCGGAAACCTCAAACGCCCCCGACGCTACGACCGGCGCCTGCTGCG
CGTGTTCTACCTCGCCGCCCTGTCCAGCCTCAAGATCGAAGGTCCCTCGCGGGCTTTCTAI I  I n n n  i i n  n  n n  n  i i n  n n n i  i i i n
CGCCTGCTACCTGTCGGCCTTGGTCAGCATCCGCACCGACCCCTCCTCGCGCACCTACTA
CGACCGCAAACGATCCGAGAACCATATCCACACCCAGGCCCTGCTTGCCCTGGCACGCCGn n n  i n n  n n  i n n n n i  i n  i n  n n n n  i n n
CGACCGAAAACGCACCGAAGGAAAACGCCACACCCAAGCCGTCCTCGCCCTGGCCCGCCG
CCACGTCGACGTCCTGTGGGCACTGCTGCGCGACAACAGAACATGGCAACCCCAGCAACCII  I 11 n n n  l l l l l l l  n n n n n i  n  i i i n n  n n n
CCGCCTCAACGTCCTGTGGGCCATGCTGCGCGACCAC GCTGTCTACCACCCC GCAACC 
AACCGTGGCAGCTGCCTGACGCACTCACCGGGCGTCCTCACCGCTTGACACGCTCATTGAI I l l l l l l l l  l l l l l l l
ACTACCGCGGCGGCTTGACAACGTCATTGA
GAII
GAAT
The last 60 nucleotides of IS901 were aligned manually to allow a 
maxium fit.
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M.avium type A
IS900 M.paratuberculosis
IS901 M.avium A/I
Figure 4.1.11: Acquisition of IS elements of a non-pathogenic M.avium parent strain 
giving rise to pathogenic M.avium A ll and M.paratuberculosis.
Mycobacterium avium A/I IS901
Mycobacterium paratuberculosis IS900 60% (49%)
Streptomyces clavuligerus 1S216 58% (50%)
Streptomyces coelicolor A3(2) l^llO 51% (32%)
S. coelicolor A3(2) mini-circle IS ii 7* 49% (27%)
Thermus thermophilus IS7(W 34% (23%)
Pseudomonas atlantica IS4P2 34% (18%)
Table 4.1.3: DNA sequence homologies and amino acid sequence homologies of the 
ORFs (in brackets) between 1^901 and IS900, ISllO, IS116, IS777, ISIOOO and IS492 
(*= DNA and amino acid homologies between ORFl of ISP07 and ORFl of ISiiT).
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Nucleotide and amino acid sequence alignment, respectively, between 1S901 and 
IS900 [(Green et ah, 1989) discussed above], ISllO  (Bruton & Chater, 1987), IS117 
(Henderson et al., 1989; Henderson et al., 1990), 1S116 (Leskiw et al., 1990), ISlOOO 
(Ashby & Bergquist, 1990) and IS492 (Bartlett & Silverman, 1989) revealed sequence 
homologies dependent on the relatedness of the respective hosts. Table 4.1.3 shows that 
greatest homology was found with IS900, followed by the Streptomyces IS elements 
IS1I6, ISllO  and IS117. ISlOOO, isolated from Thermus and IS492, isolated from 
Pseudomonas, were found to be least closely related to 1S901. Since both genera, 
Mycobacterium and Streptomyces, belong to the family of Actinomycetes, it is not 
surprising that these elements exhibit greatest homology. Several similarities exist 
between the two mycobacterial IS elements and the Streptomyces IS elements with 
respect to their terminal ends and their target sites. Whilst ISllO  and 1S117 possess 
imperfect inverted terminal repeats, these are absent in 1S116, 1S900 and IS901. 
Similarly, these three IS elements, as well as 1S117, do not produce a target site 
duplication. However, the similarities of the IS elements in both genera suggests that 
these belong to a family of related IS sequences.
CLUSTAL alignment (Higgins & Sharp, 1988) of the amino acid sequences of 
the major open reading frames of the above seven IS sequences shown in Figure 4.1.12 
revealed that homologous regions are present in each of these proteins. Homology is 
greatest among the Actinomycetes elements. Of particular interest is the conserved motif 
K-D--DA, at postion 111 to 117, which is also found in reverse transcriptase enzymes 
(Johnson et ah, 1986; Xiong & Eickbush, 1988). Additional conserved motifs are also 
present,particularly between 1S901, IS900, IS 110 and 1S116. These motifs, highlighted 
in Figure 4.1.12, are presumably conserved functional domains.
135
Figure 4.1.12: CLUSTAL alignment of IS901 ORFl, IS900 ORF1197, ISllO ORF1215, 
IS116 ORFl 197, IS117 ORFl, IS 1000 ORFIA and IS492 ORFl. Sequence identity with 
IS901 is shown (-); (.) denotes gaps and deletions in each sequence. Sequence homology 
with a reverse transcriptase motif is highlighted (rtm).
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IS901 : ..MAEPDRVWVGIDVGKSTHHACAIDDTGKWWSKKIPNEQA...AIEDLIAQGGRI.AN
15900 : ___ VAQP--A-V-A— AD-YCMV-N-DAQRLL-QRVA-DE-...-LLE AVTTL.-D
15116 : .LSTRH— I A— GH-W-V-V-AD-ETLF-T-VI-DE-...QVLT— ETA.-E.RE
ISllO : MFDT-DVG-FL-L TA— GHGLTPA— K-LD-QL— SEPRLR-VF-KL-...... AK
15117 : .MWEDSLT-FC WAERH-DV-IV TLLAKAR-TDDV-GYNKLL— L-EH-DSS-T
ISIOOO :  MTFA----S-THLDL-LVSNSP-PTRLRFPNSPEGRQALLAA-AHHNPAWV-L
IS492 : MNPKTNQS-N— V-T— FQLDIYIR...PHDIYFTVSND-KGIKE— KKIQQHSPGRIVI
— irtm —
15901 : H ..WWAIDLTSRRRRLLIAVLLSAKAEWYV.PGRTVNTMSHAFRGEG.KTDAKDARVI
XS900 : GGE—T—————NAGGAA L—lA—GQRLL—I. —HHAAGSY —— —AI—
IS116 : E «.—R——V—XSG—AST——L—L—VAHGQN— —RM—G—YK— —
ISllO : FGT-LVXV-QPASIGA-PLT-ARD-GCK-A-L.— LAMRRXADLYP— A.------- A—
XS117 ; PXP-AIETSHG — V-A-RTGSRK-FAIN-LAAARYRDRHGVSRK.-S-PG— L-L
XSIOOO : EPTGAYHLP-LKLL..........-ENRLQVALVNPYHLAAFRKAK— RQ----RQ— LLL
XS492 : EATGRLEMPFXXAC..........-N-NLPF-VANPIHXKRFAGAX-QRA----KL— QL-
XS901 : AETAR.HRRDLSPWPGEDLVAELRSLTAYRSDLMADWVRGVNRVRSMLTAXFPALEAAF
XS900 : —DQ— .M—H— Q—LRA—D—lAV X——SR V— RT—AIEPNARPAAG—LS———R——
XS116 : ——Q—— . M———FA—LDRPPEL—TT— L— NH—A— I— R— LI— L—DL——G—C——— R——
XSllO : — A— TMAHT-RSLELTDEIT SV-VGFDQ— A-EAT-TS —  X-GL— QFH-S— RVL
XS117 : -NXL-TDMHAHR-LPADSELAQAITV-ARAQQ-AVWNRQQVA-Q L-REYY— ALH—
XSIOOO : -RY-QVYHGE-WAYTLPPEALR— KA-VGY-E— AGRERAIL-QMEAAEW-GSKEVL-LL
XS492 : -HYGEAIQPK— Q. .LKP-TMQAMSD-V-R-NQ-L VMQTME....... KNRLQXL
XS901 : DY..STR........... APLILVSAMCTPGEIRSAKRAGVIKHL. .RKNRAWPNNXDTX
XS900 : — NK-RA........... -LI LL-GYQTPD-L-SAGGARVAAFLRKRKAR-A— V
XS116 : —  ..-A............ -KGPV- . . -L-EYQTPA-L-RTGV-R-TTWLG-RKVRDA— V
XSllO : GPRLDHQ........... - -TWLLERYGSPA-L-KAGRRR-VELVRPKA-RMAQRL
XS117 : QSKDGGLTRPDARVILTM— TPAKA-KL-LAQL-AGLKRSGRTRAFNTEXERLRGXFRSE
XSIOOO : QKELACV........KGLLGEVEARIQALLATLPE-EV........................
XS492 : PKELAMTXKPILTAFKNQITK-ENKIVALIESCPDYQAKNCI  ...........
XS901 : ADKGLAAAAGQIITLPGEAGTAALIKQLAARLLDLDRQIKDIDKQITNKFREHPSAAXXE
XS900 : -ATA-Q— NA-HSIV— QQLA-TVVAR— KEVMA— TE-G-T-AM-EER— R-RH-E— L
XS116 : -A-AXE— RT-Q W L — EKRATK-VCD— HQ— A— ER---N-RE-RET— TDDR-E---
XSllO : X-DXFD-LDE-TVW— TGTLDIWPS— SS-TAVHE-RRALEA— NALLEA— LSPVLT
XS117 : YARQ-P-VEDAFGHQ.........LLA-LRQ-DATCLAAD-LA-AV-DA---- ADSE-LL
XSIOOO :  LM
XS492 :    LQ
XS901 : SMPGMGPHLGAEFLVITGGNMAAFTNPGRLASFAGLVPVPRDSGRXTGNLHRPKRYNRRL
XS900 s ————F—VX————F—AA———D— ——ASAD———GV———A—————————S———K——R——D———
XS116 s ———————V—————VA—V*—DLSGYKDA—————H———A————————R———Y———Q——————
XSllO : ----V-VRT.-AV-LV-V-DGTS-PTAAH---Y---A-TTKS— TSXHGE-A-RGG— Q-
XS117 : -F— L--L RV-AEI-DDRSR— DARA-K-Y— SA-IT-A KHFVGR-FVK.-N—
XSIOOO : AL— V— QVA-AV-ALLPPELWGRAKRAASYA. .— I-EREE— KSVERSRLSKKGPPL-
XS492 : — K-I-KIAS-SIISNLPELGYMTNKQASALV..-VA-MN-E YK-L.RKXQGGRHQV
XS901 : RRVFYLAALSSLKXEGPSRAFYDRKRSENHIHTQALLALARRHVDVLWALLR.DNRTWQ.
XS900 Î L—AC——S——V—IRTDPS— TY----- T—GKR----V— RLN--- M— .—HAVYH»
XS116 ! —WL——MS—QTAMMRP————DY—LK——G—GLL——————S————R——————M—— « —K—LFT «
XSllO : K-AMF-S-FACMNADPA— TY Q-ARGKT------ R-- QRIS— F-M— .-GTFYES
XS117 : MNAGF-W-FAA-QASPGANAH-R-R-EHGDW-AA-QRH-LN-FLGQ-HHC-QTRQHFDEQ
XSIOOO : — KL-MG— VAVRHDPEM H-LLSRGKRKK V-V-HKLLRRMMGR— EYYA-QLD
XS492 : -T-L-M-MM-AIQSNPVFKET-Q-LVAAGKPKKV-II-CIRKM-VX-NSM— DGVMWEAP
XS901 : ..PQQPTVAAA
XS900 : ..-ATT-A— .
XS116 : ..-AP-VTQTA
XSllO : RM-AGVEL— .
XS117 : RAFAPLLQ— A
XSIOOO : QGVA.......
XS492 : KTTN.......
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On the whole the greatest homologies are observed at the carboxy terminal and 
it is interesting to note that the amino acid sequences of the ORFs of both 
mycobacterial IS elements terminate in three alanine residues. Both non-Actinomycetes 
IS elements, ISIOOO and IS492, appear to have undergone a large deletion of 
approximately 80 amino acids, at positions 219 to 298 with respect to the 
Actinomycetes IS elements. However, the converse may be true in that the latter 
elements may have undergone an insertion of similar length.
Alignment of the carboxy terminal 163 amino acids of each sequence allowed 
for the construction of a phylogenetic tree by the method of maximum parsimony 
using the PROTPARS program of the PHYLIP package of phytogeny inference 
programs (Felsenstein, 1990). This program estimates phytogenies from protein 
sequences, only counting those nucleotide changes that change the amino acid. The 
phylogenetic relationship is arrived at by alignment of the sequences. Figure 2.1.13 
shows the most robust and parsimonious tree, indicating that the coding region of 
IS90I is most closely related to ISII6, only slightly less related to IS900, and more 
distantly related to ISIIO, IS1I7, ISIOOO and IS492. Since the overall amino acid 
sequence homology between IS90I and IS116, and IS90I and IS900, differs only 
marginally - probably insignificantly - namely 50% and 49% respectively. Since both 
Mycobacterium and Streptomyces are two genera belonging to the family of 
Actinomycetes it is not surprising that IS90I exhibits a closer phylogenetic relationship 
to elements of this family. However, the genus Thermits is only distantly related to 
other eubacteria but possesses an atypical IS element, ISIOOO. This demonstrates that 
this class of atypical insertion sequences is not confined to the Actinomycetes and may 
be far more widely distributed that previously thought.
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1 5 9 0 0
1 5 1 1 6
1 5 9 0 1  
I S I I O
1 5 1 1 7  
ISIOOO  
1 S 4 9 2
F i g u r e  4 . 1 . 1 3 :  P h y l o g e n e t i c  r e l a t i o n s h i p  b e t w e e n  Z S 901  
a n d  o t h e r  I S  e l e m e n t s  d e r i v e d  f r o m  PHYLIP a n a l y s i s .
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4.1.3.8 Distribution of IS901 in the M.avium  complex
In order to establish the distribution of 1S901 in the M. avium complex, 
Southern blots of DNA (1/xg) from M. avium strains isolated from a variety of 
backgrounds and digested with restriction endonuclease PvuII were screened with both 
plasmids pMB22, which contains IS900, and pUS410, which contains IS901. Samples 
included isolates from AIDS patients from the developed and developing world, birds, 
animals and the environment of the developed and developing world. In addition a 
number of M.paratuberculosis DNA samples were included. Table 4.1.4 summarises 
all strains screened in this manner.
RFLP types
A/I A B M X Total
AIDS — 150 4 4 158
non-AIDS 5 49 6 16 6 82
Birds 37 1 — — 2 40
Animals 16 6 — — 4 26
Environment 8 1 7 16
Table 4.1.4: MAI strains screened for presence of 1S901 (for details of isolates see 
Appendix 1 in Section 4.2). All isolates examined came from the developed world. 
—: no strains tested.
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DNA of mycobacterial strains grown on L-J slopes was prepared as described 
previously. Similarly, Southern blotting, extraction of probe DNA and hybridisation 
were carried out as described previously. However, in order to demonstrate the 
relatedness of 1S900 with IS901, the Southern blots were first screened with pMB22 
insert DNA and washed at medium stringency to allow detection of IS90I with this 
probe. Following probe removal, the same blots were then screened with labelled 
pUS410 insert DNA, but washed at high stringency to allow only IS901 sequences to 
be detected. Figure 4.1.14 A and B show a selection of M.avium strains screened in 
the above manner.
Since this thesis also includes the analysis of M. avium strains from various 
backgrounds, but mainly from AIDS and non-AIDS patients from various parts of the 
world, using pMB22 as a probe the discussion on the distribution of IS90I in the 
M.avium complex also contains references to that section of the thesis; similarly, the 
distribution of IS90I is also discussed later in the context of mycobacterial infections 
in AIDS patients.
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Figure 4.1,14 A and B: Southern blots of M.aviwn complex DNA
PvuII, probed with A:pMB22 and B:pUS410
Lane Sample RFLP' Lane Sample RFLP
1 AIDS patient AI 9 Johne’s disease A1
2 AIDS patient A l 10 Johne’s disease IS900
3 AIDS patient A l 11 Johne’s disease IS900
4 AIDS patient X 12 Johne’s disease IS900
5 Animal isolate A/l 13 AIDS patient B
6 Animal isolate A /l 14 AIDS patient HI
7 Animal isolate A/I 15 M. intracelliilare M
8 Animal isolate A/I 16 M. scwfiilaceum X
1: RFLP as determined by hybridisation with pMB22.
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Table 4.1.4 and Figure 4.1.14 A and B demonstrate that whereas M.avium 
RFLP type A strains (lanes 1 - 3, 9) are more-or-less ubiquitous, being found in the 
environment, AIDS patients, birds and animals, M.avium type A/I strains (lanes 5 - 
8), that is those containing IS901, are only found in bird and animal isolates but not 
environmental or AIDS patients isolates. Similarly, 1S900 (lanes 10 -12) is only 
present in M.paratuberculosis strains. Neither IS900 and IS901 are found in African 
M.avium complex strains (lane 14) or M.avium RFLP type B strains, another 
ubiquitous strain commonly found in AIDS patients (lane 13). Similarly, these IS 
elements are also absent in M.intracellulare (lane 15) and M.scrofulaceum. M.avium 
strains containing 75'P(9i gave very similar banding patterns with the IS90I probe 
(Figure 4.1.14B) - although some differences in banding pattern were found - 
indicating that, like IS900, this IS element is relatively stable in the genome of 
M.avium RFLP type A/I strains, consistent with IS90I being a site-specific insertion 
sequence.
IS90I therefore segregates between two groups of M.avium (Figure 4.1.14 A): 
M.avium RFLP type A, lacking IS901, that is commonly found in the environment 
and is also commonly found in AIDS patients; and M.avium RFLP type A/I which 
contains IS90I and, like M.paratuberculosis which contains IS900, appears to be a 
more specific animal pathogen. The distribution data presented here also indicates that 
not all animal isolates are RFLP type A/I strains but animals may also be infected by 
RFLP type A strains. Type A/I strains have also been detected in Johne’s disease 
isolates and have also been observed in Crohn’s disease isolates (McFadden, 
unpublished). Of great importance was the distribution of IS90I according to 
serovars. Historically, the M.avium complex was divided according to serovars;
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serovars 1-3 were classed as "classical" M.avium, serovars 4-20 were classed as 
M.intracellulare and serovars 41-43 were classed as M.scrofulaceum (Wolinsky & 
Schafer, 1973). Serovars 1-3 included the woodpigeon bacillus. However, more 
recent studies, involving DNA homologies, RFLP anaysis and the GenProbe, suggest 
that M.avium consists of serovars 1-6 and 8-10, whilst M.intracellulare consists of 
serovars 7 and 11-21 (Baess, 1979; 1983; McFadden et al., 1987; Picken et al., 
1988). Thorel et al (1990) describe three M.avium subspeces; M.avium subsp. avium 
subsp. nov., M.avium subsp. paratuberculosis subsp. nov., and M.avium subsp. 
silvaticum subsp. nov., where the woodpigeon bacillus is thought to correspond to the 
latter subspecies. This emended description of the taxonomy of the species M.avium 
was based on numerical taxonomy, RFLP analysis, field inversion gel electrophoresis 
studies as well as a number of phenotypic studies.
Although not all strains examined in this study were serotyped, 1S901 was 
found to be invariably associated only with M.avium serovars 1, 2 and 3. However, 
this was irrespective whether isolates were from birds, animals or woodpigeon 
bacillus. The findings above, therefore, suggest that the proposed subspecies M.avium 
subsp. silvaticum subsp. nov. is infact M.avium RFLP type A/I, containing IS901. A 
distinction between M.avium strains isolated from birds and animals and the 
woodpigeon bacillus is consequently not appropriate.
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4.1.3.9 Association of IS901 with virulence in mice
The above data indicated that M. avium strains containing IS901 differed in 
host-range from those lacking 1S901. However it was not clear whether this was due 
to a difference in virulence. As part of this collaborative investigation on the "Genetic 
Analysis of MAI" virulence studies were carried out by Appelberg and Silva at the 
University of Porto, Portugal. The results obtained by Appelberg and Silva are 
discussed here in order to emphasise the possible role IS901 may play in virulence. 
The discussion also includes a brief summary of the method used.
MAI strains of interest were selected on the basis of the findings described 
above. Although the virulence studies were carried out without my involvement, the 
results of these studies are of great importance and are therefore discussed. In order 
to examine the virulence of M.avium type A and type A/I strains, the proliferation of 
two M. avium type A and two M. avium type A/I strains was studied in BALB/c mice 
which are innately susceptible to infection by these mycobacteria (Appelberg & 
Sarmento, 1990).
Mycobacterial inocula were prepared as described previously (Appelberg & 
Sarmento, 1990). Briefly, smooth-transparent colony forming bacteria from the 
different isolates, two animal-derived isolates (PE9 and PE 17) and two AIDS-patients’ 
derived isolates (1101 and 1162w), were grown until mid-log phase in Middlebrook 
7H9 medium (DIFCO) supplemented with 0.04% of Tween-80 (SIGMA). The 
bacteria were pelleted by centrifugation, resuspended in saline with 0.04% of Tween- 
80 and briefly sonicated. Aliquots were frozen at -70°C until use. Female BALB/c 
mice were obtained from the Gulbekian Institute (Oerias) and were infected at 8 to 
10 weeks of age with ca. 10^  cfu of the different M.avium isolates by inoculating the
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bacteria suspended in 0.2ml of saline/Tween-80 through one lateral vein of the tail. 
After 6 hours, three mice were killed and the number of cfu in the spleens and livers 
were evaluated as described below. This reflected the numbers of bacteria initially 
implanted in these organs (time 0). At 30 and 90 days of infection, the spleens and 
livers of infected mice (three animals per time-point) were aseptically harvested and 
homogenised in a 0.04% Tween-80 solution. The homogenates were serially diluted 
and plated in duplicate on Middlebrook 7H10 agar plates. After incubating for 2 
weeks at 37°C, the colony forming units were counted.
Results in Figure 4.1.15 A and B are shown as the mean of the log 10 cfu in 
the organs of the infected animals and the standard deviation of this geometric mean, 
indicating that the two M. avium type A strains (strains 1101 and 1162w), obtained 
from AIDS patients, were essentially avirulent in this model, exhibiting minimal 
proliferation in either the spleen (Figure 4.1.15A) or the liver (Figure 4.1.15B) of 
mice throughout the three months period of infection studied - proliferation was 
arrested after the first month of infection. In contrast, the two animal isolates (PE9 
and PE17), both ISP07-containing strains, proliferated extensively in both organs. 
Although the number of strains examined is small the difference in virulence for these 
M. avium strains that differ in possession of ISPOi, is striking. It is perhaps surprising 
that in this system the strains isolated from AIDS patients are essentially avirulent; 
indicating that other factors (eg. environmental prevalence) rather than virulence (as 
measured in BALB/c mice) may be responsible for the prevalence of these strains 
(and complete absence of type A/I strains) in AIDS. It might be argued that the 
mouse model is not appropriate for this study, for type A/I appears to have a well- 
defined host-range, namely birds and animals, whilst type A strains appear to
146
predominate in the environment and AIDS patients. However, isolation of type A/I 
from non-immunocompromised patients with MAI, and similarly isolation of type A 
from birds and animals suggests that there is a similarity in the virulence of M.avium 
in mice to that of virulence in humans.
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Figure 4.1.15 A and B: Proliferation of M.avium type A and type A/I strains in 
BALB/c mice (A: spleen, B: liver).
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4.1.3.10 PCR amplification of M.avium complex DNA
1S901 has several applications in the study of the molecular biology of the 
M.avium complex, which include its use as an epidemiological marker to study strain 
differences within the complex and its usefulness to study the genetics of virulence 
in mycobacteria. Similarly, like IS900 it could be used to integrate foreign genes into 
mycobacterial genomes (England et al., 1991). However, 1S901 may also be 
employed as a tool for rapid diagnosis of disease due to M.avium RFLP type A/I 
strains. Such specific diagnosis is of particular importance since isolates from both 
avian and animal tuberculosis, Crohn’s disease and Johne’s disease tissue may include 
M.paratuberculosis, M.avium RFLP type A and M.avium RFLP type A/I strains.
Two samples of 1 - 5 ng of template DNA purified as described previously 
and resuspended in water from M.avium RFLP type A strains, isolated from AIDS 
patients; M.avium RFLP type A/I, isolated from animals; and M.paratuberculosis, 
isolated from Johne’s disease tissue; as well as negative controls which included a 
DNA sample from M.intracellulare and a water blank, were subjected to several PCR 
reactions as described previously. The aim of this investigation was to develop PCR 
reactions which are specific only to certain members of the M.avium complex. For 
this purpose a number of primer sets were employed. Alignment of the DNA 
sequences of 1S900 and IS901 shown in Figure 4.1.10 allowed for the selection of 
primer pairs which were specific to M.paratuberculosis, containing IS900; specific 
to M.avium RFLP type A/I, containing IS901; and specific to both 
M.paratuberculosis and M.avium RFLP type A/I. A primer pair that would be 
specific to M.avium RFLP type A strains was selected from the flanking region of the 
copy of IS901 which was contained in pUS411. Table 4.1.5 summarises the primer
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pairs selected for this purpose, which included primers previously employed to 
sequence IS901 and a putative insertion site in M.avium.
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Table 4.1.5: Primer pairs selected from 1S900 and 1S901 sequence data used in PCR 
amplification of M.avium complex DNA.
A. Primers specific for M.avium  RFLP type A1 strains:
FI: CAGCCAGCCGAATGTCATCC
F2: CAACTCGCGACACGTTCACC
Primers derived 150 bp upstream and downstream IS901 in pUS411.
Expected size of PCR product = SOObp.
B. Primers specific for both IS900 and 1S901 :
900-1: CCGCGGCGAAGGCAAGACCG
900-2: CGAGGAACTCAGCGCCCAGG
Primers derived from positions 511 and 1088 of IS901, exhibiting 100% homology with IS900. 
Expected size of PCR product = 574bp {JS900) and 577bp (IS901).
C. Primers specific for M.paratuberculosis (IS900):
MP300-1: TGGACAATGACGGTTACGGAGGTGG
MP300-2: TGATCGCAGCGTCTTTGGCGTCGGT
Primers derived from positions 209 and 563 of 1S900, exhibiting 50% (primer 1) and 80% (i)rimer2) 
with IS901. Expected size of PCR product = 354bp.
D. Primers specific for M.avium  RFLP type A/I (1S901):
K11.4: GC A ACGGTTGTTGCTTGA A A
K2.13: TGATACGGCCGGAATCGCGT
Primers derived from positions 76 and 1184 of IS901, exhibiting 50% (primer 1) and 90% (primer 2) 
homology with IS900. Expected size of PCR product = 1108bp.
E. Primers specific for M.avium RFLP type A/I (IS901):
K11.5: GATTGCTAACCACGTGGTGT
K2.12: GCTTATCGATGTTCTTGATC
Primers derived from positions 376 and 998 of 1S901, exhibiting 50% (primer 1) and 55 % (primer 2) 
homology with IS900. Expected size of PCR product = 622bp.
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Figure 4.1.16 A, B, C, D and E: PCR amplification of M.avium complex DNA 
employing primer pairs described in Table 4.1.5.
Lane DNA PCR conditions
1 </>X174 HaelII DNA marker 1. dénaturation 94°C, 1min.
2 M.avium  RFLP type A 2. annealing 60°C, 30sec.
3 M.avium RFLP type A 3. extension 12°C, 2V6min.
4 M.avium RFLP type A/I (IS901) 4. dénaturation 94°C, 30sec.
5 M.avium  RFLP type A/I (IS901) Steps 2 - 4 :  29 cycles.
6 M.paratuberculosis (IS900) 5. annealing 60°C, 2min.
7 M.paratuberculosis (1S900) 6. extension 72°C, 5min,
8 M. intracellulare 7. Cooling to 4°C.
9 water blank (-ve control)
10 </)X174 HaelII D N A  marker.
I 2 3 45 G 78 310
I 2 345G783IO
I 2 345G78S10
D E
I 2 345 6 78 010 i 2 3456780 lO
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PCR amplification shown in Figure 4.1.16 A, B, C, D and E employing the 
primer pairs shown in Table 4.1.5 revealed that all primer pairs used were specific 
for the strains initially selected for. None of the pairs either amplified 
M.intracellulare (Figure 4.1.16 A, B, C, D and E lane 8) or came up with false 
positives (lane 9). All PCR products corresponded in sizes to expected products as 
determined from the DNA homology data in Figure 4.1.10. Gel electrophoresis does 
not allow for exact size determination of a DNA fragment; thus, the sizes quoted here 
are approximations of the DNA bands obtained.
PCR A (Figure 4.1.16A) using primers selected from the flanking region of 
IS901 (F1/F2) and thought to be specific for M.avium RFLP type A strains amplified 
a 300bp fragment in such strains (lanes 2,3) but also amplified M.paratuberculosis 
DNA (lanes 6,7), yielding a PCR product of similar size. This clearly suggests that 
this particular locus for IS901 in M.avium RFLP type A strains is also present in 
M.paratuberculosis. However, significantly the locus is not occupied by a copy of 
IS900. The presence of this locus in both M.avium and M.paratuberculosis is not 
surprising, considering the >98% DNA homology of these two members of the 
M.avium complex (see discussion above). PCR A also yielded PCR products of 
approximately 1770bp when using DNA from M.avium RFLP type A/I as template 
(lanes 4,5), yielding a DNA band of comparable size to the entire 1S901 copy 
including the flanking regions in pUS411. This suggests that the conditions of this 
reaction allows for an extension of at least 2kb of DNA. Thus, PCR A may 
distinguish between M.avium RFLP type A/I on the one hand and M.avium RFLP 
type A and M.paratuberculosis on the other hand but not between the latter two.
PCR B (Figure 4.1.16B) employed a primer pair which exhibited 100%
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homology between 1S900 and IS901 (900-1/2). As can be seen from Figure 4.1.16B 
this reaction is specific for M.avium RFLP type A/I (lanes 4,5) and 
M.paratuberculosis (lanes 6,7), yielding a 570bp fragment. This PCR reaction does 
not allow differentiation between the two of them. In fact, close examination of the 
DNA sequence data in Figure 4.1.10 shows that the expected PCR fragments are 
574bp {IS900) and 577bp (IS901), repectively.
PCR C (Figure 4.1.16C), utilising primers thought to be specific for IS900 
(MP300-1/2) amplified only M.paratuberculosis DNA (lanes 6,7). The PCR product 
was as expected 350bp long. PCR C was specific for M.paratuberculosis although 
great homology between these primers and IS901 was observed. This suggests that 
the PCR conditions chosen here were sufficiently stringent.
Finally, PCR D and E (Figure 4.1.16 D and E), employing primers from 
1S901 (K11.4/K2.13; K11.5/2.12) but exhibiting a degree of homology to IS900, 
amplified only M.avium RFLP type A/I DNA (lanes 4,5), yielding PCR products 
lllObp and 600bp, respectively. This again suggests that the stringent conditions 
were well chosen.
Consequently, it may be said that the combination of PCR reactions described 
above allows for the distinction of the two major pathogenic members of the M.avium 
complex, namely M.avium RFLP type A/I and M.paratuberculosis', not only between 
them but also from the major non-pathogenic and almost ubiquitous M.avium RFLP 
type A strains.
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4.1.4 Discussion
IS901 is an atypical insertion sequence present in pathogenic strains of 
Mycobacterium avium RFLP type A/I strains. Its great homology with IS900, present 
in Mycobacterium paratuberculosis and other IS elements present in Streptomyces and 
other more distantly related bacteria suggests that this class of atypical 76" elements is 
more widely distributed than previously thought. 1S901 is invariably associated only 
with the ’classical’ M.avium serovars 1, 2 and 3 and was never found in those strains 
which are commonly present in the environment and are the most common strain 
isolated from AIDS patients (in the developed world). The distribution of IS901 in 
M.avium clearly suggests that the "wood pigeon bacillus" and pathogenic strains 
found in birds and animals are in fact M.avium type A/I strains, containing IS901. A 
numerical taxonomy suggested by Thorel et al (1990) describing new sub-species for 
M.avium Chester 1901, namely M.avium subsp. avium subsp. nov., M.avium subsp. 
paratuberculosis subsp. nov., and M.avium subsp. silvaticum subsp. nov. may 
therefore not be absolutely correct, for it does not take into account that bird and 
animal isolates appear to be identical to the woodpigeon bacillus, in that they are 
M.avium type A/I strains, containing 1S901. However, it is also possible that the 
woodpigeon bacillus, bird and animal-derived strains, although similar in that all these 
strains possess IS901, may possess genetic differences which were not detected with 
the DNA probes used in this study. Since IS901 containing M.avium strains may be 
isolated from birds, animals, and Crohn’s and Johne’s disease tissue, it is important 
to establish the genetic identity of these strains, either by RFLP typing of specific 
PCR amplification in order to be able to clearly demonstrate the taxonomic 
relationship of M.avium strains.
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The evolution of M. avium type A/I (from a type A strain) clearly involved 
the acquisition of multiple copies of 1S901. Genetic changes could have taken place 
which have modified the pathogenicity and host-range of type A/I strains relative to 
type A strains. Conversely, however, such modification of pathogenicity and host- 
range may have either preceded or followed the acquisition of IS901 by type A 
strains. Similarly, it is not clear whether this acquisition occured simultaneously in 
several strains or a single isolate followed by a clonal expansion of this single isolate. 
There is of course no direct evidence to link the difference in pathogenicity to 
acquisition of 1S901 ; however, it is notable that the evolution of M. paratuberculosis 
from M. avium type A has also involved acquisition of a similar insertion sequence - 
1S900 (Green et ah, 1989). The evidence presented here clearly indicates that two 
separate insertion events involving two distinct insertion sequences gave rise to 
M.avium type A/I and M.paratuberculosis, rather than the divergence of a single 
insertion sequence after separation of M.avium type A/I and M.paratuberculosis. It 
would clearly be of interest to directly determine the phenotypic effect of infection 
of M. avium type A with ISPW or 1^901. Transposition of 1^900 into M. smegmatis 
has recently been achieved (England et ah, 1991) and it would be of great interest to 
achieve transposition of M. avium with both 1S900 and 1S901. ISP07 is a useful tool 
to study the genetics of virulence of mycobacteria; and like 1^900 (England et ah, 
1991) it could be used to obtain stable integration of foreign genes in mycobacteria. 
DNA sequence data from IS901 has been used to develop a M. cv/wm-RFLP type A/I 
specific polymerase chain reaction, similar to that already developed for M. 
paratuberculosis (Vary et ah., 1990), that could be used for rapid diagnosis of disease 
due to this pathogen.
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4.2 GENETIC ANALYSIS OF THE MYCOBACTERIUM AVIUM- 
INTRACELLULARE COMPLEX (MAI) ISOLATED FROM AIDS, NON­
AIDS PATIENTS, ANIMALS AND THE ENVIRONMENT FROM 
DEVELOPED AND DEVELOPING COUNTRIES
Summary
Infections due to the Mycobactenum-avium-intracellulare complex (MAI) 
constitute the most common cause of systemic bacterial infections in AIDS 
patients from the developed world; they are difficult to treat and are associated 
with poor prognosis. The source and route of infection of MAI in AIDS is 
unknown. This study uses DNA probes and RFLP analysis to examine MAI 
strains from AIDS patients, animals and environmental samples from the USA,
pG+iertts m
Europe, Africa and Australia. AIDS MAI strains fromAEurope, USA and 
Australia were mostly RFLP type A; whereas MAI strains from Africa were a 
distinctly different RFLP type - H. Strains isolated from AIDS patients most 
closely matched the strains found in environmental samples from the same 
locality. This study identifies the environment as the most likely source of MAI 
infection in patients with AIDS and infection via the nasopharyngeal tract and 
the gastrointestinal tract appear to be the likely route of infection. Analysis of 
individual cases suggested that MAI infection in AIDS may be due to endogenous 
reactivation of a longstanding infection but direct inoculation from the 
environment may also occur. No evidence for involvement of plasmids in 
virulence of MAI strains for AIDS was found.
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4.2.1 Introduction
Infections due to mycobacteria occupy an important place among the infections 
which develop in patients with AIDS (Collins, 1986). Two types of mycobacterial 
diseases are commonly recognised in AIDS patients. First, tuberculosis due to 
M.tuberculosis and secondly opportunistic infections, mainly due to the 
Mycobacterium avium-intracellulare complex (MAI). There is a marked geographic 
difference in the prevalence of these two diseases. MAI infections are predominant 
in AIDS patients from developed countries (Portaels, 1987; Pitchenik et al, 1988; 
Collins, 1989; Rafet al, 1989; Satheera/, 1989; Dawson, 1990; Yakrus etal, 1990; 
Hoffner et al, 1990; Portaels et al, 1990), particularly the USA, whilst tuberculosis 
constitutes the most frequent mycobacterial infection in AIDS patients in countries 
where tuberculosis itself is endemic (Portaels, 1987). This is particularly true in sub- 
Saharan countries of Africa (Harries, 1990), and also among patients living in low 
socio-economic conditions (Chaisson et al, 1990). However, tuberculosis is one of 
the few contagious respiratory diseases that occur in AIDS patients and is both 
treatable and preventable. Here, tuberculosis is thought to be attributable to both 
endogenous reactivation and exogenous reinfection.
The MAI complex is commonly found in the environment, both in the 
developed and the developing world but is also a pathogen for birds and other animals 
(Portaels, 1978; Falkinham et al, 1980; Wendt et al, 1980; Brooks et al, 1984; 
Collins et al, 1984; Grange et al, 1986). Although MAI infections were reported to 
occur in AIDS patients almost from the very beginning of the AIDS pandemic, most 
of these were reported at post-mortem, being identified by large numbers of acid-fast 
bacilli present in the blood, stool, bone marrow, lymph node and sputum
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(Modilevsky, 1989). It is now established that MAI infections are the most common 
cause of systemic bacterial infections in AIDS patients in the developed world 
(Horsburgh et al, 1989). MAI infections in AIDS patients are notoriously difficult to 
treat and are associated with a poor prognosis (Horowitz, 1988). The prevalence of 
MAI infections in AIDS patients from developing countries is largely unknown, 
mainly due to the lack of epidemiological data (Quinn et al, 1986). A recent study 
carried out in Uganda failed to detect MAI infections among AIDS patients (Okello 
et al, 1990). Cases of MAI infections have however been reported among patients 
from developing countries treated in developed countries (Blaser et al, 1986). In a 
recent study involving African AIDS patients treated in Belgium 18% of patients were 
found to have MAI infections (Portaels et al, 1990). Studies in various parts of the 
developed world have shown that here the incidence varies from 10 to 50% (Pitchenik 
et al, 1988; Young, 1988; Sathe et al, 1989). It has been suggested that vaccination 
with BCG against tuberculosis may have induced protection against MAI infections, 
thus accounting for the lower incidence of MAI infections in AIDS patients from 
countries with an established BCG vaccination programme, eg. Sweden and the U.K., 
as compared to countries lacking such a programme, eg. the U.S.A. and the 
Netherlands (Kallenius et al, 1989).
It is also possible that mycobacterial infections play a role in the overall 
clinical picture of AIDS, acting a cofactor in the downgrading of the immune system 
in HIV-positive patients leading to AIDS (Collins, 1986). Although MAI infections 
tend to occur late in AIDS, it is also thought that subclinical infection may precede 
the development (and act as cofactor) of AIDS (Collins, 1989). The source and route 
of infection of MAI infections in AIDS is unknown. MAI can be isolated from sputa
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and stools of HIV positive patients without clinical or pathological evidence of 
dissemination (Stacey, 1986). Different routes of infection, e.g. respiratory and 
gastrointestinal, are thus possible. It has been suggested that the port of entry for 
MAI is the gastrointestinal tract (Stacey, 1986). It has also been si^ested that MAI 
infections in AIDS patients may represent a reactivation of a colonisation of the gut 
by these mycobacteria. The presence of MAI in the stool of healthy persons has been 
documented (Portaels, 1988; Colebunders et al, 1990); and the disease pattern of 
MAI in AIDS patients usually commences as an intestinal infection rather than as a 
respiratory infection (Blaser et al, 1986; Hawkins et al, 1986).
One of the characteristic features of MAI infections in AIDS patients is the 
predominance of certain serotypes of the MAI complex. Both in the USA and Europe, 
serotypes 1, 4 and 8 are the most prevalent serotypes (Kiehn et al, 1985; Guthertz 
et al, 1989). However, studies in Sweden have shown that there serotype 6 
predominates in both AIDS and non-AIDS patients, suggesting a geographical as well 
as disease-related difference in the distribution of clinically important MAI serovars 
(Hoffner et al, 1990). However previous studies by restriction fragment-length 
polymorphism (RFLP) analysis have shown that serovars correspond poorly to the 
genetic identity of these strains (Hampson et al, 1989); and that Western AIDS 
patients are usually infected with a single highly conserved strain of M. ûvzwm-RFLP 
type A. Current views as regards to virulence and pathogenicity of MAI in AIDS 
suggest the possibility of plasmid encoded virulence and pathogenicity factors 
(Crawford et al, 1986; Ganghadaram et al, 1988). Although the presence of related 
plasmids has been reported in many MAI strains from AIDS patients from the 
developed world, geographic variation in the frequency of plasmid detection in such
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strains has been found (Hellyer et al, 1991).
In order to establish the genetic identity of MAI strains in AIDS patients and 
identify the likely source and route of MAI infections in AIDS, MAI isolates from 
AIDS patients, non-AIDS patients, healthy persons, animals and the environment, 
from both developing and developed countries, including Central African countries, 
the USA, Australia and various European countries were examined by restriction 
fragment length polymorphism (RFLP) analysis in order to highlight possible genetic 
variations in the geographic distribution of these isolates. For specific identification 
a selection of these strains were also subjected to a commercially available DNA 
probe, which allows for the differentiation between Mycobacterium avium and 
Mycobacterium intracellulare. In addition, plasmid profiles of these strains were 
established by hybridising DNA from MAI isolates with probes derived from 
plasmids commonly found in MAI isolates from AIDS patients.
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4.2.2 Methods and Strains 
4.2.2.1 Mycobacterial Isolates
MAI isolates from both the developing and the developed world were 
examined; these included isolates from both AIDS and non-AIDS patients, healthy 
persons, bird and animal isolates and isolates from the environment. In addition, a 
number of serotyped MAI strains, from a variety of sources, were included in this 
study. Table 4.2.1 summarises the number of isolates from various origins, 
identifying the donor and laboratory.
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Table 4.2.1: Total number of MAI isolates analysed for RFLP and presence of 
common MAI plasmids.
AIDS non-
AIDS
healthy veter- 
persons inary
bird environ
ment
sero­
types
Belgium^ 30 16 7 2 2 - 24
Denmark^ 8 21 - 4 - - -
Sweden^ 11 14 - - - - -
U.K.'* 11 - - 2 0 37 - -
Africa^ 20 9 - 10 - 16 -
Australia^ 9 7 - - - - -
U.S.A.^ 89 23 - - 1 16 17
Total 178 90 7 36 40 32 41
no isolates tested.
A ll isolates from the Institute o f  Tropical Medicine (ITM), Antwerpen.
Selection o f  serotyped laboratory strains from Royal Tropical Institute, Amsterdam. 
A ll isolates from the Statens Seniminstitut, Copenliagen.
A ll isolates from the National Bacteriological Laboratory, Stockholnm.
A ll AIDS patients isolates from St. Mary’s Hospital, London.
Veterinary isolates from St. Mary’s Hospital, London and from the Central 
Veterinary Laboratory, Weybridge.
Bird isolates from University College Middlesex School o f  M edicine and from 
St. Mary’s Hospital, London,
A ll AIDS patients isolates (Senegal and Zaire) from ITM, Antwerpen.
A ll non-AIDS patients isolates (Zaire) from ITM, Antwerpen.
A ll veterinary isolates (Zaire) from ITM, Antwerpen.
A ll environmental isolates (Zaire) from ITM, Antwerpen.
A ll isolates from State Health Laboratory, Brisbane,
9 AIDS patients isolates from Centre for Disease Control, Atlanta.
8 AIDS patients isolates from University o f  Colorado Medical School, Denver.
6 AIDS patients isolates from University o f  San Francisco, San Francisco.
66 AIDS patients isolates from Sloan Kettering Hospital, N ew  York.
24 non-AIDS patients isolates from Sloan Kettering Hospital, N ew  York.
16 environmental isolates from Virginia Polytechnic Institute, Blacksburg.
Selection o f  serotype^d laboratory strains from J.L. McClellan Memorial 
Veterans Hospital, Little Rock.
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4.2.2.2 Geographic origin of MAI strains and site of isolation
All African AIDS patients came to Belgium for treatment and in all but two 
cases MAI was isolated within three months of their arrival in Belgium. All isolates 
from the Sloan Kettering Hospital were isolates taken from patients living within the 
area of New York City. The geographical origin of the other AIDS patients-derived 
isolates from the U.S.A. is unknown. All environmental isolates from the U.S.A were 
obtained from the East and South East Coast region of the country. All African non- 
AIDS, animal and environmental isolates were obtained in Zaire.
Sites of isolation from AIDS patients, non-AIDS patients and healthy persons 
included blood, body limbs, bone marrow, bronchial aspiration, bronchio-alveolar 
lavage fluid (BAL), cerebro-spinal fluid (CSF), gastric fluid, lung biopsies, lymph 
nodes, pericardial fluid, pleural fluid, neck and rectal abbesses, sputum, stool, urine. 
In most but not all cases the site of isolation was known.
Although most cases represented single isolates from one patient, a number 
of isolates were obtained from the same source, not only from different sites but also 
at different times. These will be discussed in detail below. Environmental isolates 
from Africa and the U.S.A were obtained from aerosol, soil and water (where algae 
is synonymous to water).
It is important to stress that all MAI isolates were identified as being MAI by 
the respective donor laboratories; similarly serotypes were designated by these 
laboratories. All isolates received from the I.T.M. were identified as MAIS strains 
by a series of tests including pigmentation, catalase and urease activity and fatty and 
mycolic acid analyses (Portaels, 1978; Portaels et al, 1987). All isolates were 
identified by the donor laboratories as being MAI strains by conventional methods
164
(Jenkins et al, 1982).
In order to establish whether a relationship existed between serotypes and 
RFLP pattern, 41 serotyped MAI strains were examined in addition to examining 
clinical and environmental isolates. Like the identification of each isolate, serotyping 
was performed by the donor laboratories.
One AIDS-derived MAI isolate, LR25, and its apparently cured derivative, 
LR163 (see "Introduction: MAI and AIDS"), both extensively used in pathogenicity 
studies (Crawford et al, 1986; Ganghadaram et al, 1988) were also typed in this 
manner. All samples received were sent on L-J slopes and incubated at 37°C for up 
to several weeks in order to obtain sufficient bacterial growth for DNA extraction 
(carried out as described in "Methods").
4.2.2.S RFLP typing and plasmid analysis
RFLP typing of DNA isolated from MAI strains was performed as described 
in "Materials & Methods". Briefly, Southern blots of 0.5-1.0)Ug DNA from MAI 
strains digested with restriction endonuclease PvuII for 3-4 hours, 37°C were probed 
with ^^P-dCTP-radiolabelled DNA probes, including pMB19, pMB20 and pMB22 
(McFadden, 1987). Recombinant plasmids pMB19 and pMB20 are two random clones 
from an M.paratuberculosis plasmid library, whilst clone pMB22 contains a 5.3kb 
DNA insert which is comprised of a copy of the 1.45kb long insertion sequence 1S900 
plus 3.85kb flanking DNA. It is this flanking DNA which gives rise to the RFLPs 
observed in this study. Digestion and purification of insert DNA to be used as probes 
was performed as described above. The usefulness of these probes in an 
epidemiological investigation of MAI complex strains had been demonstrated by
165
Hampson et (1989).
Following probe removal as described previously, the same Southern blots 
were screened for the presence of plasmids by hybridising the blots with probes 
derived from MAI plasmids pLR7 and pLR20 (Crawford et al, 1981). These two 
plasmids, which exhibit no homology between them, detect the vast majority of 
"small" plasmids present in MAI isolates (Crawford, Falkinham & Hellyer; personal 
communications). Approximately half of all strains were also screened with a third 
MAI plasmid, pVT2 (Tucker et al, 1990); however, in only five cases were additional 
plasmid sequences (not detectable with either pLR7 or pLR20) identified. This is not 
surprising, for Crawford & Falkinham (1990) demonstrated that pVT2 is very closely 
related to pLR20. For this reason, screening with pVT2 was discontinued. In addition 
to hybridising Southern blots containing MAI DNA digested with PvuII, blots 
containing undigested DNA samples from the same MAI strains were probed with the 
same MAI plasmids. This excluded the possibility that plasmid related sequences 
contained within the MAI genomes would erronously be identified as plasmid 
sequences.
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4.2.2.4 Gen-probe test
Subsequent to RFLP typing, a number of strains were tested with the Gen- 
Vïoht Mycobacterium avium Complex, Rapid Diagnostic System. This was performed 
according to manufacturer’s instructions. Both radioactive and non-radioactive probes 
were used. The system consists of two tests - one specific for Mycobacterium avium 
and the other specific for Mycobacterium intracellulare. Although only a very limited 
number of strains were tested in this manner as part of this thesis, a much larger 
number of strains were tested at the Institute of Tropical Medicine, Antwerpen as part 
of this collaborative project on the "Genetic Analysis of the MAI Complex". Since 
the results obtained at the I.T.M. are more representative, they will also be discussed.
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4.2.3 Results
4.2.3.1 RFLP typing and plasmid analysis
Screening Southern blots of DNA from MAI strains with probe pMB22 
revealed the existence of several restriction fragment-length polymorphisms (RFLP) 
which could be grouped according to their banding patterns. The banding patterns, 
shown diagrammatically in Figure 4.2.1, were grouped into major RFLP types, 
namely RFLP types A, A/I, B, H, M, and X; where X denotes various, but not 
necessarily related, banding patterns which did not correspond to any of the specific 
RFLP types.
Each major RFLP type could be further subdivided into several related RFLP 
types - notably type A into Al, A2 and A3 and type H into HI and H2 - whose 
banding pattern is compatible with the loss or acquisition of restriction endonuclease 
sites (Figure 4.2.1). The relationship of these subtypes, obtained when screening MAI 
DNA with pMB22, was confirmed by screening the same isolates with pMB19 and 
pMB20.
Figure 4.2.2 A (TOP), B (TOP) and C show a selection of Southern blots of 
MAI DNA digested with restriction endonuclease PvuII and probed with ^^P-dCTP 
labelled pMB22, depicting the major RFLP types identified in this study. Figure 4.2.2 
A (BOTTOM) and B (BOTTOM) also show the banding patterns of MAI plasmids 
detected in these isolates when the same blots were screened with plasmids pLR7. 
Several banding patterns were observed among plasmids identified with probes pLR7 
(Figure 4.2.2 A and B) suggesting that plasmids other than pLR7, but related to 
pLR7, were detected in this way. Hybridisation with pLR20 yielded fewer banding 
patterns, suggesting that fewer MAI plasmids exhibit homology to pLR20.
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Figure 4.2.2 A: Southern blot of MAI DNA digested with PvuII, hybridised with 
pMB22 (TOP) and pLR7 (BOTTOM).
Lane: 1 2 3 4 5 6 7 8 9 10
RFLP: * - B B B H2 H2 B B X
Lane: 11 12 13 14 15 16 17 18 19 20
RFLP: X A l A l M Al A2 HI A l — pLR7
*: lambda H indlll DNA marker; pLR7; plasmid digested with PvuII.
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Figure 4.2.2 B: Southern blot of MAI DNA digested with PvuII, hybridised with 
pMB22 (TOP) and pLR7 (BOTTOM).
Lane: 1 2 3 4 5 6 7 8 9 10
RFLP: * - X A l A l A3 A l A l A2 A l
Lane: 11 12 13 14 15 16 17 18 19 20
RFLP: A l A l A l A l Al AX A l X — pLR7
*: lambda H indlll DNA marker; pLR7: digested with PvuII.
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Figure 4.2.2 C: Southern blot of MAI DNA digested with PvuII and hybridised with 
pMB22.
Lane: 1 2 3 4 5 6 7 8 9 10
RFLP: * - X X A/I A/1 X A/I A/I A /I
Lane: 11 12 13 14 15 16 17 18
RFLP: A l A/I A l A/I A/1 A/1 A3 M
*: lambda H indlll marker.
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The RFLP types of all strains screened with pMB22, as well as displaying the 
presence of plasmid sequences related to pLR7 and pLR20 are shown in Appendix 
1 at the end of this chapter. Appendix 1 is divided according to geographic origin and 
clinical status of the host, as shown in Table 4.2.1, and includes data as to strain 
designation, serotype and site of isolation. In some cases the site of isolation was 
unknown; similarly, only a few of the isolates shown here were serotyped.
The cumulative data shown in Appendix 1 is summarised in Table 4.2.2, 
where the RFLP types and frequency of plasmid detection are shown in relation to 
geographic and host origin.
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Table 4.2.2; RFLP types and plasmid presence o f M A I isolates.
AIDS
Total
U.S.A.
Europe
Australia
Africa
Non-AIDS
U.S.A.
Europe
Australia
Africa
Total
A/I
89(61) - 
53(22) - 
8(4) -
2(0) -
152(87)-
16(15) 1(0) 
27(5) 4(0)
5(1) -
48/21 5(0)
RFLP/Plasmid 
B H M
4(0)
5(0)
9(0)
6(0)
9(0)
15(0)
10(0)
10(0)
X
3(0)
1(0)
3(0)
7(0)
3(0) 3(2)
11(3) 3(1)
2(0) -
16(3) 6(3)
Total
89(61)
60(22)
9(4)
20(0)
178/87
23(17)
51(9)
7(1)
9(0)
90(27)
Healthy Europe
Total
Veterinary
animal Eur/USA 
bird
monkey Africa
Total
Environment
U.S.A. aerosol 
water 
soil
Total
Africa water 
-soil 
-algae
Total
Serotypes
Kolk
Crawford
6(1)
1(0)
7(1)
4(3)
1( 1)
3(3)
8(7)
7(0)
7(0)
16(0) - 
37(0) -
9(0)
53(0) 9(0)
5(0)
3(0)
8(0)
1(0)
1(0)
1(0)
1(0)
4(0)
2(0)
1(0)
7(0)
7(4)
7(4)
5(0)
2(0)
7(0)
7(0)
7(0)
26(1)
40(0)
10(0)
76(1)
4(3)
8(5)
4(3)
16(11)
10(0)
3(0)
3(0)
16(0)
8(3) 6(0)
8(nt) 3(nt)
7(1) 3(1) 24(5)
5(nt) l(nt) 17(nt)
( ): number of isolates exhibiting presence of plasmids as determined by hybridisation with pLR7 and 
pLR20; nt: not tested; no RFLP type identified. Data on plasmids does not include 
isolates where presence of plasmids was not clear.
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Appendix 1 and Table 4.2.2 show that RFLP type A is the predominant type 
found in isolates from both AIDS and non-AIDS patients from the developed world. 
It was however not found among isolates from AIDS and non-AIDS patients from 
Africa. Type A is also found in the environment of the developed world (in this case 
the U.S.A.) and animal and bird isolates. Two type A strains detected in two isolates 
from African AIDS patients are discussed below. Type A/I strains, characteristic in 
bird and animal isolates, were also detected in non-AIDS patients isolates from both 
Europe and the U.S.A.
There is some geographic variation in the prevalence of type A strains. Table
4.2.2 clearly shows that 100% of all isolates from AIDS patients from the U.S.A. 
were type A, whilst corresponding isolates from Europe (88%) and Australia (89%) 
also contained other types, namely types B and X. This variation in the prevalence 
of RFLP type A is also seen in isolates from non-AIDS patients from the U.S.A. 
(71%), Europe (53%) and Australia (71%).
As regards to variation within the RFLP type A group, the data shown in 
Appendix 1 shows that greater homogeneity was observed among isolates from the 
U.K., Sweden and Denmark, where isolates tended to be (almost) exclusively type 
A l. Belgian AIDS isolates, on the other hand, exhibited an almost equal proportion 
of type Al and A3 patterns, whilst isolates from the U.S. displayed all three type A 
sub-types, namely A l, A2 and A3.
RFLP type A/I described in Section 4.1 was the predominant type found in 
veterinary and bird isolates but was also detected - if infrequently - among non-AIDS 
patients isolates from the developed world.
RFLP type H, on the other hand, was found to be exclusive to isolates from
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African AIDS patients and the African environment, supporting the view that 
geographic differences in the genetic variation of the MAI complex exist.
A fourth RFLP type, type B, was found to be present in clinical isolates from 
both the developed and developing world (in this case Europe and Africa, 
respectively) as well as in isolates from healthy Europeans.
M.intracelMare, which has a distinct RFLP type, type M, was identified 
predominantly in isolates from non-AIDS patients from the developed world and in 
only one isolate from the environment of the developing world.
Screening of MAI isolates for plasmids related to pLR7 and pLR20 revealed 
that such plasmids are only present in type A, type M and type X strains but absent 
in type A/I, type B and type H strains. Among AIDS patients isolates from the 
developed world, plasmids were only present in type A isolates, whilst among isolates 
from non-AIDS patients and the environment plasmids were also found in type M and 
type X strains.
Geographic variation in the presence of plasmids was observed among AIDS 
patients isolates from the developed world, in that plasmids were more prevalent in 
US isolates (68%) and less common in European (37%) and Australian (44%) 
isolates. A further breakdown of the European isolates reveals that even within 
Europe there is variation in the presence of plasmids in AIDS patients isolates. Whilst 
18% of U.K. isolates contained plasmids, this figure was 57% for Belgian isolates, 
25% for isolates from Denmark and only 9% for isolates from Sweden. The only 
Swedish AIDS isolate containing plasmids came from a foreigner living in Sweden 
(no further details known).
Within the RFLP type A group, no correlation was found between plasmid
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presence and particular type A sub-types.
Similarly, no major difference was found between the prevalence of plasmids 
in AIDS and non-AIDS isolates from the developed world. As part of this study AIDS 
and non-AIDS isolates from New York City were analysed (samples SK). Amongst 
SK isolates plasmids appeared to be present at almost equal frequencies in MAI 
isolates from both groups of patients.
Figure 4.2.3 shows the distributions of RFLP type A isolates (in %) in AIDS 
and non-AIDS patients in various countries, whilst Figure 4.2.4 shows the distribution 
of plasmids (in%) in MAI isolates from the same AIDS and non-AIDS patients.
In order to determine the significance of the correlations and differences found 
in terms of RFLP types and plasmid presence, ChP tests were performed on a 
number of parameters, including the distribution of RFLP type A in AIDS and non- 
AIDS isolates (in individual countries) and the distribution of plasmids in MAI 
isolates in AIDS and non-AIDS isolates (in individual countries). These results are 
summarised in Table 4.2.3.
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% RFLP type A
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B eri B ari Den* Den^ Swe* Swe^ UK *" USA* USA^
AIDS VS N o n -A I D S
Figure 4.2.3: Distribution of RFLP type A in MAI from AIDS ^and non-AIDS'^ 
patients (in %). No data available for non-AIDS patients from U.K.
178
% plasm ids in RFLP type A
100
Bel* Bel^ D en Den^ Sw e' S w e' UK" USA USA^
AIDS vs  N o n -A ID S
Figure 4,2.4: Distribution of plasmids in MAI RFLP type A from AIDS^and non- 
AIDS patients (in%). No data available for non-AIDS isolates from U.K.
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Table 4.2.3: ChF tests of distribution of RFLP type A and plasmids in AIDS vs non- 
AIDS isolates.
ChF = E[(A-E)%]
RFLP A* Plasmids-
Belgium 2.01 4.92
Denmark 2.09 0.001
Sweden 0.14 0.03
Australia 0.14 1.07
USA 1.31 1.54
*: frequency o f  RFLP type A in AIDS vs non-AIDS; frequency o f  plasmids in AIDS vs non-AIDS.
A  =  actual frequency E =  expected frequency Degrees o f  freedom =  1 
90% confidence level: probability value =  2.71 99% confidence level: probability value =  10.83
If  Chi^ <  2 .71 , then 90% confidence that frequencies not significantly different.
I f  Chi^ <  10.83 then 99% confidence that frequencies not significantly different.
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Table 4.2.3 clearly shows that there is no significant difference in either the 
distribution of RFLP type A or the presence of plasmids in AIDS and non-AIDS MAI 
isolates from the developed world, both at the 99% and 90% confidence level, the 
exception being the distribution of plasmids in Belgian isolates. Although the sample 
sizes were small, this confirms that although there is geographic variation in the 
frequency of MAI in both AIDS and non-AIDS patients, this variation does not exist 
within a given geographic region.
The data in Appendix 1 clearly identifies the environment as the likely source 
of MAI infection in AIDS patients, in that RFLP types identified in AIDS patients 
isolates are found in their corresponding environment - namely type A in the 
developed world and type H in Africa. These strains were associated with soil, water 
and aerosol (in the U.S.A.), suggesting that possible routes of infection must include 
the nasopharyngeal and gastrointestinal tracts. However, RFLP type B, on the other 
hand, was not only detected in AIDS patients isolates but also in non-AIDS patients 
and the stool of healthy persons. This indicates that MAI - or type B strains at least - 
may be a constituent of the normal gut flora. Thus, in this case MAI infection in 
AIDS patients may result from activation of this gut constituent.
4.2.3.2 Identity of MAI strains by Gen-Probe
Table 4.2.4 summarises the the results of the GenProbe test applied to a 
selection of MAI strains. The strains selected were predominantly RFLP types B, H 
and X. Both the radioactive and non-radioactive tests were used. However, the results 
of these test show that there is a discrepancy between the radioactive and non­
radioactive version of the test.
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4.2.4: GenProbe analysis of MAI strains
radioactive non-radioactive
Strain RFLP M. a M. i M.a M.i
1812' H - 4- nt nt
1675' B - - nt nt
1815' X - + nt nt
11074 H - - -
925 H - + - +
1329 H - + - - •
1794 H - - - -
1818 H - - - -
2069 H - - - -
2620 H - + - -
3087 H - - - -
5779 H - - - -
2629 H - - - -
2070 A /I + - -
2073 X - - - -
2074 A /I + - + -
2076 X - - - -
4427' nt + - nt nt
4429' nt + nt nt
h radioactive test on these isolates performed as part o f  this thesis; all isolates also repeatedly tested  
at the IT M , Antwerpen using both radioactive and non-radioactive tests.
M.a: M.avium; M.i: M.intracellulare.I: M.avium reference strains (Portaels, unpublished), nt: not 
tested.
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Testing MAI strains with the commercially available Gen-Probe revealed that 
the RFLP type B strain was negative for both the M.avium and M.intracellulare 
components of the test. The precise identity of type B strains is therefore still unclear. 
Recent lipid analyses have shown that strains classified as type B do exhibit lipid 
patterns characteristic for the MAI complex (Portaels, unpublished). Of all ten RFLP 
type H isolates tested with the Gen-Probe all were negative for M.avium, whilst only 
four were positive for M. intracellulare when using the radioactive version of the test 
kit. However, when the non-radioactive version of the test kit was used, the number 
of isolates testing positive for M. intracellulare was reduced to one. This suggests that 
type H is a member of the MAI complex but the probe is too specific to detect this 
distantly related member, for like RFLP type B strains, type H strains exhibit certain 
phenotypic characteristics, including lipid analysis, catalase and urease activity and 
pigmentation pattern, which allow for their inclusion into the MAI complex.
RFLP types A and M have been shown to be positive for M.avium and 
M.intracellulare, respectively (Brown; Crawford, personal communication).
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4.2.3.3 Multiple isolates from patients and "odd ones out"
Several isolates from African AIDS patients revealed unexpected RFLP types 
(Table 4.2.5). However, this data confirmed the suggested origin of MAI infections 
in AIDS patients. A number of multiple isolates from the same AIDS patients were 
examined (Table 4.2.6 A and B). Generally, multiple isolates from different sites of 
a given patient exhibited the same RFLP type; however, differences in plasmid 
content were detected. Although suggesting that these represent different strains, this 
finding must be considered carefully since the rate of plasmid isolation is dependent 
on a number of factors, including growth conditions, media, and age of the culture.
Table 4.2.5: RFLP of African AIDS isolates 
strain RFLP
4386 A
1329 H
1329w H
Table 4.2.6 A: Multiple isolates from an African AIDS patient
months site ref. RFLP
0 stool 1575 X
6 lymph 1815 X
14 blood 2296 A2
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Table 4.2.6B: Multiple isolates from a Belgian AIDS patient
months site ref. RFLP pi:
0 blood 1581 A3 +
0 sputum 1582 A3 +
I stool 1678 A3 +
1 stool 1713 A3 +
12 stool 2256 A3 +
14 blood 2435 A3 +
14 blood 2436 A3 +
14 blood 2437 A l -
17 blood 2341 A3 +
28 blood 3267 A3 +
Isolate 4386 (Table 4.2.5) came from a European person who lived in Rwanda 
in 1989, where he/she was diagnosed with AIDS. Upon returning to Europe the 
patient was found to have a M.xenopi infection. Several months after that, MAI was 
isolated - exhibting RFLP type A. This indicates that the patient was infected in 
Europe rather than in Africa.
Isolates 1329 and 1329w (Table 4.2.5), again, came from a European living 
in Africa and being diagnosed for AIDS whilst there. Upon coming to Belgium for 
treatment, these two isolates were obtained from the patient, both exhibiting RFLP 
type H. In this case the indication is that the patient picked up his/her MAI infection 
in Africa.
Multiple isolates from an African AIDS patients shown in Table 4.2.6A taken 
over a period of 14 months subsequent to arriving in Belgium for treatment show that 
the first two isolates obtained after 0 and 6 months were type X, whilst the last isolate
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obtained after 14 months was a type A strain. Here, the converse is demonstrated, in 
that the patient was probably infected with this type A strain during his/her stay in 
Belgium.
These cases identify the environment as the likely source of MAI infection in 
AIDS patients.
Multiple isolates from a Belgian AIDS patient taken over a period of 28 
months, shown in Table 4.2.6B, show almost complete homogeneity both in terms 
of RFLP type and plasmid content;similarly, no difference in RFLP type was found 
with respect to the site of isolation. Except for one of the three isolates obtained after 
14 months all isolates were found to be type A3, all containing plasmids related to 
pLR7 but not to pLR20. Except for this single isolate at 14 months (isolate 2437), 
one may have been able to conclude that MAI infections in AIDS patients appear to 
be a one-off infection which ultimately becomes chronic. There is a distinct possibility 
that this particular isolate may be a contaminant, for two other isolates obtained from 
this patient at the same time exhibit an RFLP type A3 as well as identical plasmid 
patterns.
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4.2.3.4 RFLP typing of serotyped strains
As part of this study, serotyped MAI strains were typed according to their 
RFLP. The results in Appendix 1 show that the DNA probe employed in this study 
allowed identification of members of the MAI complex at the species level. MAI 
strains of serotypes 1-6 and 8-11, considered to be M. avium strains were invariably 
RFLP type A, A/I and X. A number of anomalies were found, namely strain 163 
(Crawford) designated serotype 6 but exhibiting an RFLP type M, which is 
characteristic for M.intracellulare. Similarly, strain 158 (Crawford) designated 
serotype 10 but again exhibiting an RFLP type M. Finally, strain 141 (Crawford) 
designated serotype 26 exhibited an RFLP type A, characteristic for M.avium. It 
should be noted that some classification systems, such as conventional taxonomic 
tests, still regard certain serotypes, such as 4-6 and 8-11, as being "intermediate" 
MAI strains, rather than defining these as either M.avium of M.intracellulare.
Characteristically, RFLP type A/I strains, those possessing 1S901, were 
invariably associated with serotypes 1, 2 and 3 - often referred to as the "classical" 
M. avium strains.
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4.2.3.5 Genetic identity of strains LR25 and LR163
As described previously, MAI strains LR25 and its supposed "cured" 
derivative LR163 have been employed extensively in pathogenicity studies of the MAI 
complex. In order to reduce the possibility of contamination, two different sets of 
isolates from two laboratories, each supplied by Crawford with the original strains, 
were tested. However, as can been seen in Table 4.2.7, in both cases LR25 differs 
from LR163 in its RFLP.
Table 4.2.7: RFLP of MAI strains LR25 and LR163 
Received from Falkinham (Virginia State Poly):
Refer list RFLP Plasmids
1 2
LR25 F21 A3 + +
LR163 F22 M
Received from Hellyer (St. Mary’s Hospital):
LR25 T13 A3 + +
LR163 T14 M
1: pLR7; 2: pLR20.
Whereas strain LR25 exhibits an RFLP type A3 pattern, containing plasmids 
related to the plasmid probes used in this study, its supposedly "cured" strain LR163 
does not correspond to RFLP type A3, instead displaying a type M RFLP, which is 
characteristic for M.intracellulare. The genetic divergence of LR25 and LR163 has 
been confirmed by Crawford by means of Gen-Probe testing, confirming that LR163
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is not the cured derivative of LR25. A communication to this effect is presently being 
drafted by Kunze, McFadden, Falkinham and Crawford.
This important finding invalidates a series , of studies (described previously) 
involving the use of these two strains - based on the assumption that LR163 is the 
cured derivative of LR25 - concerning the pathogenicity of the MAI complex, 
restriction modification systems in MAI and catalase activity in MAI. As described 
previously Ganghadaram et al (1988; 1989a; 1989b) suggested that virulence and 
pathogenicity of MAI in AIDS patients may be related to the presence of plasmids. 
Crawford & Bates (1981b) suggested the presence of a plasmid-encoded restriction- 
modification system in MAI and Pethel & Falkinham (1989) attributed differences in 
catalase activity among MAI strains to the presence of plasmids.
The findings and conclusions of these studies must now be assumed to be 
erroneous. With respect to the pathogenicity and virulence of MAI infection in AIDS 
patients, this renews the entire debate as to factors contributing to MAI infections in 
AIDS patients.
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4.2.4. Discussion
This data confirms earlier findings concerning the specificity of M.avium 
RFLP type A in AIDS but finds that this association is confined to Western AIDS 
patients. In African AIDS patients a second RFLP type predominates - type H. The 
finding of similar distributions of strain types in AIDS as in environmental samples 
for both African and U.S.A. strains - although different types - identifies the 
environment as the likely source of infection. A breakdown of the environmental 
sources of MAI revealed that these strains were associated with soil, water and 
aerosols, indicating that infection may occur both via the nasopharyngeal and 
gastrointestinal tracts. Significantly, strains isolated from birds and animals were 
almost always M.avium type A/I, which is closely related to type A but contains the 
insertion sequence 1S901 (Section 4.1); type A/I strains have not been detected in 
AIDS patients isolates. Clearly, hosts of type A/I strains are not a likely source of 
MAI infection in AIDS patients. M. avium A/I strains also differ from type A strains 
in the complete absence of plasmids related to those found in AIDS isolates.
Infection from an environmental source rather than person-to-person may also 
explain why MAI infections are equally abundant among different high-risk groups 
within a given developed country. Although many RFLP types were identified in 
environmental samples, only type A and type H appear to have the potential for 
causing disease in AIDS patients. The factors responsible for virulence of these 
strains in AIDS is unknown. Moreover, no evidence for plasmid involvement in 
virulence of MAI strains in AIDS was found.
The identity of type H strains is still unclear, for although they exhibit 
phenotypic characteristics which permit their classification into the MAI complex,
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their genetic identity differs markedly from those of M. avium, (type A) and 
M.intracellulare (type M). Similarly, type B strains identified in ÀIDS and non-AIDS 
isolates do not appear to belong to the MAI complex.
Although the environment is the likely source of MAI infections in AIDS this 
could be due to a longstanding endogenous infection that reactivates at the onset of 
AIDS or due to direct inoculation via the respiratory or digestive tracts. This is 
clearly important to any attempts to prevent MAI infections in AIDS.
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Appendix 1: RFLP analysis and plasmid screening of MAI isolates 
RFLP probe: pMB22; plasmid probes: 1) pLR7, 2) pLR20.
Ref: reference from donor laboratory; list: thesis list; strain; designation by donor 
laboratory; ser: serotype designated by donor lab (where known); origin: site of 
isolation. Isolate details not known are left blank.
ISOLATES FROM US AIDS PATIENTS
No Ref. list Strain Ser Origin RFLP Plasmids
1 2
1 1101 52 M.avium 8 blood A1 - -
2 1102 53 M. avium 4 blood A3 + -
3 1103 54 M. avium 4 blood A1 + -
4 1104 55 M. avium 4/1 blood A1 ? -
5 1105 56 M. avium 4 blood A1 - -
6 1107 57 M. avium 8 blood A1 + ?
7 1108 58 M. avium 8 blood A1 - -
8 1109 59 M. avium 8 blood A1 + -
9 1110 510 M. avium 8 blood A1 - -
10 3278 1662 MAIS 7 8 A1 nt
11 3279 1663 MAIS 7 A1 nt
12 3281 1665 MAIS 7 A1 nt
13 3282 1666 M. avium A2 nt
14 3284 1668 M. avium A1 nt
15 3285 1669 M. avium A1 nt
16 3286 1670 M. avium A3 - -
17 3287 1671 MAIS 7 A1 + -
18 150232 SK2 MAIS pleur, fl. A1 + +
19 121619 SK3 MAIS sputum A1 ? 7
20 294169 SK5 MAIS 13 knee A2 + nt
21 161340 SK8 MAIS blood A1 + -
22 281690 SK9 MAIS blood A1 + -
23 274479 SKIO MAIS blood A2 7 -
24 362853 SK12 MAIS blood A1 + +
25 310865 SK13 MAIS AX + -
26 256930 SK14 MAIS sputum A1 + -
27 249479 SK15 MAIS blood A3 - -
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28 119627 SK17 MAIS blood A3 4- -
29 283342 SKI 8 MAIS pericar.fl A2 + -
30 282984 SK19 MAIS blood A2 + -
31 291229 SK20 MAIS stool A1 4" -
32 212244 SK22 MAIS stool A2 7 -
33 241092 SK23 MAIS blood A2 4" -
34 243930 SK24 MAIS urine A2 - -
35 252522 SK25 MAIS periton.fl A1 4" -
36 189833 SK26 MAIS lymph node A2 4* -
37 381504 SK27 MAIS blood A1 4- -
38 339241 SK29 MAIS BAL A2 4" 4-
39 264849 SK32 MAIS stool A2 4~ -
40 277751 SK33 MAIS stool A1 4- 4-
41 193982 SK34 MAIS urine A2 4- -
42 138759 SK36 MAIS blood A1 4“ 4"
43 191469 SK39 MAIS blood A1 4- -
44 281949 SK40 MAIS stool A1 4- -
45 227733 SK42 MAIS blood A2 4* 4-
46 249054 SK43 MAIS sputum A3 7 -
47 218274 SK44 MAIS sputum A1 4- -
48 226468 SK45 MAIS blood A1 4- 4-
49 194125 SK46 MAIS stool A1 4" -
50 211825 SK47 MAIS stool A1 4- -
51 322570 SK49 MAIS sputum A1 4- -
52 302077 SK50 MAIS pleur, fl A3 4“ -
53 276501 SK55 MAIS sputum A1 4" -
54 269457 SK56 MAIS BAL A1 4" -
55 169839 SK58 MAIS AX 4- -
56 199412 SK59 MAIS 3 BAL A1 4- -
57 337272 SK60 MAIS lym.n. biop. A1 4" -
58 369968 SK61 MAIS lung biopsy A1 4" 4-
59 338197 SK62 MAIS 3 rect. abcess A1 4" -
60 132778 SK64 MAIS blood A1 4" -
61 116113 SK65 MAIS blood A2 4“ 4-
62 152539 SK67 MAIS urine A3 4- 4-
63 165748 SK68 MAIS BAL A1 4" -
64 186497 SK70 MAIS A2 4- _
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65 268451 SK72 MAIS BAL A1 + -
66 136580 SK76 MAIS stool A1 + -
67 135296 SK77 MAIS stool A1 + -
68 279039 SK78 MAIS blood A1 + -
69 253422 SK79 MAIS blood A1 7 -
70 256038 SK80 MAIS A1 + +
71 264373 SK81 MAIS A1 + +
72 210119 SK83 MAIS blood A1 + -
73 339268 SK84 MAIS bone-marrow A2 + -
74 370403 SK85 MAIS urine A1 + -
75 202454 SK87 MAIS BAL A3 + -
76 120839 SK38 MAIS BAL A3 + -
77 280241 SK91 MAIS blood A1 + -
78 278155 SK92 MAIS blood A2 + -
79 351110 SK93 MAIS sputum A1 + +
80 320937 SK94 MAIS BAL AX + -
81 365789 SKOO MAIS BAL A1 + -
82 245580 SKOl MAIS stool AX + -
83 253768 SK02 MAIS blood A1 - -
84 101 IBl MAIS 1 A1 - -
85 102 IB2 MAIS lOA A1 - -
86 103 IB3 MAIS 1 A1 - -
87 104 IB4 MAIS 1 A1 - -
88 105 IB5 MAIS 8 AI - -
89 113 IB6 MAIS 13 A3 - -
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ISOLATES FROM US NON-AIDS PATIENTS
No Refer list Strain Ser Origin RFLP Plasmids 
1 2
1 150452 SKI MAIS pleural fl. A1 +
2 155972 SK7 MAIS sputum XIO +
3 286943 SKll M.intracell. sputum M -  -
4 113788 SK16 MAIS blood,SCID XIO +
5 284489 SK21 MAIS urine A2 +
6 188545 SK27 MAIS pleural fl A2 +
7 190001 SK38 MAIS SCID XIO -  -
8 281790 SK41 MAIS BAL A2 +
9 285475 SK48 MAIS stool M -  -
10 330482 SK51 MAIS AX +
11 330386 SK52 MAIS sputum M -
12 319183 SK53 MAIS lung biopsy A2 +
13 172093 SK57 MAIS urine A1 +
14 301809 SK63 MAIS BAL A3 +
15 176289 SK69 MAIS lung A3 +
16 263027 SK73 MAIS urine A/I -
17 212687 SK86 MAIS sputum A2 +
18 119874 SK89 MAIS sputum A2 +
19 362092 SK90 MAIS sputum A2 +
20 225013 SK96 MAIS urine A2 +
21 220984 SK97 MAIS A1 +
22 219834 SK98 MAIS urine A2 +
23 200209 SK99 MAIS stool A2 ?
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ISOLATES FROM THE US ENVIRONMENT
No Refer list Strain Ser Origin RFLP Plasmids 
1 2
1 DE20 F3 MAIS water A1 + +
2 SR353 FIO MAIS water X2 - -
3 SR481 F ll MAIS water X2 - -
4 SR522 F12 MAIS water X7 - -
5 W279 F14 MAIS water XI - -
6 W291 F15 MAIS water X2 - -
7 DE6 F23 MAIS water X2 - -
8 DE25 F24 MAIS water X4 - -
9 4S F6 MAIS aerosol A3 - +
10 5S F7 MAIS aerosol A3 - +
11 12S F8 MAIS aerosol A2 + -
12 13S F28 MAIS aerosol A1 - -
13 978 F16 MAIS soil A1 - +
14 1158 F17 MAIS soil A1 - +
15 1232 F18 MAIS soil M - ?
16 1233 F19 MAIS soil A1 + +
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ISOLATES FROM EUROPEAN AIDS PATIENTS
No Refer list Strain Ser Origin RFLP Plasmids 
1 2
a) United Kingdom:
1 13665 IB7 MAIS 9 stool A1 -
2 12881 IBS MAIS 28A stool A1 -
3 13749 IB9 MAIS 28A stool A1 -
4 10344 IBIO MAIS 28A stool A1 -
5 12174 IBll MAIS 4 stool A1 -
6 3093 IB 12 MAIS 1 stool A1 +
7 3094 IB13 MAIS stool A1 +
8 12878 IB14 MAIS 28A stool A1 -
9 12879 IB15 MAIS 28A stool A1
10 12880 IB16 MAIS 28A stool A1 -
11 ? IB17 MAIS 28A stool A1 — —
b) Belgium:
1(1) 1581pa 43 M. avium blood A3 -
2(1) 1581SmS 44 M. avium blood A3 + -
3(1) 1582SmS 45 M. avium sputum A3 + -
4(1) 1713 47 M. avium 1 stool A3 + -
5 1157 511 MAIS 7 1 blood A1 - -
6 1158 512 MAIS 6 4 blood A1 + -
7 1159 513 MAIS 8 4 blood A1 7 -
8 1160 514 MAIS 6 4 blood A1 + -
9 1161 515 MAIS 6 8 blood A1 + -
10 1162w 516 M. avium 8 blood A1 + -
11 1162g 517 MAIS 4 8 blood A1 + -
12 1163w 518 M.avium 4 blood A3 - -
13 1163g 519 MAIS 4 4 blood A1 + -
14 1164 520 MAIS 7 blood A3 + -
15(1) 1678 92 M. avium stool A3 + -
16(1) 2256 911 M.avium 1 stool A3 + -
17(2) 1673 103 MAIS 3 stool B - -
18(2) 1792 105 MAIS 7 stool B - -
19 1793 106 MAIS 7 1 stool B - _
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20(2) 1712 1022 MAIS 7 stool B - -
21 3509 1680 M.avium stool A1 + -
22 4925 1681 MAIS sputum X4 - -
23(1) 3267 189 M.avium blood A3 + -
24 3939 1810 M.avium sputum X3 - -
25 2459 1814 M.avium sputum A1 7 -
26(1) 2437 1815 M.avium blood A1 - -
27(1) 2436 1816 M. avium blood A3 + -
28(1) 2435 1817 M.avium blood A3 - -
29(1) 2341 1818 M.avium blood A3 + -
30 4583 2216 M.avium sputum A1 - -
c) Sweden:
1 S089/87 SI M.avium 6 lymph node A1 - -
2 S104/87 S2 M. avium 6 blood A1 - -
3 S136/87 S3 M. avium 6 sputum A1 - -
4 S002/88 84 M.avium 6 blood A1 + -
5 S019/88 S5 M. avium 6 stool A1 - -
6 S091/88 S14 M. avium 2 blood A1 - -
7 S115/88 S16 M.avium 6 blood A1 - -
8 S037/89 S18 M. avium 4 blood A1 - -
9 S90/89 S22 M. avium 2 blood A1 - -
10 418/89 S24 M. avium 1 bone marrow A1 - -
11 822/89 S25 M. avium 2 blood A1 - -
d) Denmark
1 E8114 DK24 M. avium stool X - -
2 E6447 DK25 M. avium stool A1 - -
3 T2797 DK26 M.avium lymph node A1 + -
4 T7020 DK27 M. avium blood A1 - -
5 E2975 DK28 M.avium sputum AX - -
6 T6932 DK29 M.avium stool AX + -
7 2738 1812 M.avium A1 - -
8 2737 1813 M. avium A1
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ISOLATES FROM EUROPEAN NON-AIDS PATIENTS
No Refer list Strain Ser Origin
a) Belgium:
RFLP Plasmids 
1 2
1 1693 412 M. avium bronch.aspir. AX
2 1805 525 M.avium AX
3 2228 910 MAIS 8 lymph node X4
4 1576 102 M. avium lymph node B
5 2051 107 MAIS 7 stool B
6 2052 108 MAIS 3 stool B
7 2053 109 MAIS 7 stool B
8 2254 1010 M.avium sputum A/I
9 1983 182 M.avium sputum A/I
10 1985 183 M.avium sputum A/I
11 2485 184 M. avium pus A1
12 2588 185 M. avium biopsy B
13 2632 186 M. avium lymph node B
14 3042 187 M. avium gastr. fluid A1
15 3128 188 M.avium lymph node A1
16 4581 2215 M.avium A1
b) Sweden:
1 S021/84 S8 M. avium 6 sputum A1
2 S033/84 S9 M.avium 6 sputum A1
3 6918/83 S26 M. avium 1 lymph node A1
4 2282/84 S27 M. avium 1 lymph node M
5 S012/84 S28 M.avium 4 lymph node A2
6 0727/85 S29 M. avium 4 lymph node A1
7 S I15/85 S30 M. avium 4 lymph node A2
8 S027/84 S31 M. avium 6 lymph node A1
9 3796/83 S32 M. avium 1 pulmonary A1
10 4178/84 S33 M.avium 4 pulmonary A1
11 7629/84 S34 M. avium 4 pulmonary A2
12 S061/84 S35 M. avium 9 pulmonary A
13 0792/85 S36 M. avium 9 pulmonary A1
14 5101/86 S37 M.avium 16 pulmonary M
+
+
+
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1 R3749 DK2 M.avium sputum A1 - -
2 E24644 DK3 M.avium sputum A1 - -
3 E34633 DK4 M.avium sputum A1 - -
4 R4172 DK5 M.avium sputum A1 - -
5 E13861 DK6 M. avium sputum A1 - -
6 R800 DK7 M.avium sputum M - -
7 T771 DK8 M.avium sputum A/I - -
8 R2927 DK9 M.avium sputum A1 - -
9 R3062 DKIO M.avium sputum A1 + -
10 V3549 DK ll M. avium gastr. lavage A1 + ?
11 R4457 DK13 M. intracell. sputum M + -
12 E8527 DK14 M. intracell. sputum M - -
13 E38989 DK16 M. intracell. sputum M 7 -
14 R4545 DK17 M. intracell. sputum M - -
15 E16191 DK18 M. intracell. sputum M ? +
16 R416 DK19 M. intracell. sputum A1 - -
17 R333 DK20 MATS sputum X2 7 -
18 E6880 DK21 MAIS sputum M + -
19 7598 DK22 MAIS sputum M - -
20 E16232 DK23 MAIS sputum X2 + -
21 R4328 DK42 MAIS sputum M - -
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ISOLATES FROM HEALTHY EUROPEAN PERSONS (Belgium)
No Refer list Strain Ser Origin RFLP Plasmids 
1 2
1 649 11 MAIS stool B
2 695 12 MAIS stool B
3 700 13 MAIS stool B
4 725 14 MAIS stool B
5 653 21 MAIS stool B
6 655 22 MAIS stool B
7 603B 31 MAIS stool B
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ISOLATES FROM AFRICAN AIDS PATIENTS
No Refer list Strain Ser Origin RFLP Plasmid
1 2
1(1) 925 15 MAIS 3 16 blood H2 -
2(1) 926 24 MAIS 3 16 sputum H2 -
3(3) 1812 48 M.avium 1/5 sputum HI -
4(3) 1818 49 M.avium 1/5 stool HI -
5 11074 410 M.avium sputum HI -
6(3) 1788 523 MAIS 3 1/5 CSF HI -
7(4) 1675 85 MAIS 3 stool B -
8(4) 1676 86 MAIS 3 stool B -
9(4) 1674 91 MAIS 5 stool B -
10(3) 1794 93 MAIS 7 sputum HI -
11 2069 94 M. avium 5 sputum HI -
122») 1575 101 M.avium stool X6 -
13 1711 104 MAIS 7 stool B -
14(5) 2296 1012 M.avium blood A2 -
15 1670 1020 M. avium stool B -
16 928 1637 MAIS 6 stool X2 -
17(5) 1815 1650 M. avium lymph node X5 -
18 4386 2031 M. avium blood A1 -
19(2) 1329 1640 MAIS 3 sputum H I -
20(2) 1329w 1820 MAIS 3 sputum H I - -
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ISOLATES FROM AFRICAN NON-AIDS PATIENTS
No Refer list Strain Ser Origin RFLP Plasmids 
1 2
1 1656 1013 MAIS 3 or 7 stool B
2 1659 1014 MAIS 3 stool B
3 1661 1015 MAIS 3 stool B
4 1662 1016 M.avium stool B
5 1663 1017 M.avium stool B
6 1666 1018 MAIS 3 stool B
7 1668 1019 MAIS 7 stool B
8 1670 1020 M. avium stool B - -
9 1681 1021 MAIS 7 stool B
ISOLATES FROM THE AFRICAN ENVIRONMENT (Zaire)
No Refer list Strain Ser Origin RFLP Plasmids 
1 2
1 2620 161 MAIS water HI
2 2629 163 MAIS water HX -
3 3087 164 MAIS algae HX -
4 3087SmS 165 MAIS algae HX -
5 4350 166 MAIS water X2
6 5076 168 MAIS soil X4
7 5779 1610 MAIS water HI
8 3091 1682 MAIS water HI
9 2630 2021 MAIS water XI
10 5074 2022 MAIS soil X5
11 5161 2023 MAIS water XI
12 5164 2024 MAIS water X4
13 2635 222 MAIS 7 soil M
14 3087S 224 M. avium algae HX -
15 5161 225 M.avium water HX -
16 5164 226 MAIS water X3
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ISOLATES FROM AUSTRALIAN AIDS PATIENTS
No Refer list Strain Ser Origin RFLP Plasmids
1 2
1 4189 201 M. avium 8 blood A1 + +
2 4190 202 M.avium 9 sputum X2 7
3 4191 203 M.avium 5 blood A3 -
4 4192 204 M. avium 9 bone marrow A1 -  -  ■
5 4193 205 M. avium 4 stool A2 -  -
6 4195 207 M.avium 2 bone marrow A1 -
7 4196 208 M. avium 8 stool A1 +
8 4197 209 M. avium 4 stool A1 +
9 4198 2010 M. avium 1/8/21 tdood A1 +
ISOLATES FROM AUSTRALIAN NON-AIDS PATIENTS
No Refer list Strain Ser Origin RFLP Plasmids
1 2
1 4199 2011 M.avium 1 sputum M -
2 4202 2014 M.avium 1/8/21 pus neck A1 -
3 4204 2016 M.avium 4 lymph node A1 -  -
4 4205 2017 M. avium 8 lymph node A1 ?
5 4206 2018 M. avium 8 sputum A1 -
6 4207 2019 M.avium 9 sputum AX +
7 4208 2020 M.avium 9 sputum M -
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VETERINARY ISOLATES (animals)
No Refer list Strain Ser Origin RFLP Plasmids
1 2
1 M144 T4 MAIS 1 cow A/I - -
2 M232 T5 MAIS 2 cow A/I - -
3 M506 T6 MAIS 3 pig A/I - -
4 M512 T7, MAIS 1 pig A1 + +
5 M520 T8 MAIS 4 pig A1 - -
6 M603 T9 MAIS 8 pig A/I - -
7 2070 95 M.avium reptile A/I - -
8 2076 98 MAIS 7 python XIO - -
9 246790 CVLl M.avium deer XI - -
10 250890 CVL2 M.avium deer A/I - -
11 251490 CVL3 M.avium bovine A/I - -
12 251990 CVL4 M.avium bovine X2 - -
13 254890 CVL5 M.avium bovine XI - -
14 258790 CVL6 M.avium badger A/I - -
15 258890 CVL7 M.avium badger A/I - -
16 258990 CVL8 M.avium badger A/I - -
17 261090 CVL9 M.avium deer A/I - -
18 8589 213 M.avium goat A/I - -
19 F9 DK31 MAIS pig A1 - -
20 F828 DK37 MAIS pig A1 - -
21 F841 DK40 MAIS pig A1 - -
22 F842 DK41 MAIS pig A1 - -
23 JD88 MRl M. avium deer A/I - -
24 AF2362 MR2 M.avium deer A/I - -
25 AF3985 MR3 M.avium deer A/I - -
26 AF1351 MR4 M.avium deer A/I - -
27 1453 136 MAIS 3 monkey,stool B - -
28 1455 137 MAIS 3 monkey,stool B - -
29 1456 138 MAIS 4 monkey,stool B - -
30 1458 139 MAIS 3 monkey,stool B - -
31 1459 1310 MAIS 3 monkey,stool B - -
32 1463 1313 MAIS 7 monkey,stool B - -
33 1464 1314 MAIS 7 monkey,stool B - -
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34 1496 1315 MAIS 3 monkey,stool B - -
35 1786 1319 MAIS 8 monkey,stool X2 - -
36 1787 1320 M.avium monkey,stool B
ISOLATES FROM BIRDS
No Refer list Strain Ser Origin RFLP Plasmids
1 2
1 ? PEI M.avium teal A/I - -
2 86/154 PE2 M.avium pintail A/I - -
3 87/12A PE3 M.avium Carolina A/I - -
4 87/61A PE4 M. avium longtail duck A/I - -
5 87/65 PE5 M. avium pintail A/I - -
6 87/74A PE6 M. avium longtail duck A/I - -
7 87/114 PE7 M. avium smew A/I - -
8 87/114A PE8 M. avium goosander A/I - -
9 87/120 PE9 M.avium yellowbill A/I - -
10 87/124 PEIO M. avium Carolina A/I - -
11 87/138 PEll M. avium yellowbill A/I - -
12 87/160 PEI 2 M.avium Carolina A/I - -
13 87/211 PE13 M. avium falcated duck A/I - -
14 87/223 PE14 M.avium merganser A/I - -
15 87/231 PE15 M. avium pintail A/I - -
16 87/248 PEI 6 M.avium teal A/I - -
17 88/8 PE17 M. avium wood duck A/I - -
18 88/9 PEI 8 M. avium scaup A/I - -
19 88/12X PE19 M. avium mallard A/I - -
20 S1765 PE20 M. avium wood duck A/I - -
21 7888 PE21 M. avium goosander A/I - -
22 5988 PE22 M.avium Carolina A/I - -
23 87/214 PE23 M. avium ne-ne A/I - -
24 88/8A PE24 M.avium red breasted A/I - -
25 88/12 PE25 M. avium barnacle A/I - -
26 88/31 PE26 M.avium barnacle A/I - -
27 88/91 PE27 M.avium barnacle A/I - -
28 87/65A PE28 M. avium trumpeter A/I - -
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29
30
31
32
33
34
35
36
37
38
39
40
87/222
88/4X
7859
M12
M14
M109
M607
M608
M697
2073
2074 
230534
PE29
PE30
212
T1
T2
T3
TIO
T il
T12
96
97
SK30
M. avium
M.avium
M.avium
MAIS
MAIS
MAIS
MAIS
MAIS
MAIS
M.avium
M.avium
MAIS
black A/I
whooper A/I
wood pigeon A/I
6 chicken A/I
6 ferai pigeon A/I
song thrush X9
3 wood-pigeon A/I
1 wood-pigeon A/I
1 Keny flamin. A/I
10/11 swallow XIO
goose A/I
pig.livbiop A6
1 - 22: Ducks, 3 -2 7 : Geese, 28 - 30: Swans from Arundel.
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MAI SEROTYPES FROM KOLK
No Refer list Strain Ser Origin RFLP Plasmids 
1 2
1 5879 AKl MAIS 2 X2 “
2 5886 AK4 MAIS 1 A/I •  -
3 5890 AK9 MAIS 2 A/I -
4 5888 AKIO MAIS 2 A/I -
5 5889 AKll MAIS 2 A/I -
6 5891 AK13 MAIS 2 A/I -
7 5893 AK17 MAIS 3 A/I -
8 5938 AK24 MAIS 4 Al -
9 5900 AK29 MAIS 4 Al +
10 5903 AK31 MAIS 5 A3 -
11 5908 AK36 MAIS 7 M 7
12 5907 AK37 MAIS 7 X +
13 5910 AK40 MAIS 8 Al +
14 5927 AK43 MAIS 9 AX -
15 5928 AK44 MAIS 9 X -
16 5896 AK48 MAIS 11 Al -
17 5934 AK49 MAIS 11 Al +
18 5897 AK50 MAIS 11 Al -
19 5929 AK58 MAIS 15 M ?
20 5931 AK61 MAIS 16 M 7
21 5921 AK63 MAIS 17 M -
22 5920 AK64 MAIS 18 M -
23 5923 AK65 MAIS 19 M -
24 5922 AK66 MAIS 19 M +
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MAI SEROTYPES FROM CRAWFORD
No Refer list Strain Ser Origin RFLP Plasmids
1 147 STl MAIS 1 A/I nt
2 593 ST2 MAIS 1 A/I nt
3 594 ST3 MAIS 1 A/I nt
4 107 ST4 MAIS 3 Al nt
5 541 ST5 MAIS 4 Al nt
6 542 ST6 MAIS 4 Al nt
7 163 ST7 MAIS 6 M nt
8 150 ST8 MAIS 8 Al nt
9 551 ST9 MAIS 8 Al nt
10 553 STIO MAIS 8 .A2 nt
11 158 STll MAIS 10 M nt
12 105 ST12 MAIS 11 A3 nt
13 127 ST13 MAIS 19 M nt
14 120 ST14 MAIS 20 M nt
15 152 ST15 MAIS 21 M nt
16 141 ST16 MAIS 26 A3 nt
17 195 ST17 MAIS 42 X3 nt
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CONCLUSIONS
5. CONCLUSIONS
This investigation has shown that most MAI infections in AIDS patients from 
the developed world MAI infections are caused by specific M. avium strains - referred 
to as RFLP type A strains. Such strains were also isolated and identified fi*om 
environmental samples, notably water and soil samples. MAI infections in AIDS 
patients from Africa, on the other hand, are usually infected by another specific MAI 
strain, referred to as RFLP type H strain. Analogous to type A strains, type H strains 
are found in the corresponding environment. This suggests that the environment is the 
likely source of MAI infection in AIDS patients. Furthermore, it suggests that 
possible routes of infection may include both the respiratory and digestive tracts. 
Although infection may occur through direct inoculation from the environment, the 
possibility of endogenous reactivation may not be ruled out.
A commercially available DNA probe (Gen-Probe) specific for the M. avium 
complex, allowing differentiation between M.avium and M.intracellulare proved to 
be unreliable when tested against RFLP type H strains.
Plasmids, which may be involved in virulence and pathogenicity of MAI in 
AIDS, were found to exhibit similar distributions in isolates firom AIDS patients, non- 
AIDS patients and the environment of the developed world; although variations in the 
frequency of plasmids in MAI in different countries were observed. Plasmids appear 
to be associated with RFLP type A strains, rahtre than isolates from AIDS patients. 
The role of plasmids in the pathogenicity and virulence of MAI infections AIDS 
remains unclear.
In order to identify the source of MAI infection in AIDS a more 
comprehensive study of environmental MAI isolates is required. Furthermore,
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screening for MAI of both healthy persons as well as HIV positive persons who do 
not yet exhibit clinical symptoms associated with AIDS is essential in establishing the 
onset of MAI infections in AIDS. It would also be useful in determining whether 
MAI is in fact a causal cofactor in AIDS or merely a casual opportunist. In addition, 
early diagnosis would clearly facilitate both prophylactic and therapeutic treatment. 
Such early diagnosis may be achieved by means of the polymerase chain reaction 
(PCR). This thesis has shown that DNA from members of the MAI complex is 
selectively amplifyable using specific primers.
A supposedly ’cured’ MAI strain from an AIDS patient, which has been 
extensively employed in pathogenicity studies of MAI in AIDS, was shown to differ 
phenotypically from its parent strain. This important finding invalidates previous 
studies suggesting possible roles of MAI plasmids in pathogenicity, restriction 
modification systems and certain enzyme functions.
The opposite approach from past ’cured’ strain studies is required in order to 
establish a possible role for plasmids in the pathogenicity and virulence of MAI in 
AIDS. Transforming MAI isolates lacking plasmids with known, characterised MAI 
plasmids, such as pLR7 or pLR20, and using these transformed strains in conjunction 
with strains lacking plasmids studies would pinpoint plasmid-attributable 
characteristics more reliably.
Unlike M.avium isolates from AIDS patients, pathogenic isolates from birds 
and animals possess an insertion sequence - IS901. As part of this genetic analysis of 
the M.avium complex IS901 was sequenced. The nucleotide and amino acid sequence 
characteristics of IS901 were compared with other characterised IS elements present 
in hoihActinomycetes and other more distantly related bacteria. This analysis revealed
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that 1S901 is a member of a widespread class of atypical insertion sequence. M.avium 
strains containing 1S901, referred to as RFLP type A/I strains, were almost 
exclusively associated with pathogenic isolates from birds and animals, including the 
wood pigeon bacillus. Invariably such strains were found to correspond to M. avium 
serotypes 1, 2 and 3 - often referred to as the classical M.avium strains. Like 
M.paratuberculosis, which contains 1S900, M.avium containing JS901 has evolved 
from M.avium by acquiring multiple copies of this insertion sequence.Type A/I 
strains are more virulent (in an animal model) than type A strains. Sequence data 
from IS901 was used to amplify MAI DNA; thus allowing identification and 
differentiation of several members of the M.avium complex, notably pathogenic 
M.avium (containing IS901), M.paratuberculosis and M.avium associated with AIDS. 
Amplification of MAI in clinical samples may facilitate early diagnosis of such 
infections in AIDS patients. Like IS900, IS901 is a useful tool to study the molecular 
biology of the M.avium complex. It may be used to obtain stable integration of 
foreign genes in mycobacteria, thereby allowing cloning and expression of 
mycobacterial genes in mycobacteria. Furthermore, IS901 may be employed to study 
the genetic basis of virulence of mycobacteria.
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